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This thesis reports the development of novel methodologies for the solid-phase synthesis 
of purine derivatives.  
The first project involves the solid-phase synthesis of 2,9-disubstituted-6-oxopurines 
using Wang resin. The synthetic strategy involves loading 6-chloropurine scaffolds 
directly onto the solid support via an ether linker. Following this, combinatorial 
modifications include Mitsunobu alkylation at the N9 position, amination or Sonogashira 
coupling at the C2 position, bromination and subsequent alkylation at the C8 position 
were carried out. Then resin was eventually cleaved and 2,9-disubstituted-6-oxopurines 
were released. A small library of purine derivatives was prepared and overall yields 
obtained were 24-70%. The effects of these compounds on multidrug resistance protein 4 
(MRP4/ABCC4) facilitated bimane-GS efflux were examined. Compounds 2-16 and 2-
25d were active in inhibiting MRP4 mediated efflux of the bimane-glutathione conjugate. 
In addition, both compounds were also able to reverse MRP4 mediated resistance to the 
anti-cancer drug 6-thioguanine.  
The second project focuses on the investigation of the regioselective solid-phase 
synthesis of N7-substituted purine using REM resin. The synthetic strategy was devised 
to anchor the REM resin at N9 of 6-chloropurine via Michael addition, leaving N7 as the 
steric priority for alkylation. Subsequent hydrolysis of 6-chloride was carried out 
followed by alkylation at N1. The resin bound N1-substituted purine was then 
quaternized at N7 with different alkylation agents. The 1,7-disubstituted-6-oxopurine 
derivatives were released from the resin via Hofmann elimination. With this method, a 
library of 15 1,7-disubstituted-6-oxopurines was synthesized in high purity and good 
 v
yields. This study gives the first example of a highly regioselective solid-phase synthesis 
of 1,7-disubstituted-6-oxopurine derivatives. 
The third project centers on widening the solid-phase synthesis of purines based on the 
purine ring construction strategy. The synthetic strategy was designed to load the 5-
amino-4,6-dichloropyrimidine onto BOBA resin via an amine linker to construct the 
diamine key intermediate for elaboration to various substituted purines. After cyclization, 
the N7 position possesses the steric priority to be alkylated. This, in turn, resulted in a 
regioselective N7 alkylation being achieved. At the end of the reaction, the BOBA linker 
was easily cleaved and the target purines were released. During this study, we have also 
extended the use of the key intermediate polymer supported diamine for other solid-phase 
synthesis including 1,7,8-trisubstituted purines, 8-unsubstituted purines, 8-azapurines and 
[i]-condensed purines.  
In all these three projects, solid-phase-oriented synthesis in solution was examined to 
establish the requisite solid-phase reaction conditions.  
 vi
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CHAPTER 1: Introduction 
 
 1.1 Solid-phase synthesis (SPS) 
Solid-phase synthesis (SPS) is a methodology whereby the reactions take place on the 
molecule attached to an insoluble material referred to as a solid support. Such a SPS is 
composed of a polymer bead (generally cross-linked, insoluble, polymeric material inert 
to the conditions of synthesis) and a linker (a bifunctional chemical moiety that joins the 
polymer and the molecule to be synthesized). A building block is firstly coupled to the 
solid support via the functionality present on the solid support. Several modification steps 
can be performed to achieve the solid support bound final molecule and eventually it is 
cleaved from the solid support (Figure 1.1).   
 
Figure1.1 Illustration of a solid-phase synthesis  
 
This concept of solid-phase synthesis was first raised by R. B. Merrifield in 1963 for 
efficient peptides synthesis.[1] Later this methodology was expanded to synthesize other 
bio-oligomers such as oligonucleotides and oligosaccharides.[2] Today it is a powerful 
method for the synthesis of small molecules with biological importance. The main 
advantage of SPS is the convenience of purification. Only simple filtration is needed for 
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the purification because compounds are bound to the solid support. The filtration and 
washing steps can easily remove the excess reagents used. Other benefits include the 
possibility of using excess reagents to force the chemical reaction to completion and the 
ease of straightforward automation. However solid-phase synthesis needs large amount of 
reagents and solvents, and, depending on the synthetic strategy, extra attachment and 
cleavage steps are at times also required. In addition, it is also more difficult to monitor 
the progress of a solid-phase reaction because the substrate and product are attached to 
the solid support which reduces spectral resolution. 
 
1.1.1 Solid supports  
Solid support is an insoluble material to which molecules may be attached (via a linker). 
This insoluble material allows the full separation of the solid support from excess 
reagents, soluble by-products, or solvents by filtration. Many solid supports have been 
developed for SPS of organic molecules. This includes cross-linked organic polymer, 
linear organic polymer, dendrimers and inorganic supports.[3] The most frequently used 
solid supports are 1) hydrophobic polystyrene resin; 2) hybrid hydrophilic polystyrene 
resin; and 3) macroporous non-swelling resin.  
The hydrophobic polystyrene resin is normally cross-linked with 1-2% divinylbenzene 
(DVB). This cross-linking increases the mechanical stability, diffusion and swelling 
property of the resin. Swelling is an essential property of resin in SPS because it 
manifests an internal flexibility of the polymer backbone that can move to maximize the 
available functionality. It also allows free diffusion of solvents and reagents into the 
beads. The swollen resin beads thus have an enlarged surface area to obtain optimum 
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reaction efficiency. The sizes of polystyrene beads commonly used in SPS are between 
90-200 μm. These resins are fairly cheap and easily functionalized with high loading. 
Thus it is the most extensively used resin in SPS.  
Hybrid hydrophilic polystyrene resin is a grafted polystyrene resin with hydrophilic 
monofunctional or bifunctional polyethylene glycol (PEG) chains.[4] The monofunctional 
PEG grafted polystyrene resin is commonly named Tentagel (TG) and bifunctional PEG 
grafted polystyrene resin is called Argogel (AG). This kind of resin shows better swelling 
property in aqueous solution and has less mechanical stability compared to hydrophobic 
polystyrene resin. However, these resins are very expensive and have lower loading value 
which limits their use in SPS.  
Macroporous non-swelling resin contains macroscopic pores embedded inside their rigid 
structure which does not give any swelling. The rigid structure increases the mechanical 
stability. This type of solid support is usually applied for automated oligonucleotide and 
peptide synthesis.   
 
1.1.2 Linkers 
Linker is another vital component for SPS and it is a molecular moiety connecting the 
solid support and the compound to be prepared. This molecular moiety is tethered to the 
solid support and contains a reactive functional group which is ready for the attachment 
of the first reactant (Figure 1.1). In fact most resins today are named to indicate the linker 
grafted onto them. For example Wang resin is named to define the p-alkoxybenzyl 





linker linking functional group
 
Figure 1.2 Structure of Wang resin 
 
An ideal linker has to meet some criteria. It should be stable enough to tolerate all the 
reaction conditions. On the other hand it is supposed to be sensitive enough to be cleaved 
after the reaction is completed.  
Many linkers used in SPS can be categorized according to their cleavage condition,[5] 
such as acid labile linkers, base labile linkers, photo labile linkers, metal-assisted cleaved 
linkers, oxidative/reductive cleaved linkers, cyclatively cleaved linkers, safety-catch 
linkers, traceless linkers and multifunctional linkers, etc. However, it is obvious that 
some linkers are attributed to more than one family. The most frequently used families of 
linkers such as the acid labile linkers, base labile linkers, photo labile linkers, safety-catch 
linkers, traceless linkers and cyclatively cleaved linkers are described below.         
 
1.1.2.1 Acid labile linkers 
This is the most widely used class of solid-phase linker. Its popularity may be attributed 
to the ease of reaction–––cleavage of the acid labile linker and the deprotection of 
protecting groups on the resin bound compound sometimes can be achieved in a single 
step. Many historically important resins (Merrifield, Wang, Sasrin, Rink resins) have 
linkers that are cleaved under acidic conditions. The acids used are normally TFA, HBr, 
HF, acetic acid etc. The commonly used acid labile resins and their cleavage conditions 
are listed in Table 1.1. [5c] 
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Table 1.1 Acid labile solid-phase linkers 
Name of linker Structure Cleavage conditionsa 
Wang O
OH  

















0.1 % TFA/DCM, rt,  
5 min or 










0.2 % TFA/DCM, rt,  
3 min or 50% TFA/DCM, 





















0.5% TFA/DCM or 
AcOH/TFE/DCM=1/1/8 
or HFIP/DCM=1/4 
a)  Cleavage conditions depend on particular compound prepared 
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1.1.2.2 Base/nucleophile labile linkers 
Although not as popular as the acid labile linker, the nucleophile labile linker has also 
been developed to some extent. The cleavage mechanism normally involves β-
elimination, hydrolysis, hydrazinolysis or aminolysis. The main advantage of this linker 
is its ability to introduce diversity in the cleavage step. Scheme 1.1 gives an example of a 
nucleophilic cleavage. p-Thiophenol linker prepared from methyl amine linker was first 
anchored at chloropyridazine and then after combinatorial modification, the final product 
3,6-disubstituted pyridazine was released from the solid support by treatment with 




















Scheme 1.1 Nucleophilic cleavage of p-thiophenol linker 
 
1.1.2.3 Photo labile linkers 
Photo labile linkers use a photon source to cleave the bond between the final compound 
and solid support. The target molecule is released into solution and no additional step is 
needed to remove the cleavage reagent. Photolytic conditions can be mild and selective. 
Only compounds with specific structures can be cleaved photochemically. This kind of 
linker usually contains an o-nitrobenzyl group which can be cleaved by a 350 nm light. 
















MeOH, rt, 24 h
R'COOH
 
Scheme1.2 Photo cleavage of o-nitrobenzyl bromide linker 
 
1.1.2.4 Safety-catch linkers 
Safety-catch linker is the linker that is only labile after activation which increases the 
lability of the linker to the cleavage conditions. Thus this kind of linker involves two-step 
cleavage: activation and cleavage. This linker makes the linkage moiety completely 
stable enough to a wide range of reaction conditions during the synthesis unless it is 
activated.  An example of a safety-catch linker, called the Kenner sulfonamide-based 
linker, is shown in Scheme 1.3.[8] This linker was initially coupled with carboxylic acid. 
After synthetic elaboration, treatment of diazomethane activated the linker which was 
subsequently cleaved with a nucleophile such as NH3, hydrazine or NaOH to release the 



















Scheme 1.3 Kenner sulfonamide-based safety-catch linker 
 
1.1.2.5 Traceless linkers 
A major drawback to traditional linker is that after cleavage, a specific functional group 
through which the compound was attached to the solid support would be left on the target 
molecule, e.g. carboxylic acids and amides in peptide synthesis. The presence of these 
appendages is acceptable if the target molecule embodies these functionalities. However, 
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complications may arise if these vestigial functionalities are redundant and affect the 
activities of the compounds. To address this issue, traceless linkers were developed. A 
traceless linker does not leave a residual functional group after cleavage. It normally 
creates a C-C or C-H bond at the site of cleavage. Traceless linkers are so called because 
an examination of the final compound reveals no trace of the anchoring point. However, 
some traceless linkers are also known as multifunctional linkers when cleavage causes an 
introduction of a new functionality at the linkage site by either nucleophilic or 
electrophilic substitutions.[9] Presently development of traceless linkers is a major area of 
interest in SPS.[9, 10] Some commonly used traceless linkers are illustrated below.  
 
1.1.2.5.1 Silyl-based traceless linker 
The first and most widely explored traceless linker is the silyl-based linker. It was first 
reported by Ellman in 1995 and now it is called Ellman silyl linker.[11] Silicon attached to 
a phenyl group can be cleaved by either acids or a fluoride ion, leaving hydrogen on the 
aromatic ring (Scheme 1.4). In this case traceless cleavage gave a C-H bond at the 























Scheme 1.4 Traceless SPS of benzodiazepines using silyl linker 
 9








Showalter silyl linker  
Figure 1.3 Silyl linkers for traceless SPS 
 
1.1.2.5.2 Sulfur-based traceless linker 
The first sulfur traceless linker was the aryl sulfide linker developed by Suto in 1997.[12] 
The aryl sulfide linker was activated by oxidation with mCPBA to form a sulfone linker 
which was then cleaved with primary or secondary amine to give 2-aminopyrimidines 
(Scheme 1.5). This linker is also a typical example for safety-catch linker because the 
oxidation can be considered as an activation of the linker for the final cleavage. 
Meanwhile it is also regarded as a multifunctional linker because the final cleavage 



















Scheme 1.5 Traceless cleavage of aryl sulfide-based linker 
 
Besides aryl sulfide-based traceless linker, alkyl sulfide linker was also reported for 
traceless SPS of biarylmethane through Pd-catalyzed release of resin bound 













Scheme 1.6 Traceless SPS of biarylmethane 
 
Sulfone linker is another well-developed sulfur-based traceless linker. This linker 
provides tethers robust to various chemical transformations.[14] Sodium benzenesulfinate 
is an example of a traceless sulfone linker. After combinatorial modifications, 


















Scheme 1.7 Traceless cleavage of sulfone linker 
 
1.1.2.5.3 Selenium-based traceless linkers 
Selenium and sulfur share similar properties. However, the use of selenium reagents is 
often preferable to sulfur because not only the oxidation of selenides proceeds more 
quickly than that of sulfides but s C-Se bond is weaker than the C-S bond.[15] Selenium 
has proven to be a useful element for traceless SPS and many studies on selenium-based 
traceless linker have been reported.[16] An example is given in Scheme 1.8. The selenium 
linker was obtained form Merrifield resin first. After elaboration to resin bound 



































Scheme 1.8 Traceless SPS of 2,2-dimethylbenzopyran 
 
1.1.2.5.4 Nitrogen-based traceless linker 
The first nitrogen-based traceless linker was developed by Komogawa in 1983 as a 
sulfonylhydrazone linker.[17] Sulfonylhydrazone linker was easily prepared from sulfonyl 
hydrazine resin. After being treated with ketone or aldehyde, the modified resin then was 
cleaved either under reduction condition to generate alkane or under basic condition to 

















Scheme 1.9 Sulfonylhydrazone traceless linker 
 
Amongst the various nitrogen-based traceless linkers, the triazene linker is the most well 
studied and frequently used.[10a, 18] Triazene linker, such as T1 linker, has shown the 
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versatility of diazonium type anchoring and its suitability for traceless cleavage. T1 
triazene traceless linker was first developed for SPS of arene. The triazene linker was 
prepared from diazotization of secondary amine resin and aniline. After chemical 

















Scheme 1.10 Traceless SPS of arene via T1 linker. 
 
1.1.2.6 Cyclative cleavage strategy 
Cyclative cleavage is also an often-used strategy and has begun to play an increasingly 
important role in SPS. It produces the intramolecular cyclization of resin bound 
intermediate and releases the final cyclized product from the solid support. The 
advantage of cyclative cleavage is the ability to generate the final cyclized product in 
high purity since any uncyclized side products still remain on the solid support. However 
this kind of cleavage is restricted to substrates that contain the structural requirements for 
ring closure. An example of cyclative cleavage is shown in Scheme 1.11. The REM 
linker was first treated with primary amine followed by the reaction with isocyanate to 
yield β-ureido ester as the precursor for ring closure. Treatment of β-ureido ester under 
acidic condition gave a direct formation of the final product with concomitant cleavage 

















Scheme 1.11 Traceless SPS of 1,3-disubstituted-5,6-dihydropyrimidine-2,4-diones 
 
1.1.3 Reaction monitoring in solid-phase synthesis  
Although the nature of solid-phase reaction makes it ‘blind’ to some extent and its 
reaction monitoring is not as easy as in solution, there are still some methods available 
for solid-phase reaction monitoring. These analytical methods can be classified as off-
beads method and on-beads methods. In off-beads method, the resin-bound intermediate 
is cleaved off the resin and characterized by classical analytical techniques. This method 
is accurate but time-consuming and sometimes the reagents used for cleavage may cause 
contamination. In on-beads method, the characterizations are carried out directly on the 
resin-bound compounds. Compared with off-beads method, on-beads method is rapid and 
more straightforward. The frequently used on-beads methods are on-beads IR, gel phase 
NMR, HRMAS-NMR and MS. Despite these methods, solid-phase reaction monitoring is 
still a big challenge because the substrate and product are attached to the solid support 
which could reduce spectral resolution and new methods and techniques are still required. 
 
1.1.4 Solid-phase synthetic libraries---from peptides to small organic molecules 
In 1963 Merrifield realized the efficient synthesis of L-leucyl-L-alanylglycyl-L-valine on 
solid support.[1] In order to extend the peptide chain, the deprotection, neutralization and 
coupling steps were repeated for each of the subsequent amino acid until the desired 
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sequence was assembled. Finally, the completed peptide was deprotected and cleaved 
from the solid support. Due to its speed and simplicity, this technique eventually led to 
the rapid development of solid-phase peptide synthesis. Although peptide library is the 
most exploited oligomeric molecule generated by SPS, this synthetic methodology was 
also extended to the preparation of other biologically important oligomeric molecules 
such as oligonucleotides and oligosaccharides.[2] SPS was used to prepare only oligomers 
for almost three decades until in 1992 Ellman published their convenient and high yield 
synthesis of a library of ten 1,4-benzodiazepine analogs.[20] This was a turning point in 
the history of SPS.  From then on, the center of SPS was directed at small organic 
molecules because many of these molecules were potential lead compounds for drug 
discovery. During a drug exploration process, a large number of libraries of organic 
molecules are needed for lead discovery and lead optimization and SPS technique can be 
used to provide a large collection of small organic molecules expediently. However SPS 
of small organic molecules is more challenging. Unlike oligomers, the reaction 
conditions for the synthesis of small molecules are more versatile. It requires the solid 
support and linker to be stable under the various reaction conditions. To date many small 
organic molecule libraries have been prepared as bioactive templates using SPS 
technique.   
It is worth noting that, during SPS of small organic molecules, after designing the solid-
phase synthetic route, a solution-phase synthesis validation is usually examined to 
establish the requisite solid-phase reaction conditions. This validation of the planned 
synthetic route is necessary to carry out successful corresponding reactions on the solid 
phase. Normally the solution-phase synthetic route must provide all the intermediates and 
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target compound with good yield and high purity before it is transferred onto the solid 
support. Meanwhile because of different nature of solid-phase reactions from solution-
phase ones, some modifications of the reaction conditions are still necessary to achieve 
better results in solid-phase reactions. For example sometime a specific co-solvent should 
be added to the solid-phase reaction to allow the resin to achieve better swelling property.  
 
1.2 Solid-phase synthesis of purine  
The purine ring is a critical structural element in biology because of its potential as a 
target nucleotide-binding protein and its important role in numerous cellular processes. A 
large number of purine syntheses have been developed in solution.[21] Ever since Gray 
discovered the trisubstituted purine as cyclin-dependent kinase (CDK) inhibitors, [22] SPS 
of purines have been developed to cater to the demand of purine derivatives with higher 
diversity. SPS has proved to be an effective and convenient technique to generate purine 
library. From 1990’s various methods for the SPS of purine derivatives have been 
reported. These methodologies generally involve two main strategies. In the first strategy, 
a halogenated/aminated purine is usually used. Modification on such purine ring can 
generate purine libraries. The second strategy is based on the construction of the purine 
ring. This is achieved via the synthesis of substituted pyrimidine ring followed by closure 
of the imidazole ring or through the generation of the imidazole ring first followed by 
cyclocondensation of the pyrimidine ring.  
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1.2.1. SPS of purines based on halogenated/aminated purine 
This strategy involves loading the purine scaffold bearing halo- or amino- functional 
groups directly onto the solid support. After modification at various positions, the 
substituted purine is released. Although it looks there are seven positions on the purine 
ring which can be used as points of attachment to the solid support, only three of them are 













Figure 1.4 Purine structure and numbering 
 
1.2.1.1 Purine scaffold connected to solid support at N9 
In 1996 Norman and co-workers devised a strategy to load the modified purine onto the 
aminoalkyl solid support.[23] 2-amino-6-chloropurine was firstly alkylated at N9 to form 
2-amino-6-chloro-9-(2-hydroxyethyl)purine, which was then treated with dihydropyran to 
generate the hydroxyethyl-THP linker. After loading on the aminoalkyl solid support, 
alkylation at the amino group on C2 exocyclic nitrogen and amination on C6 position 
were carried out. This was followed by cleavage from the support giving 2,6-
diaminopurine alcohols as final products (Scheme 1.12). However this work has obvious 
limitations as only amino substituents could be introduced at the C2 and C6 positions. In 
addition, the substituent at N9 is invariable because ethyl alcohol was always obtained 

















































In 1997 Nugiel reported another similar SPS of C2 and C6-focused purines (Scheme 
1.13).[24] This method was inspired by the purine tetrahydropyranyl (THP) protection. 
THP linker was first generated from Merrifield resin and attached to the N9 position of 
2,6-dichloropurine. Different amination conditions were required for reactions at the C6 
and C2 positions–––displacement at C6 was carried out first with 5 equiv. of amine and 5 
equiv. of TEA at 80oC for 3 h while the amination at C2 had to be carried out at elevated 
temperature and using amine as the reaction solvent. This is because the C6-chloro 
position was the more reactive site and with an amino group at C6, the amination at C2 
became more difficult. Finally 2,6-diaminopurine was easily released by treating the resin 
with mild acid. This procedure could be considered as a traceless cleavage.  However, 








































In 2001 Brill and co-workers reported the SPS of 2,6,8-trisubstituted purine (Scheme 
1.14). In his strategy, the resin bound purine was prepared by treating activated Rink acid 
resin with 2,6-dichloropurine. After which the introduction of amino substituents was 
accomplished sequentially by displacement of chlorides. Alkylation at C2 with boric acid 
could also be performed successfully.  Incidentally this work presented an effective 
method for the bromination at C8 position, which provided the possibility of further 








































1.2.1.2 Purine scaffold connected to solid support at C2 
In this strategy the purine scaffold was usually attached to the solid support through an 
amine linker.  
In 1996 glycinamide linker was applied to SPS of 2-(acylamino)-6-aminopurines 
(Scheme 1.15).[23] Starting with 2-amino-6-chloropurine, the purine core was attached to 
the Rink amide resin at the C2 position. This was followed by the combinatorial acylation 
at the exocyclic nitrogen and displacement of C6-chloro by primary or secondary amines. 
Since an exocyclic nitrogen was required for the attachment to the solid support, the 
diversity at C2 was limited. Furthermore, functionalization at N9 had to be performed in 
solution before the purine framework was put onto solid support. Hence this method is 













































To circumvent the limitation that one substituent is held invariant in order to anchor the 
purine to the solid support, Ding and co-workers reported a traceless SPS of 2,6,9-
trisubstituted purines (Scheme 1.16).[26] Starting with 2-fluoro-6-phenylsulfenylpurine, 
Mitsunobu reaction was carried out in solution to introduce the first point of diversity at 
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the N9 position. At the same time, primary amines were coupled with the 4-formyl-3,5-
dimethoxyphenoxymethyl-functionalized resin by reductive amination in order to 
generate a PAL linker. The modified purine scaffold was then loaded onto the solid 
support via the C2 position. The C6-thioether was then oxidatively-activated to a sulfone 
so that C6 amination could be achieved. Although the PAL linker allowed traceless 
cleavage, only amino substituents could be introduced at the C2 and C6 positions and 
only a secondary amino at C2 could be obtained. Besides these drawbacks, since 
oxidation to convert 6-thioether to sulfone had to be performed for further substitution, 
substituents sensitive to the oxidative conditions could not be introduced in the first two 
combinatorial modification steps. In addition, C6 displacement of sulfone was restricted 














































1.2.1.3 Purine scaffold connected to solid support at C6 
This is the most common strategy used in the SPS of purine derivatives. In this strategy, 
the purine scaffold was attached to a solid support through either an amine linker or a 
thioether linker. 
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1.2.1.3.1 Purine scaffold connected to solid support at C6 via amine linker 
PAL linker can be attached to purine via the C2 position (as shown in Scheme 1.16) or at 
C6 position (Scheme 1.17).[27]. In this report 4-formyl-3,5-dimethoxyphenoxy methyl-
functionalized resin was coupled with the 2-fluoro-6-(4-aminobenzylamino)purine core 
via a reductive amination in the presence of sodium triacetoxyborohydride. Following 
this, Mitsunobu reaction at N9 and displacement of C2-fluoro with amines were easily 
achieved. Finally cleavage with TFA yielded 2,9-substituted purines. It is obvious that 
the disadvantage of this method is that one potential combinatorial site is lost. To 
















































This modified synthetic route (Scheme 1.18) commenced with the coupling of 4-formyl-
3,5-dimethoxyphenoxymethyl-functionalized resin with a series of primary amines via 
reductive amination. This was followed by loading the 6-chloro-2-fluoro-9-SEM purine 
core onto the solid support via PAL linker. The purpose of introducing 9-trimethyl 
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silylethoxy methyl (SEM) to the purine core before loading onto the solid support was to 
increase the electrophilicity of the purine ring so that a resin capture at C6 could be 
performed. Subsequent deprotection of the SEM group, Mitsunobu alkylation at N9 and 
amination at C2 position could be carried out. Since the purine was attached to the solid 
support at C6 via an amine linker, this implied that only secondary amine can be 



















































In 2001 a similar method was reported by Dorff and co-workers.[29] However, instead of 
using a PAL linker, the purine core was attached to the solid support via an indole linker 
(Scheme 1.19). 
From the synthetic routes described above, it is observed that 2,6-dihalopurine is the most 
frequently used purine core to be loaded onto a solid support. Nucleophilic substitution of 
the C2-halogen with amine is a common way to introduce diversity at the C2 position. 
However this displacement usually requires harsh reaction conditions and long reaction 
time. Thus in 2002 Austin et. al. reported a microwave assisted SPS of 2,6,9- 
trisubstituted purine.[30] The synthetic route is similar to the method shown in Scheme 
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1.18. PAL linker was also employed to connect the purine core and solid support. 










































1.2.1.3.2 Purine scaffold connected to solid support at C6 via thioether linker 
In 2001 Brun and co-workers published the SPS of 2,6,9-trisubstituted purine using 
Merrifield-SH resin (Scheme 1.20).[31a] The resin was anchored onto the C6 position of 2-
chloro-2-iodo-9-isopropylpurine. This was followed by substitution at the C2 position 
with primary and secondary amines. After oxidative activation of the thioether to sulfone, 
both amination and cleavage from the resin was carried out at the C6 position. In order to 
expand the scope of substituents at C2, the same group, in 2002, reported the solid-phase 
alkylation at C2 using palladium catalyzed cross coupling reactions such as Suzuki and 
Sonogashira coupling.[31b] This method expands the diversity at C2 position because both 




























R1=amino or alkyl  
Scheme 1.20 
 
In 2002 a similar method was also reported by the Schultz group (Scheme 1.21).[32] 
Instead of 6-chloro-2-iodo-9-alkylpurine, 6-chloro-2-fluoro-9-alkylpurine was used as the 
initial purine scaffold. Amination at C2 was then applied followed by oxidation at C6 and 
















































1.2.2. SPS of purine based on purine ring construction 
SPS of purine library based on loading halogenated/aminated purine directly onto solid 
support can easily provide purine derivatives with diversity on C2, C6 and N9 positions. 
However, SPS of purine library based on imidazole ring formation has an important 
 25
advantage of providing the possibility of introducing C8 substituents more easily, 
although it is less straightforward than the first method. This strategy usually commences 
with the attachment of substituted pyrimidine on the solid support followed by functional 
group generation, combinatorial modification and ring closure.  
In 2000 Lucrezia et al reported the first SPS of purine from pyrimidine.[33] In this method 
(Scheme 1.22), Rink amide resin was attached to 4,6-dichloro-5-nitropyrimidine via the 
C6 position of the pyrimidine ring. Subsequent amination at C4 and reduction of nitro 
group at C5 provided the precursor for closure of the imidazole ring. Elaboration to 
purine was achieved by cyclization with isothiocyanate, formamide or aldehyde. 
Although this work gave only 8,9-disubstituted purines, it provides an avenue for 
cyclization to be carried out on solid phase to generate purines with C8 diversity. 
However, with the Rink amide resin, only adenine analogs could be prepared as cleavage 
resulted in the generation of a NH2 group. Moreover the overall yield is only ~7% 


































In 2002, the SPS of 2-(6-(benzylamino)-9-methyl-9H-purin-2-yl-amino)ethanol 
(olomoucine) based on purine imidazole ring formation was also reported (Scheme 
1.23).[34] Argogel MB-CHO resin was coupled with benzylamine by reductive amination. 
The resin bound secondary amine was then attached to 4,6-dichloro-2-(methylthio)-5-
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nitropyrimidine. After substituting the C4-chloro with methylamine, the C2-thiomethyl 
was oxidized to sulfone followed by substitution with protected ethanolamine. The nitro 
group was reduced and the imidazole ring was closed with trimethyl orthoformate. 
Subsequent deprotection and cleavage provided olomoucine. Although this report offered 
only olomoucine one compound, it provides an opportunity to generate purine library 
with higher diversity by varying of the individual amines used in the displacement steps 




















































In 2005 He reported the SPS of 1,3-substituted xanthines.[35] This study gave the first 
example of SPS of purines obtained by generating both the imidazole and pyrimidine ring 
on solid support (Scheme 1.24). Starting from glycine ethyl ester, PS-MB-CHO resin 
bound substituted imidazole ring was first constructed. After treatment with various 
isocyanates, the pyrimidine ring was closed under basic condition. Additional diversity at 











































1.3 Purpose of the research work in this thesis 
With the solid-phase synthetic methods described in Section 1.2, various substituted 
purine derivatives have been prepared. However, those methods mostly focus on 
adenines (6-aminopurines) synthesis. The SPS of 6-oxopurines is unexplored. Therefore 
one of the purposes of our research is to develop novel methodologies to traceless SPS of 
6-oxopurine derivatives.  
As described in Section 1.2, the SPS of purines has concentrated on the synthesis of N9 
substituted purine derivatives. In recent years, there has been much interest in the N7 
regioisomers due to its unique biological activities. Hence the second goal of this 
research is to investigate the regioselective SPS of N7-substituted purine derivatives. 
Finally, the extent to which reported SPS of purines could be applied to generate more 
diversity in purine is limited. For this reason, our research aims to widen the existing SPS 
protocol for purine so as to enable one to prepare purine derivatives with higher diversity.  
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CHAPTER 2: Design, Synthesis and Biological Evaluation of 2,9-




2.1.1 Importance of purine 
Purine ring is a critical structural element in biology because it is the component of 
nucleoside and nucleotide. Amongst the various purine derivatives, hypoxanthine and 
guanine (Figure 2.1) have found applications in a variety of therapeutics[1] and are known 
to (i) modulate multidrug resistance[2]; (ii) represent important anti-infective, anti-herpes 
and antitumor agents; and (iii) act as selective agonists and antagonists of specific 
receptors in cardiovascular or central nervous system complaints.[1] It is therefore 
reasonable to expect that combinatorial libraries of 6-oxopurine derivatives may provide 
inhibitors of these processes and act as useful biological probes or lead molecules for 











hypoxanthine guanine  
Figure 2.1 Structures of hypoxanthine and guanine  
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2.1.2 Multidrug resistance protein (MRP) 
The ATP-binding cassette (ABC) transporters are membrane proteins that facilitate the 
transport of a diverse variety of molecules. In humans, there are 48 ABC transporters 
belonging to 6 different subfamilies.[3] Members of the human ABC superfamily have 
been implicated in multidrug resistance in chemotherapy. To date, P-glycoprotein 
(Pgp/MDR1/ABCB1) is the best studied in terms of its role in multidrug resistance.[4] 
Other human ABC transporters that are implicated in drug resistance include the breast 
cancer resistance protein (BCRP/ABCG2) and the multidrug resistance protein 1 
(MRP1/ABCC1).[5]  
The ABCC subfamily has 12 members of which 9 are MRP proteins (MRP1-6/ABCC1-6 
and MRP7-9/ABCC10-12).[6] Although most ABC proteins contain two transmembrane 
domains and two nucleotide binding domains, some MRP proteins also contain a third 
transmembrane domain at the N-terminal.[6] These include MRP1-3, MRP6 and MRP7. 
In contrast, MRP4, MRP5, MRP8 and MRP9 all have the typical two transmembrane 
domains and two nucleotide binding domains topology. 
 MRP1 was cloned in 1992 and studies with cell lines overexpressing MRP1 showed that 
MRP1 is able to confer resistance to anthracyclines, vinca alkaloids, 
epipodophyllotoxins, camptothecins and methotrexate.[7] However, to date, the 
expression of MRP1 in clinical samples has not been systematically examined and the 
contribution of MRP1 to resistance to the anti-cancer drugs in humans is still not well 
established.[5a] Similar to the observations for MRP1, overexpression of MRP4 and 
MRP5 too can confer resistance to therapeutic agents. However, unlike MRP1, MRP4 
and MRP5 confer resistance to nucleoside and nucleobase analogs which are used 
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therapeutically as anti-cancer or anti-viral agents. These include compounds such as 6-
mercaptopurine, 6-thioguanine (6TG), 9-(2-phosphonylmethoxyethyl)adenine (PMEA) 
and azidothymidine (AZT).[8] Overexpression of MRP4 also results in resistance to 
camptothecins.[9] In addition to therapeutic agents, MRP4 is also able to transport various 
endogenous molecules including cAMP and cGMP as well as conjugated steroids, bile 
acids, prostaglandins and glutathione.[8, 10] 
To date, various compounds have been shown to inhibit the activities of MRP4. These 
include probenecid, sulfinpyrazone, indomethacin, dipyridamole and compounds 
containing the purine (eg. 6TG and PMEA).[10d, 11]   
 
2.2 Outline of our synthetic strategy 
In this project, we have designed a general method for the traceless SPS of 2,9-
disubstituted-6-oxopurine derivatives (Scheme 2.1). The strategy involves the direct 
loading of the purine scaffold onto the solid support. This was achieved through a resin 
capture-release chemistry whereby the purine was initially captured on the Wang resin at 
the 6-position through a C6-O bond. After various combinatorial modifications on the 



















Scheme 2.1 Overall strategy 
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2.3 Results and discussions   
2.3.1 Solution-phase study 
Prior to the solid-phase synthesis, preliminary solution-phase studies were carried out to 
survey the requisite reaction conditions and establish the modifications required for solid-
phase organic synthesis. 
 





































Scheme 2.2 Simulation of resin capture-release chemistry in solution 
 
2.3.1.1.1 Synthesis of 6-(benzyloxy)-9H-purine (2-3) 
We first examined the resin capture-release chemistry (Scheme 2.2). Benzyl alcohol was 
used to mimic the structure of Wang resin in solution-phase study. According to the 
literature, the chloride at the 6-position can be easily replaced by benzyl thiol.[12] 
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However sulfur is better nucleophile than oxygen. Hence we needed to convert the 6-
chloride in compound 2-1 into a better leaving group. A standard method is to convert the 
6-chloride into a 6-ammonio species.[13] This is commonly achieved through the reaction 
of 6-chloropurine with trimethylamine. However, the latter reagent being very volatile 
and toxic is difficult to handle, especially on a large scale. In addition, alkylation on the 
methyl group of trimethylammonio will be an undesirable competitive reaction during the 
subsequent displacement reaction. Hence in our synthesis, 1,4-diazabicyclo-[2.2.2]octane 
(DABCO) was used instead of trimethylamine.[14] Treatment of 2-1 with DABCO gave 
the DABCO-purine salt 2-2 which was reacted with sodium benzyloxide in DMF at room 
temperature to give 6-benzyloxypurine 2-3 in 91% yield. Attempts to carry out the 
reaction at 100oC resulted in a series of side-products and 2-3 was isolated in a much 
lower yield (22%). The X ray crystal structure of 2-3 is shown in Figure 2.2. 
 





2.3.1.1.2 Solution-phase N9 alkylation  
According to the literature, distribution between N9 and N7 alkylated products is strongly 
dependent on the substituents at the 6-position of purine, the choice of the base used and 
the reaction temperature.[15] Thus, to establish a regioselective N9 alkylation, various 
conditions were examined (Table 2.1).  
Table 2.1 Synthesis of compound 2-4a 
 Reaction conditions Ratio of N9:N7a 
1 nBuBr/LiH or NaH, 80°C,  6 h 1:1 
2 nBuBr/LiH, rt, 4 h 3:2 
3 PhSO3nBub/K2CO3/18-crown-6, rt, o/n 1:1 
4 ROH/DiAD/PPh3, rt, o/n 1:0 
            a) Determined by 1HNMR(C2H integral value). b) Prepared from benzenesulfonyl chloride and 1- 
butanol. 
 
Kjellberg and coworker have reported the regioselective N9-alkylation of 6-alkoxy-9H-
purine with LiH or NaH. [15] However our attempts to alkylate 2-3 with 1-bromobutane in 
the presence of LiH or NaH provided the N7 and N9 alkylated regioisomers in a 1:1 ratio 
(Entry 1). Reaction at lower temperature favored the N9 isomer and the N9 and N7 
alkylated regioisomers were obtained in a 3:2 ratio (Entry 2). Treatment of 2-3 and 
PhSO3nBu in the presence of K2CO3 and 18-crown-6 also gave poor selectivity and the 
N7:N9 isomers were obtained in a 1:1 ratio. To selectively alkylate the N9-position, we 
therefore proceeded to explore the Mitsunobu reaction. Reaction of 2-3 with 1-butanol 
under Mitsunobu condition gave exclusively the N9 isomer 2-4a (determined by 






















































Scheme 2.3 Mechanism of Mitsunobu reaction 
 
When 2-propanol was used for N9 Mitsunobu alkylation, 6-(benzyloxy)-9-isopropyl-9H-
purine (2-4b) was obtained exclusively. Figure 2.3 shows the X ray crystal structure of 2-
4b. 
 
2.3.1.1.3 Synthesis of 9-butyl-1H-purin-6(9H)-one (2-5) 
After the N9 alkylation, the benzyl group can be easily removed by catalytic 
hydrogenation or acid hydrolysis. Since the conditions for catalytic hydrogenation could 
not be conveniently adapted onto the solid-phase format, we proceeded to investigate the 
removal of the benzyl group using acid hydrolysis. In our study 2-benzyloxy-9-
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butylpurine 2-4 was hydrolyzed in 30% TFA/DCM or 1 M HCl in methanol to afford 9-
butyl-1H-purin-6(9H)-one 2-5. IR spectrum of compound 2-5 showed a C=O stretch at 
1692 cm-1 which could be attributed to the cyclic amide carbonyl group.  
 
 
Figure 2.3 X ray crystal structure of compound 2-4b 
 
 
2.3.1.2 Solution-phase study towards 2,9-disubstituted-6-oxopurines 
The above study in solution phase demonstrated the efficiency of our resin capture-
release strategy for the synthesis of 6-oxo-purine derivatives. To achieve combinatorial 
modification at the C2 position, 6-chloro-2-iodopurine 2-9 was prepared as the starting 
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halogenated purine scaffold. The solution-phase synthesis of 2,9-disubstituted-6-

































































Scheme 2.5 Overall solution-phase study 
 
2.3.1.2.1 Synthesis of 6-chloro-2-iodopurine (2-9) as starting material  
6-Chloro-2-iodo-purine (2-9) was obtained from 6-chloropurine (2-1) via protection of 
N9 with DHP, lithiation-mediated stannyl migration, subsequent iodination and final 




































Scheme 2.4 Preparation of 6-chloro-2-iodopurine (2-9) 
 
2.3.1.2.2 Synthesis of 6-(benzyloxy)-9-butyl-2-iodo-9H-purine (2-12) 
6-benzyloxy-2-iodopurine (2-11) was obtained using the same procedure as the synthesis 
of 6-benzyloxy-purine (2-3). It was noted that dihalogenated purines have different 
reactivities at the C2 and C6 positions. Earlier studies have shown that nucleophilic 
reactions with 2-iodo (or bromo- or chloro)-6-chloropurines would occur preferably at 
the C6 position instead of the C2 position.[17] Hence treatment of 6-chloro-2-iodopurine 
with DABCO/PhCH2OH/NaH provided regioselectively 2-11. Reaction of 2-11 under 
Mitsunobu condition resulted in the key intermediate 2-12 which facilitated further 
modifications on purine ring. In this project, we have examined the modifications by 1) 
amination via nucleophilic aromatic substitution, and 2) arylation via Suzuki coupling. 
 
2.3.1.2.3 Synthesis of 6-(benzyloxy)-9-butyl-2-morpholino-9H-purine (2-13) 
Halogens on purines can be readily replaced by various nucleophiles. Since the halogen 
at the C2 position has a lower reactivity than those at the C6 position, harsher reaction 
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condition was required for the substitution of C2-I by an amine. Treatment of 2-12 with 
morpholine at 120°C overnight in the presence of tripropylamine gave 2-13 in 83% yield.  
 
2.3.1.2.4 Synthesis of 6-(benzyloxy)-9-butyl-2-(4-methoxyphenyl)-9H-purine (2-15) 
The C2 aryl substituted 2-15 can be formed via Suzuki cross coupling of 2-12 and 4-
methoxyphenylboronic acid. Suzuki reaction is the coupling of an aryl or vinyl boronic 
acid with an aryl or vinyl halide using a palladium catalyst. Compound 2-12 was coupled 
with 4-methoxyphenylboronic acid in the presence of tetrakis(triphenylphosphine) 
palladium(0) via Suzuki cross coupling procedure to give 2-15 in 94% yield. The 
mechanism of this reaction involves oxidative addition, transmetalation, and reductive 
















Scheme 2.6 Mechanism of Suzuki cross coupling 
 
 2.3.1.3 Study of bromination at C8 position in solution 
In order to provide the possibility of modification at the C8-position, different 
halogenation conditions (Br2/DMF, NBS/DMF, NBS/THF and NIS/DMF) were examined 
but none provided the desired 8-halopurine. While Br2-2,6-lutidine[18] complex succeeded 

























Scheme 2.7 Bromination of 2-13 at C8 position 
 
After the N9 and C2 modifications, compounds 2-13, 2-15 and 2-17 were then 
hydrolyzed with 30% TFA/CH2Cl2 to give the respective substituted 6-oxopurines. 
 
2.3.2 Solid-phase Study 
2.3.2.1 Solid-phase synthesis of 2,9-disubstituted-6-oxopurine 
Having corroborated the approach in solution, we proceeded to apply the method to SPS. 
Scheme 2.8 summarizes our solid-phase process.  The starting purine scaffolds, either 6-
chloropurine (2-1) or 6-chloro-2-iodo-purine (2-9), were first loaded on the Wang resin. 
The resin bound purine 2-19 was N9-alkylated under Mitsunobu condition. The 
alkylation of resin bound purine can be monitored by High-Resolution Magic Angle 
Spinning (HRMAS) NMR for the appearance of peaks corresponding to the alkyl group. 
After obtaining the resin bound key intermediate 2-20, further modifications were carried 
out in accordance to the solution-phase study. 
C2-amino groups were introduced through the reaction of resin 2-20b with a variety of 
primary and secondary amines in DMA at 120˚C. Meanwhile key intermediate 2-20 was 






























































2-20a   X=H













2-2   X=H
2-10  X=I
 
Scheme 2.8 Solid-phase studies 
 
However the established solution-phase C2-alkylation via Suzuki cross coupling gave a 
less clean reaction on solid phase. This may be attributed to the low solubility of the 
Pd(PPh3)4 catalyst in the reaction solvent thus preventing the reaction from being carried 
out efficiently on solid phase. Hence we proceeded to examine the C2-alkylation using 
Sonogashira coupling. This coupling of terminal alkynes with aryl or vinyl halides was 
performed with a palladium catalyst, a copper (I) co-catalyst, and an amine as base under 
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anhydrous and anaerobic conditions. Resin 2-20b was reacted with different alkynes in 
the presence of [1,2-bis(diphenylphosphino)ethane] dichloro palladium(II), copper(I) 
iodide and DiEA to give 2-alkylated compound 2-24. The target molecule 2-25 was 
finally efficiently cleaved from the solid support with 30% TFA in CH2Cl2. The 

















Scheme 2.9 Mechanism of Sonogashira coupling 
 
Thus an efficient and novel SPS of 6-oxopurine derivatives using Wang resin as solid 
support was developed. The synthetic strategy was designed to load the purine scaffold 
directly onto the solid support. 6-Chloropurine was captured onto Wang resin at C6 
position via an ether linker. After modifications at N9 and C2, the resin was cleaved, 
resulting in 2,9-disubsittued-6-oxopurine derivatives. 
To illustrate the versatility of this chemistry, a small library of C2 and N9 focused 6-
oxopurine derivatives was synthesized. The structures are illustrated in Figure 2.4. The 
overall yields obtained were 24-70% (purities of >95% by NMR), indicating an average 
















































































2-23a   70% 2-23c   40%
2-22a   28% 2-22c   29%
2-22g   32%2-22e   26% 2-25a   33%
2-22d   29%
2-25b   28%
2-22f   24%
2-23b   47% 2-23d   28%
2-22b   24%





2-25d   28%
 
Figure 2.4 Library of 6-oxopurine derivatives 
 
The crystal structures of 2-23a, 2-23b and 2-23d are shown in Figure 2.5, Figure 2.6 and 
Figure 2.7 respectively. 
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Figure 2.5 X ray Crystal Structure of 2-23a 
 
 
Figure 2.6 X ray Crystal Structure of 2-23b 
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Figure 2.7 X ray Crystal Structure of 2-23d 
 
2.3.2.2 Solid-phase bromination and further C8 modification study 
Although bromination of 6-benzyloxy-9-nbutyl-2-morpholin-4-yl-9H-purine 2-13 can be 
carried out in solution, on solid phase, it gave a very complex product mixture upon 

















Scheme 2.10 Bromination of resin 2-21 
 
However we found that bromination of resin bound 9-nbutylpurine 2-20a showed a 
positive result (Scheme 2.11). Treatment of 2-20a with bromine-lutidine complex 
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followed by Sonogashira coupling with 3-methyl-pent-1-yn-3-ol and cleavage yielded 8-




























Scheme 2.11 Bromination of resin 2-20a 
 
The bromination site on the purine ring could be identified from the position of the 
alkyne group introduced during Sonogashira coupling. In order to determine this position 
in 2-26 (R=3-hydroxy-3-methyl-pent-1-ynyl), NOESY experiment was carried out and 
compared with the NOESY spectrum of 2-25a which was obtained via 6-chloro-2-
iodopurine (2-9) on solid phase. The interaction between C8H and N9CH2 was observed 
in the NOESY spectrum of 2-25a (Figure 2.8). No such interaction was observed 
between C2H and N9CH2 in 2-26 which indicates that the alkyne substituent in 2-26 is at 


































Figure 2.9 NOESY spectrum of 2-26 
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2.3.3 Biological evaluation of 2,9-disubstituted-6-oxopurines as MRP4 inhibitor 
2.3.3.1 Effects of 2,9-disubstituted-6-oxopurines on bimane-GS efflux 
MRP4 is able to mediate the transport of conjugated molecules. These include molecules 
conjugated with glucuronate or with glutathione.[10d,11b] It has been reported that cells 
overexpressing MRP4 is able to mediate the efflux of the fluorescent bimane-glutathione 
(bimane-GS) adduct.[10d] Thus we first examined the effects of 2,9-disubstituted-6-
oxopurines on MRP4-mediated bimane-GS efflux. This was carried out using HepG2 
cells stably overexpressing MRP4 (denoted as MRP4/HepG2). Cells stably transfected 
with the empty vector (denoted as V/HepG2) served as the control. Similar to 
observations in an earlier study, MRP4/HepG2 cells were able to facilitate the efflux of 
bimane-GS at a significantly highly rate than that of V/HepG2. 
Of the screened 2,9-disubstituted-6-oxopurines, only 2-16 and 2-25d were able to 
influence the bimane-GS transport ability of MRP4 at 100 μM. The presence of 25 μM of 
2-16 led to significant reduction in MRP4-mediated transport (Table 2.2). The efflux was 
reduced from 7.7 nmol/mg protein to 2.9 nmol/mg protein. Significant inhibition of 
MRP4-mediated transport was also observed in the presence of 25 μM of 2-25d although 
the degree of inhibition was much less than that observed for 2-16. At 25 μM both 2-16 
and 2-25d did not affect efflux from the control V/HepG2 cells. In addition, the effects of 
both compounds were specific to the efflux process as there were no differences in the 
total bimane-GS synthesis between cells that were exposed to 2-16 or 2-25d and those 
that were not. Significant inhibition of MRP4-mediated transport was also observed at 50 
μM of 2-16 and 2-25d but at this concentration, there was also significant reduction in 
the efflux from the control V/HepG2 cells. 
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0 μM (control) 
 
48.2 + 1.1 / 
48.5 + 1.7 
 
14.6 + 0.7 
 
22.3 + 1.0 
 
7.7 + 0.5 
25 μM  
 
50.2 + 3.5 / 
48.3 + 3.4 
 






50 μM  
 
50.0 + 3.7 /  
49.5 + 2.5 
 
11.8 + 1.3a 16.0 + 1.4a 4.3 + 1.3a 
0 μM (control) 
 
50.5 + 2.4 /  
49.2 + 2.8 
 
15.6 + 0.6 23.3 + 0.9 7.7 + 0.4 
25 μM  
 
49.7 + 2.4 /  
50.0 + 3.8 
 








51.0 + 2.0 /  
50.2 + 1.8 
 
13.1 + 1.1a 19.2 + 0.6a 6.1 + 0.7a 
   a) Compared with the corresponding untreated cells, p<0.05, ANOVA analysis. 
 
2.3.3.2 Effects of 2,9-disubstituted-6-oxopurines on 6TG resistance 
Given the fact that MRP4 has the ability to mediate resistance to nucleoside and 
nucleobase analogs, and also to transport the phosphorylated metabolites of 
mercaptopurines,[11, 19] it is highly possible that the expression of MRP4 may play a role 
in the pharmacokinetics of resistance to these therapeutic molecules. Thus one of the 
aims of this study was to examine if it were possible to reverse the MRP4-mediated 
resistance to 6TG. The approach in this study was to use a series of 2,9-disubstituted-6-
oxopurines which are not cytotoxic to the cells. Given the fact that 2-16 and 2-25d were 
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active in inhibiting MRP4 mediated bimane-GS efflux, the effects of these analogs on 
resistance to 6TG were also investigated.  
MRP4/HepG2 cells (M) and V/HepG2 cells (V) were first treated with 0-100 μM of these 
compounds for 48 h to examine the effects on cell proliferation. As shown in Table 2.3, 
the IC50 for each of these compounds was >100 μM. There was no effect on cell growth 
and proliferation when the cells were exposed to 10 μM of compound 2-16 and 25 μM of 
compounds 2-25d for 48 h. Thus these concentrations were used for the next series of 
experiments.  
Table 2.3 Viability of M and V following exposure to 2-16 and 2-25da 
Concentration  0 μM 10 μM 25 μM 50 μM 100 μM 
M 100% 94% ± 1.0% 87% ± 0.5% 77% ± 0.3% 76% ± 0.5% 2-16  
  V 100% 93% ± 0.1% 90% ± 4.6% 78% ± 2.2% 68% ± 3.0%
M 100% ND 96% ± 0.3% 86% ± 0.4% 84% ± 0.9%
2-25d  
V 100% ND 97% ± 2.3% 83% ± 0.8% 77% ± 2.3%
   a) The cells were exposed to compound 2-16 and 2-25d at the concentrations indicated for 48 h. 20 μL 
of MTS reagent was then added and cells were incubated at 37ºC for 1 h. The absorbance at 490 nm 
was measured. Each concentration was carried out in triplicate. Data are expressed as mean ±S.D. from 
three independent experiments. 
 
The IC50 values for 6TG for the MRP4/HepG2 cells were significantly reduced in the 
presence of both compounds as shown in Table 2.4. The concentrations used to achieve 
this reversal of resistance ranged from 10 μM to 25 μM. At these concentrations, the 
compounds had no adverse effects on cell proliferation and viability (Table 2.3). It is also 
obvious that the purine analog inhibitors did not affect the uptake or metabolism of 6TG 
as the IC50 values in the control V/HepG2 cells were not affected by the presence of these 
analogs (Table 2.4). 
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Table 2.4 IC50 for 6TG in the presence of the purine derivatives 
IC50  (μM) 
 1MRP4/HepG2 2V/HepG2 Fold resistance (1/2) 
10 μM 2-16 18.5±0.3a 13.0±1.1 1.4 
25 μM 2-25d 29.4±0.9a 15.3±1.0 1.9 
Control 37.1±3.8 13.9±0.6 2.7 
   a) Compared with the corresponding untreated cells, p<0.05, ANOVA analysis. 
 
MRP4 can confer resistance to nucleoside-based drugs such as 6TG. In the earlier study, 
it was observed that 6TG is capable of inhibiting MRP4-mediated efflux of bimane-
GS[10d]. In this study, two 2,9-disubstituted-6-oxopurines, 2-16 and 2-25d, were found to 
inhibit MRP4-mediated efflux of bimane-GS. This inhibition was solely on the efflux as 
the synthesis of bimane-GS was not affected by the compounds. A comparison of the 
effectiveness of these inhibitors with 6TG revealed that 2-16 was a better inhibitor than 
6TG (Table 2.5).  
Table 2.5 Effects of inhibitors on MRP4-mediated efflux of bimane-GS 
Inhibitor Percent of control (%) 
None 100a 
100 μM 6TG 56±9b 
25 μM 2-16 37±9c 
25 μM 2-25d 70±14c 
                          a) Export in the absence of inhibitor was designated as 100%. b) Data for 6TG was 
previously published by Bai et al., 2004.[10d] c) Compared with export in the absent 
of an inhibitor, p<0.05, ANOVA analysis. 
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2.4 Conclusions  
The strategy for the SPS of 2,9-disubstituted-6-oxopurines was described. Key steps in 
the synthesis include: (i) attachment of the 6-chloropurine scaffold onto the Wang resin, 
(ii) Mitsunobu alkylation at the N9 position, (iii) amination or alkylation at the C2 
position, (iv) bromination and alkylation at the C8 position, and (v) traceless product 
release by debenzylation. Since a variety of reagents can be used in steps (ii), (iii) and 
(iv), the overall strategy appears applicable for library generation. With this strategy a 
small library of 2,9-disubstituted-6-oxopurines was synthesized in good yield and high 
purity. The effects of these compounds on multidrug resistance protein 4 
(MRP4/ABCC4) facilitated efflux was examined. Compounds 2-16 and 2-25d were 
active in inhibiting MRP4 mediated efflux of the bimane-glutathione conjugate. In 
addition, both compounds were also able to reverse MRP4 mediated resistance to the 
anti-cancer drug 6-thioguanine.  
 
2.5 Experimental 
General Procedures. All chemicals were obtained from commercial suppliers and used 
without purification. Column chromatography was performed with silica gel (Merck, 
230-400 mesh). NMR spectra (1H and 13C) were recorded using Bruker DPX300 or 
AMX500, and chemical shifts are expressed in parts per million related to internal TMS. 





2.5.1 Synthesis of 6-(benzyloxy)-9H-purine (2-3) 0 
6-Chloropurine (2-1) (0.46 g, 3.00 mmol) and DABCO (1.85 g, 16.50 mmol) were 
dissolved in DMF (5 mL). The reaction mixture was stirred at room temperature for 3.5 
h. Meanwhile benzyl alcohol was added to a suspension of NaH in anhydrous DMF and 
the reaction was stirred at room temperature for 1 h. The DABCO-purine mixture was 
then added to sodium benzyloxide and the reaction mixture was stirred at room 
temperature for 48 h. After which, the reaction mixture was cooled in an ice water bath 
and neutralized with 5% HCl to pH7. The aqueous layer was extracted with ethyl acetate. 
The combined organic layer was washed with brine, dried with MgSO4 and purified by 
silica gel column chromatography (CH3OH/CH2Cl2=1/19) to give 2-3 as a white solid 
(0.43 g, 94.3%). 1HNMR (CDCl3, 300 Hz) δ(ppm): 5.70 (s, 2H, PhCH2), 7.32-7.55 (m, 
5H, ArH), 8.10 (s, 1H, C8H), 8.61 (s, 1H, C2H). 13CNMR (CD3OD, 300 Hz) δ(ppm): 
68.88, 117.86, 128.49, 128.62, 128.71, 136.74, 143.13, 152.21, 155.81, 159.62. 
HRMS(EI) Calcd for C12H10N4O 226.0855; found 226.0853.     
 
2.5.2 Synthesis of 6-(benzyloxy)-9-butyl-9H-purine (2-4a) 
6-Benzyloxy-9H-purine (2-3) (0.75 g, 3.30 mmol), 1-butanol (0.42 g, 5.61 mmol) and 
PPh3 (1.56 g, 5.95 mmol) were dissolved in THF (20 mL). DiAD (1.00 g, 4.95 mmol) 
was then added dropwise under ice water bath temperature. The reaction was stirred at 
room temperature overnight. The solvent was evaporated and the residue was dissolved in 
ethyl acetate and water. The aqueous layer was extracted with ethyl acetate. The 
combined organic layer was washed with brine, dried over MgSO4 and purified by silica 
gel column chromatography (EtOAc/hexane=1/2) to give 2-4a as a white solid (0.63 g, 
68%). 1HNMR (CDCl3, 300 Hz) δ(ppm): 0.97 (t, J=7.3 Hz, 3H, CH3), 1.31-1.44 (m, 2H, 
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CH2), 1.84-1.94 (m, 2H, CH2), 4.22-4.27 (t, J=7.3 Hz, 2H, N9CH2), 5.68 (s, 2H, PhCH2), 
7.31-7.40 (m, 5H, ArH), 7.90 (s, 1H, C8H), 8.55 (s, 1H, C2H). 13CNMR (CDCl3, 500 Hz) 
δ(ppm): 14.13, 20.51, 32.69, 44.56, 69.02, 122.20, 128.75, 128.98, 129.09, 136.89, 
142.80, 152.56, 153.00, 161.21. HRMS(EI) Calcd for C16H18N4O 282.1481; found 
282.1481.     
 
2.5.3 Synthesis of 9-butyl-1H-purin-6(9H)-one (2-5) 
To solution of 2-4 (88.70 mg, 0.31 mmol) in CH2Cl2 (4 mL) was added TFA (2 mL). The 
reaction was stirred at room temperature for 4 h. The solvent was removed and the 
residue was dissolved in ethyl acetate and NaHCO3 (aq.). The aqueous layer was 
extracted with ethyl acetate and the combined organic layer was washed with brine, dried 
with MgSO4 and purified by silica gel column chromatography (CH3OH/CH2Cl2=1/10) to 
give 2-5 as a white solid (51.30 mg, 85%). 1HNMR (CD3OD, 300 Hz) δ(ppm): 0.97 (t, 
J=7.3 Hz, 3H, CH3), 1.29-1.42 (m, CH2), 1.82-1.92 (m, CH2), 4.25 (t, J=7.1 Hz, 2H, 
N9CH2), 8.03 (s, 1H, C8H), 8.06 (s, 1H, C2H). 13CNMR (CD3OD, 500 Hz) δ(ppm): 
19.19, 26.15, 38.66, 50.36, 130.55, 147.52, 151.84, 155.68, 164.43. HRMS(EI) Calcd for 
C9H12N4O 192.1011; found 192.1012.     
 
2.5.4 Synthesis of 6-chloro-2-iodopurine 
2.5.4.1 6-Chloro-9-(tetrahydropyran-2-yl)-9H-purine (2-6) 
6-Chloro-9H-purine (2-1) (1.86 g, 12.00 mmol), p-toluenesulfonic acid (cat.) and DHP 
were dissolved in CH3CN (40 mL). The mixture was stirred at 55°C overnight. The 
solvent was evaporated and the residue was dissolved in ethyl acetate and ammonium 
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hydroxide. The aqueous layer was extracted with ethyl acetate and the combined organic 
layer was washed with brine, dried with MgSO4 and purified by silica gel column 
chromatography (EtOAc:Hexane = 1:2) to give 2-6 as a white solid (2.53 g, 88%). 
1HNMR (CDCl3, 300 Hz) δ(ppm): 1.65-2.20 (m, 6H, H2’+H3’+H4’), 3.75-3.84 (td, J=2.8 
Hz, J=11.2 Hz, 1H, H5’), 4.17-4.22 (m, 1H, H5’), 5.80 (dd, J=2.4 Hz, J=10.1 Hz, 1H, 
H1’), 8.34 (s, 1H, C8H), 8.76 (s, 1H, C2H). 13CNMR (CDCl3, 300 Hz) δ(ppm): 21.93, 














Figure 2.10 Structure of compound 2-6 
 
2.5.4.2 6-Chloro-9-(tetrahydropyran-2-yl)-2-tributylstannanyl-9H-purine (2-7)   
6-Chloro-9-(tetrahydropyran-2-yl)-9H-purine, 2-6, (2.61 g, 10.93 mmol) in THF (8 mL) 
was added dropwise to a THF solution of LiTMP (54.64 mmol, 5 equiv.) under dry 
nitrogen atmosphere, while maintaining the reaction temperature below -70°C. After 
stirring for 5 min, nBu3SnCl (8.89 g, 27.32 mmol, 2.5 equiv.) was added and stirring was 
continued for an additional 1 h. The reaction was quenched with aqueous NH4Cl. The 
aqueous layer was extracted with ethyl acetate and the combined organic layer was 
washed with brine, dried with MgSO4 and purified by silica gel column chromatography 
(EtOAc:Hexane = 1:5-1:2) to give 2-7 as a pale yellow oil (5.59 g, 97%). 1HNMR 
(CDCl3, 300 Hz) δ(ppm): 0.90 (t, J=7.3 Hz, 9H, 3CH3), 1.18-1.20 (t, J=8.0 Hz, 6H, 
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3SnCH2), 1.23-1.42 (m, 6H, 3CH2CH3), 1.57-1.69 (m, 12H, H2’, 3’, 4’+3CH2Et), 3.78 (td, 
J=3.5 Hz, J=10.8 Hz, 1H, H5’), 4.17-4.21 (m, 1H, H5’), 5.78 (dd, J= 2.8 Hz, J=10.1 Hz , 
1H, H1’), 8.21 (s, 1H, H8). MS(ESI, M+H): 528.9. 
 
2.5.4.3 6-Chloro-2-iodo-9-(tetrahydropyran-2-yl)-9H-purine (2-8)   
A solution of 2-7 (5.59 g, 10.6 mmol) and iodine (3.23 g, 12.72 mmol) in THF (60 mL) 
was stirred at room temperature for 1 h. The reaction mixture was diluted with 5% 
aqueous Na2S2O3. The aqueous layer was extracted with ethyl acetate and the combined 
organic layer was washed with brine, dried with MgSO4 and purified by silica gel column 
chromatography (EtOAc:Hexane = 1:2) to give 2-8 as a pale yellow oil (2.83 g, 73%). 
1HNMR (CDCl3, 300 Hz) δ(ppm): 1.65-2.18 (m, 6H, H2’, 3’, 4’), 3.78 (td, J=3.3 Hz, J=11.1 
Hz, 1H, H5’), 4.16-4.20 (m, 1H, H5’), 5.78 (dd, J=2.8 Hz, J=10.1 Hz, 1H, H1’), 8.24 (s, 
1H, C8H). 13CNMR (CDCl3, 500 Hz) δ(ppm): 151.58, 150.36, 143.01, 131.59, 116.52, 
82.37, 68.88, 32.06, 24.70, 22.47. HRMS(EI) Calcd for C10ClH10IN4O 363.9588; found 
363.9586.    
 
2.5.4.4 6-Chloro-2-iodo-9H-purine (2-9)   
A solution of 2-8 (1.57 g, 4.32 mmol) and TFA (13 mL) in CH2Cl2 (50 mL) was stirred at 
room temperature for 1 h. The volatile material was evaporated on the rotavapor and the 
residue obtained was dissolved in ethyl acetate and saturated aqueous NaHCO3. The 
aqueous layer was extracted with ethyl acetate and the combined organic layer was 
washed with brine, dried with MgSO4 and purified by silica gel column chromatography 
(EtOAc:Hexane = 1:1-2:1) to give 2-9 as a white solid (0.88 g, 73%). 1HNMR (CD3OD, 
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300 Hz) δ(ppm): 8.50 (s, 1H, C8H). 13CNMR (CD3OD, 500 Hz) δ(ppm): 157.81, 149.74, 
148.28, 131.12, 118.24. HRMS(EI) Calcd for C5ClH2IN4 279.9013; found 279.9000.     
 
2.5.5 Synthesis of 6-(benzyloxy)-2-iodo-9H-purine (2-11) 
Compound 2-11 was prepared from 2-9 as described in Section 2.5.1. 1HNMR (DMSO-
d6, 500 Hz) δ(ppm): 5.56 (s, 2H, PhCH2), 7.37-7.55 (m, 5H, ArH), 8.34 (s, 1H, C8H). 
13CNMR (CDCl3, 500 Hz) δ(ppm): 68.09, 116.97, 127.82, 127.91, 128.19, 128.69, 
132.25, 135.18, 142.69, 156.95. HRMS(EI) Calcd for C12H9IN4O 351.9821; found 
351.9820.      
 
2.5.6 Synthesis of 6-(benzyloxy)-9-butyl-2-iodo-9H-purine (2-12) 
Compound 2-12 was prepared from 2-11 as described in Section 2.5.2. 1HNMR (CDCl3, 
500 Hz) δ(ppm): 0.96 (t, 3H, J=7.2 Hz, CH3), 1.31-1.38 (m, 2H, CH2), 1.83-1.89 (m, 2H, 
CH2), 4.19 (t, 2H, J=7.2 Hz, N9CH2), 5.62 (s, 2H, PhCH2), 7.31-7.56 (m, 5H, ArH), 7.78 
(s, 1H, C8H). 13CNMR (CDCl3, 500 Hz) δ(ppm): 13.44, 19.78, 31.89, 43.95, 69.38, 
117.23, 128.44 (x2), 128.93 (x2), 135.55, 141.92, 153.09, 159.25. HRMS(EI) Calcd for 
C16H17ION4 408.0447; found 408.0451.   
 
2.5.7 Synthesis of 6-(benzyloxy)-9-butyl-2-morpholino-9H-purine (2-13) 
A solution of 2-12 (0.1 g, 0.245 mmol), morpholine (0.064g, 0.735 mmol) and 
tripropylamine (0.105 g, 0.733 mmol) in DMF (7 mL) was stirred at 120°C under 
nitrogen for 24 h. After evaporating all the volatile materials, the residue was dissolved in 
CH2Cl2 and water. The aqueous layer was extracted with CH2Cl2. The combined organic 
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layer was washed with brine, dried with MgSO4 and purified by silica gel column 
chromatography (EtOAc:Hexane = 1:1) to give 2-13 as a white solid (0.073 g, 83%). 
1HNMR (CDCl3, 500 Hz) δ(ppm): 0.95 (t, 3H, J=7.4 Hz, CH3), 1.30-1.79 (m, 2H, CH2), 
1.79-1.85 (m, 2H, CH2), 3.76-3.81 (m+m, 4H+4H, 2CH2N+2CH2O), 4.06 (t, 2H, J=7.2 
Hz, N9CH2), 5.56 (s, 2H, PhCH2), 7.29-7.50 (m, 5H, ArH), 7.58 (s, 1H, C8H). 13CNMR 
(CDCl3, 500 Hz) δ(ppm): 13.47, 19.75, 31.79, 43.02, 45.07, 66.84, 67.73, 114.81, 127.83, 
127.99, 128.37, 154.35, 158.50, 160.26. HRMS(EI) Calcd for C20H25N5O2 367.2008; 
found: 367.2009.   
 
2.5.8 Synthesis of 9-butyl-2-morpholino-1H-purin-6(9H)-one (2-14) 
9-Butyl-2-morpholino-1H-purin-6(9H)-one (2-14) was prepared from 2-13 as described 
in Section 2.5.3. 1HNMR (CDCl3, 500 Hz) δ(ppm): 0.95 (t, J=7.3 Hz, 3H, CH3), 1.31-
1.38 (m, 2H, CH2), 1.77-1.83 (m, 2H, CH2), 3.76-3.85 (m+m, 4H+4H, 2CH2N +2CH2O), 
4.01 (t, J=7.3 Hz, 2H, CH2N9), 7.51 (s, 1H, C8H), 11.51 (s, 1H, NH). 13CNMR (CDCl3, 
500 Hz) δ(ppm): 13.47, 19.70, 31.95, 43.07, 45.61, 66.43, 117.09, 138.10, 151.47, 
152.51, 159.29. HRMS(EI) Calcd for C13H19N5O2 277.1539; found:277.1543. 
 
2.5.9 Synthesis of 6-(benzyloxy)-9-butyl-2-(4-methoxyphenyl)-9H-purine (2-15) 
K2CO3 (61.00 mg, 0.44 mmol), Pd(PPh3)4 (17.00 mg, 0.0145 mmol), and 4-
methoxyphenylboric acid (74.00 mg, 0.44 mmol) were added to the solution of 2-12 
(120.00 mg, 0.29 mmol) in DMF. The reaction mixture was stirred in the dark at 100oC 
for 48 h and then evaporated to dryness and chromatographed on a silica gel column 
(EtOAc:Hexane = 1:2) to give 2-15 as a pale yellow solid (107.00 mg, 94%). 1HNMR 
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(CDCl3, 500 Hz) δ(ppm): 0.96 (t, J=7.4 Hz, 3H, CH3), 1.32-1.40 (m, 2H, CH2), 1.85-1.95 
(m, 2H, CH2), 3.86 (s, 3H, OCH3), 4.24 (t, J=7.2 Hz, 2H, N9CH2), 5.77 (s, 2H, PhCH2), 
6.98-8.48 (m, 9H, ArH), 7.83 (s, 1H, C8H). 13CNMR (CDCl3, 500 Hz) δ(ppm): 13.39, 
19.73, 31.90, 43.43, 55.25, 67.92, 113.60, 119.67, 127.87, 128.24, 128.31, 129.68, 
130.75, 136.69, 141.83, 153.34, 158.15, 159.88, 161.30. HRMS(EI) Calcd for 
C23H24N4O2 388.1899; found: 388.1893.   
 
2.5.10 Synthesis of 9-butyl-2-(4-methoxyphenyl)-1H-purin-6(9H)-one (2-16)  
2-16 was prepared from 2-15 using the method described in Section 2.5.3. 1HNMR 
(CDCl3, 500 Hz) δ(ppm): 0.99 (t, J=7.4 Hz, 3H, CH3), 1.01-1.46 (m, 2H, CH2), 1.86-1.96 
(m, 2H, CH2), 3.89 (s, 3H, OCH3), 4.22 (t, J=7.2 Hz, 2H, N9CH2), 7.06-8.27 (m, 4H, 
ArH), 7.77 (s, 1H, C8H) 11.98 (s, 1H, NH). 13CNMR (CDCl3, 500 Hz) δ(ppm): 13.44, 
19.76, 32.18, 43.63, 55.47, 114.46, 122.40, 124.55, 129.34, 139.89, 150.03, 153.13, 
159.18, 162.39. HRMS(EI) Calcd for C16H18N4O2 298.1430; found: 298.1432.   
 
2.5.11 Synthesis of 8-bromo-9-butyl-2-morpholino-1H-purin-6(9H)-one (2-18)  
2.5.11.1 Preparation of Br2-lutidine complex  
Br2 (1.54 mL, 29.26 mmol) was added dropwise to 2,6-lutidine at 0°C in 40 min and the 
reaction mixture was stirred at 0°C for 2 h. Then the precipitate was filtered, washed with 
n-pentane, dissolved in 1,2-dichloroethane (10 mL) and re-precipitated by adding n-




Brominating reagent: Br2-lutidine complex (0.27 g) was added to a mixture of 2,6-
lutidine (0.11 g) and NMP (10 mL).  
 
2.5.12 Synthesis of 6-(benzyloxy)-8-bromo-9-butyl-2-morpholino-9H-purine (2-17) 
from compound 2-13 
To 2-13 (20.00 mg, 0.05 mmol) was added the brominating reagent (10 mL). The reaction 
mixture was stirred at room temperature for 6 h. After which, the reaction mixture was 
dissolved in ethyl acetate and brine. The aqueous layer was extracted with ethyl acetate 
and the combined organic layer was washed with brine, dried with MgSO4 and purified 
by silica gel column chromatography (EtOAc:Hexane = 1:4) to give 2-17  (10.70 mg, 
44%). 1HNMR (CDCl3, 300 Hz) δ(ppm):  0.94 (t, J=7.3 Hz, 3H, CH3), 1.25-1.47 (m, 2H, 
CH2), 1.72-1.82 (m, 2H, CH2), 3.77 (m, 8H, 2CH2N+2CH2O), 4.07 (t, J=7.1 Hz, 2H, 
CH2N9), 5.53 (s, 2H, PhCH2), 7.29-7.49 (m, 5H, ArH). HRMS(EI) Calcd for 
C20H24BrN5O2 445.1113; found: 445.1109, 447.1098.    
 
2.5.13 Synthesis of 8-bromo-9-butyl-2-morpholino-1H-purin-6(9H)-one (2-18) 
A solution of 2-17 (11.00 mg, 0.05 mmol) and TFA (0.5 mL) in CH2Cl2 (2 mL) was 
stirred at room temperature for 4 h. After evaporating all the volatile materials, the 
residue was neutralized with saturated aqueous NaHCO3. The reaction mixture was 
concentrated under reduced pressure and the residue obtained was purified by silica gel 
column chromatography (CH3OH:CH2Cl2 = 1:20) of to give 2-18 as a white solid (6.80 
mg, 80%). 1HNMR (CDCl3, 300 Hz) δ(ppm): 0.96 (t, J=7.2 Hz, 3H, CH3), 1.25-1.38 (m, 
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2H, CH2), 1.70-1.80 (m, 2H, CH2), 3.73-3.84 (m+m, 4H+4H, 2CH2N+2CH2O), 4.02 (t, 
J=7.2 Hz, 2H, CH2N9). HRMS(EI) Calcd for C13H18BrO2N5 355.0644; found: 355.0633.   
 
2.5.14 Preparation of resin bound 2-19 
2-1 or 2-9 (0.39 g, 0.395 mmol) and DABCO (0.86 g, 7.67 mmol) were dissolved in 
DMF (10 mL). The reaction mixture was stirred rapidly at room temperature for 4 h. A 
suspension of Wang resin (1.15 mmol/g, 0.60 g) in DMF was treated with 5 equiv. of 
sodium hydride at room temperature for 4 h. The DABCO-purine mixture was then added 
and the suspension was shaken at room temperature for 48 h. The resin was filtered, 
washed successively with DMF, H2O, EtOH, CH2Cl2 and Et2O and dried in a vacuum 
oven at 40°C. 
 
2.5.15 General procedure for the N9 Mitsunobu alkylation of resin bound purine (2-
20) 
Resin 2-19 was swollen in THF at room temperature for 30 min. Alcohol (1.5 equiv.) and 
PPh3 (1.7 equiv.) were added and then DiAD (1.8 equiv.) was added dropwise under ice 
water bath temperature. The mixture was allowed to shake at room temperature 
overnight. The resin was then filtered, washed successively with THF, EtOH, CH2Cl2 and 
Et2O and dried in a vacuum oven at 40°C. 
 
2.5.16 General procedure for the C2 amination of resin bound purine (2-21) 
Resin 2-20b was swollen in DMA at room temperature for 30 min. The respective amine 
(10 equiv.) and tripropylamine (3 equiv.) were added and the mixture was then stirred 
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slowly at 80°C under nitrogen for 24 h, filtered, washed successively with DMF, H2O, 
EtOH, CH2Cl2 and Et2O and dried in. 
 
2.5.17 General procedure for the C2-C bond formation via Sonogashira coupling of resin 
bound purine (2-24) 
Resin 2-20b was swollen in DMA at room temperature for 30 min. To the suspension was 
added dichloro(1,2-bis(diphenylphosphino)ethane)-palladium(II) (1.1 equiv.), DiEA (30 
equiv.), CuI (2.2 equiv.) and alkyne (20 equiv.). The mixture was stirred slowly at 100°C 
in the dark for 48 h and then filtered. The resin was washed successively with DMF, H2O, 
EtOH, CH2Cl2 and Et2O and dried in a vacuum oven at 40°C. 
 
2.5.18 Bromination of resin bound 9-nbutyl-purine (2-20a) 
Loaded resin 2-20a was swollen in NMP for 30 min. Then brominating reagent (prepared 
as described in Section 2.5.11.1) (10 mL) was added and the mixture was shaken at room 
temperature in the dark for 7 h. Then the solution was drained. This process was repeated 
for 4 times and the resin was washed with DMF, H2O, EtOH, CH2Cl2 and Et2O and dried 
in a vacuum oven at 40°C. 
 
2.5.19 General procedure for the cleavage of resin bound purine 
A suspension of resin in 30% TFA/CH2Cl2 was shaken at room temperature for 5 h. The 
resin was removed by filtration and washed with MeOH and CH2Cl2. The filtrate and 
washings were combined and neutralized with saturated aqueous NaHCO3. The mixture 
was then concentrated under reduced pressure and the residue obtained was purified by 
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1HNMR (CDCl3, 500 Hz) δ(ppm): 0.95 (t, J=7.3 Hz, 3H, CH3), 1.31-1.38 (m, 2H, CH2), 
1.77-1.83 (m, 2H, CH2), 3.76-3.85 (m+m, 4H+4H, 2CH2N+2CH2O), 4.01 (t, J=7.2 Hz, 
2H, CH2N9), 7.51 (s, 1H, C8H), 11.51 (s, 1H, NH). 13CNMR (CDCl3, 500 Hz) δ(ppm): 
13.47, 19.70, 31.95, 43.07, 45.61, 66.43, 117.09, 138.10, 151.47, 152.51, 159.29. 
HRMS(EI) Calcd for C13H19N5O2 277.1539; found: 277.1543. 
 
2-22b: 9-Isopropyl-2-morpholino-1H-purin-6(9H)-one 
1HNMR (CDCl3, 300 Hz) δ(ppm): 1.53 (d, J=7.0 Hz, 6H, 2CH3), 3.43-3.82 (m+m, 
4H+4H, 2CH2N+2CH2O), 4.57-4.66 (m, 1H, CHN9), 7.60 (s, 1H, C8H). 13CNMR 
(CDCl3, 300 Hz) δ(ppm): 22.50, 45.58, 46.71, 66.38, 115.48, 135.77, 152.32, 159.39. 
HRMS(EI) Calcd for C12H17N5O2 263.1382; found: 263.1361.    
 
2-22c: 9-Benzyl-2-morpholino-1H-purin-6(9H)-one 
1HNMR (CDCl3, 300 Hz) δ(ppm): 3.78-3.79 (m+m, 4H+4H, 2CH2N+2CH2O), 5.19 (s, 
2H, PhCH2), 7.33-7.56 (m, 5H, ArH), 7.56 (s, 1H, C8H). 13CNMR (CDCl3, 300 Hz) 
δ(ppm): 45.55, 46.98, 66.34, 116.42, 127.72, 128.28, 128.95, 132.97, 135.74, 137.98, 





1HNMR (CD3OD, 300 Hz) δ(ppm): 0.99 (t, J=7.3 Hz, 3H, CH3), 1.31-1.43 (m, 2H, 
CH3CH2), 1.79-1.96 (m, 8H, CH3CH2CH2+H3’+H4’+H5’), 3.57 (t, J=5.4 Hz, 2H, CH2N1’), 
3.75 (t, J=5.4 Hz, 3H, CH2NHC2), 4.07 (t, J=7.2 Hz, 2H, N9CH2), 7.75 (s, 1H, C8H). 
13CNMR (CD3OD, 300 Hz) δ(ppm): 13.89, 20.86, 22.96, 24.06, 32.89, 36.85, 44.53, 
54.12, 55.97, 117.43, 139.45, 151.99, 153.47, 158.86. HRMS(ESI, M+H) Calcd for 
C16H27N6O 319.2246; found 319.2254. 
 
2-22e: 9-Benzyl-2-(2-(piperidin-1-yl)ethylamino)-1H-purin-6(9H)-one 
1HNMR (CD3OD, 300 Hz) δ(ppm): 1.62 (m, 2H, H4’), 1.80-1.84 (m, 4H, H3’+H 5’), 3.30-
3.32 (m, 2H, NHCH2), 3.35-3.36 (m, 4H, H2’+H6’), 3.69 (t, J=5.8 Hz, 2H, N1’CH2), 5.27 
(s, 2H, PhCH2), 7.29-7.34 (m, 5H, ArH), 7.81 (s, 1H, C8H). 13CNMR (CD3OD, 300 Hz) 
δ(ppm): 23.37, 24.50, 24.58, 54.57, 56.76, 117.41, 128.81, 129.17, 129.94, 137.76, 





















1HNMR (CDCl3, 300 Hz) δ(ppm): 0.94-1.03 (m, 6H, 2CH3), 1.38-1.52 (m, 4H, 
2CH3CH2), 1.61-1.70 (m, 2H, CH2CH2NH), 1.91-2.01 (m, 2H, CH2CH2N9), 3.40-3.47 
(m, 2H, CH2NH), 4.22 (t, J=7.2 Hz, 2H, CH2N9), 7.74 (s, 1H, C8H), 10.29, 13.08 (s+s, 
2H, 2NH). 13CNMR (CD3OD, 300 Hz) δ(ppm): 13.34, 13.73, 19.57, 20.04, 30.96 (x2), 
41.09, 45.28, 119.33, 133.05, 138.62, 150.61, 154.89. HRMS(EI) Calcd for C13H21N5O 
263.1746; found 263.1743. 
 
2-22g: 9-Benzyl-2-(butylamino)-1H-purin-6(9H)-one 
1HNMR (DMSO-d6, 300 Hz) δ(ppm): 0.89 (t, J=7.3 Hz, 3H, CH3), 1.28-1.38 (m, 2H, 
CH2), 1.44-1.54 (m, 2H, CH2), 3.24-3.32 (m, 2H, NHCH2), 5.16 (s, 2H, PhCH2), 7.33-
7.34 (m, 5H, ArH), 7.79 (s, 1H, C8H). 13CNMR (CDCl3, 500 Hz) δ(ppm): 13.16, 18.98, 
30.38, 38.16, 45.52, 115.89, 127.17, 127.32, 128.05, 136.66, 136.73, 150.40, 152.27, 
156.52. HRMS(EI) Calcd for C16H19N5O 297.1590; found: 297.1591.    
 
2-23a: 9-Butyl-1H-purin-6(9H)-one  
1HNMR (CD3OD, 300 Hz) δ(ppm): 0.97 (t, J=7.3 Hz, 3H, CH3), 1.29-1.42 (m, CH2), 
1.82-1.92 (m, 2H, CH2), 4.25 (t, J=7.2 Hz, 2H, CH2N9), 8.03 (s, 1H, C8H), 8.06 (s, 1H, 
C2H). 13CNMR (CD3OD, 500 Hz) δ(ppm): 19.19, 26.15, 38.66, 50.36, 130.55, 147.52, 






1HNMR (CD3OD, 300 Hz) δ(ppm): 1.61 (d, J=6.6 Hz, 6H, CH3+CH3), 8.03 (s, 1H, 
C8H), 8.15 (s, 1H, C2H). 13CNMR (CD3OD, 300 Hz) δ(ppm): 21.87, 124.64, 139.05, 
145.32, 148.95, 158.25. HRMS(EI) Calcd for C8H10N4O 178.0855; found 178.0855.     
 
2-23c: 9-Butyl-2-iodo-1H-purin-6(9H)-one 
1HNMR (CD3OD, 300 Hz) δ(ppm): 0.98 (t, J=7.2 Hz, 3H, CH3), 1.29-1.43 (m, 2H, 
CH2CH3), 1.82-1.90 (m, 2H, CH2CH2N9), 4.24 (t, J=7.2 Hz, 2H, CH2N9), 8.33 (s, 1H, 
C8H). 13CNMR (CD3OD, 500 Hz) δ(ppm): 13.74, 20.67, 32.98, 45.59, 108.88, 122.73, 
141.39, 149.75, 157.85. HRMS(EI) Calcd for C9H11IN4O 317.9978; found: 317.9981.   
 
2-23d: 2-Iodo-9-isopropyl-1H-purin-6(9H)-one 
1HNMR (CD3OD, 500 Hz) δ(ppm): 1.59 (d, J=6.47 Hz, 6H, 2CH3), 4.75-4.79 (m, 1H, 
CH), 8.08 (s, 1H, C8H). 13CNMR (CDCl3, 500 Hz) δ(ppm): 22.69, 48.82, 106.92, 124.95, 
139.55, 149.66, 159.07. HRMS(ESI, M+H) Calcd for C8H10IN4O 304.9899; found: 
304.9893.    
 
2-25a: 9-Butyl-2-(3-hydroxy-3-methylpent-1-ynyl)-1H-purin-6(9H)-one 
1HNMR (CD3OD, 300 Hz) δ(ppm): 0.94 (t, 3H, J=7.3 Hz, CH3CH2CH2), 1.08 (t, J=7.5 
Hz, 3H, CH2CH3C), 1.11-1.37 (m, 2H, CH3CH2CH2), 1.54 (s, 3H, CCH3), 1.76-1.88 (m, 
4H, CH3CH2C+NCH2CH2), 4.20 (t, J=7.3 Hz, 3H, N9CH2), 8.09 (s, 1H, C8H). 13CNMR 
(CD3OD, 300 Hz) δ(ppm): 9.15, 13.81, 20.72, 28.72, 33.23, 37.03, 44.98, 69.29, 76.81, 
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97.63, 125.16, 139.76, 142.79, 149.86, 158.80. HRMS(ESI, M+H) Calcd for C15H21N4O2 
289.1665; found 289.1661. 
 
2-25b: 9-Benzyl-2-(3-hydroxy-3-methylpent-1-ynyl)-1H-purin-6(9H)-one 
1HNMR (CD3OD, 300 Hz) δ(ppm): 1.09 (t, J=7.3 Hz, 3H, CH3CH2C), 1.54 (s, 3H, 
CH3C), 1.76-1.86 (m, 2H, CH3CH2C), 5.39 (s, 2H, N9CH2), 7.28-7.34 (m, 5H, ArH), 8.11 
(s, 1H, C8H). 13CNMR (CD3OD, 300 Hz) δ(ppm): 9.13, 28.70, 37.04, 69.32, 76.85, 
97.75, 125.19, 128.77 (x2), 129.32, 129.99 (x2), 137.33, 140.11, 142.72, 158.86. 
HRMS(ESI, M+H) Calcd for C18H18N4NaO2 345.1327; found 345.1322.     
 
2-25c: 9-Benzyl-2-(hept-1-ynyl)-1H-purin-6(9H)-one 
1HNMR (CDCl3, 300 Hz) δ(ppm): 0.89 (t, J=7.2 Hz, 3H, CH3), 1.25-1.66 (m, 6H, 3CH2), 
2.42 (t, J=7.2 Hz, 2H, CCH2), 5.59 (s, 2H, N9CH2), 7.36 (s, 5H, ArH), 8.10 (s, 1H, C8H). 
13C NMR (CD3OD) δ 13.87, 19.16, 22.09, 27.45, 31.03, 50.95, 74.19, 94.98, 128.12, 
128.18, 128.74(×2), 129.15(×2), 135.27, 138.14, 154.81. HRMS(EI) Calcd for 
C19H20N4O 320.1637; found 320.1633.    
 
2-25d: 9-Butyl-2-(hept-1-ynyl)-1H-purin-6(9H)-one  
1H NMR (CD3OD) δ 0.87-0.98(m, 6H, 2CH3), 1.28-1.38 (m, 6H, 3CH2), 1.60-1.71 (m, 
4H, 2CH2), 1.82-1.92 (m, 6H, 3CH2), 2.49 (t, J=7.1 Hz, 2H, CCH2), 4.39 (t, J=7.3 Hz, 
2H, N9CH2), 8.17 (s, 1H, C8H). 13C NMR (CD3OD) δ 13.84, 14.24, 19.72, 20.51, 23.22, 
28.67, 30.74, 32.19, 34.41, 74.98, 95.41, 116.64, 130.69, 140.27, 145.67, 156.21. 




1HNMR (CD3OD, 300 Hz) δ(ppm): 0.97 (t, J=7.3 Hz, 3H, CH3CH2CH2), 1.12 (t, J=7.5 
Hz, 3H, CH3CH2C), 1.34-1.41 (m, CH3CH2CH2), 1.57 (s, 3H, CCH3), 1.78-1.89 (m, 4H, 
CH3CH2C+NCH2CH2), 4.29 (t, J=7.3 Hz, 3H, N9CH2), 8.06 (s, 1H, C8H). 13CNMR 
(CD3OD, 300 Hz) δ(ppm): 9.33, 13.95, 20.83, 28.99, 32.89, 37.16, 44.97, 69.48, 101.56, 
124.99, 131.50, 132.26, 135.46, 147.27, 158.35. HRMS(EI, M+) Calcd for C15H20N4O2 
288.1586; found 288.1586. 
 
2.5.20 Biological evaluation of 2,9-disubstituted-6-oxopurines as MRP4 inhibitor 
2.5.20.1 Cell lines and culture conditions 
HepG2 cells stably expressing the human MRP4 protein were previously described [20]. 
The MRP4 clone used in this study was MRP4/HepG2. The blasticidine clone, V/HepG2 
which was transfected with the pcDNA6 vector was included as the control. Cells were 
routinely grown in complete medium consisting of Dulbecco’s Modified Eagle Medium 
(DMEM), 1 mM sodium pyruvate, 2 mM glutamine, 0.1 mM non-essential amino acids, 
100 units/mL penicillin, 100 μg/mL streptomycin, 10% fetal bovine serum and 0.25 
μg/mL blasticidin. The cells were grown at 37oC in a humidified atmosphere of 95% air 
and 5% CO2. 
 
2.5.20.2 Bimane-glutathione efflux  
The measurement of bimane-GS synthesis and efflux from MRP4/HepG2 and V/HepG2 
cells was carried out as previously described.[10d] In brief, cells were seeded in triplicate 
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at a density of 6 x 105 cells per well into 6-well plates and incubated at 37ºC for 24 h. The 
cells were then incubated with 1 mL DMEM medium containing 100 μM 
monochlorobimane (MCB) at 10oC for 60 min with different concentrations of the purine 
derivatives. Controls consist of cells incubated with DMSO, which was used to dissolve 
the compounds. After pretreatment with MCB, the plates were placed on ice, the medium 
was removed and the cells were washed with cold Hank’s balanced salt solution (HBSS), 
without glucose twice. The cells were then incubated with 0.6 mL HBSS containing 5.6 
mM glucose and different concentrations of synthesized compounds at 37oC for 5 min. 
0.2 mL of the incubation buffer and 0.2 mL of the cell lysate (in 0.2% sodium dodecyl 
sulfate, SDS) were collected. The bimane-GS content in the sample was measured by 
determining the fluorescence intensity at an excitation wavelength of 385 nm and an 
emission wavelength of 478 nm in a Gemini XS microplate spectrofluorometer from 
Molecular Devices Corp, USA. A series of bimane-GS standards was used to generate a 
calibration curve for quantifying the amount of bimane-GS. The protein determination 
was carried out using the Bio-Rad Protein Dye with bovine serum albumin dissolved in 
0.2% SDS as the standard. 
 
2.5.20.3 Effects of the purine derivatives on 6TG resistance 
Cells were plated in triplicate at the density of 4 x 103 per well in 96-well tissue culture 
plate. After 24 h of incubation at 37ºC, the cells were treated with 6TG or the purine 
derivative or both. Control cells were incubated either with medium containing 0.1% 
DMSO or in medium only. 48 h later, 20 μL of 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium /phenazine ethosulfate 
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(MTS/PES) reagent (Promega) was added to each well. After incubation at 37ºC for 60 
min, absorbance was measured at 490 nm. The data were used to calculate the 50% 
growth inhibitory concentration (IC50). At least five 6TG concentrations were used to 
determine the IC50 value. 
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CHAPTER 3: Traceless Solid-phase Synthesis of 1,7-Disubstituted 
Purines 
 




























Figure 3.1  
 
Although N9-substituted purines are the natural nucleosides, in recent years, there has 
been much interest in the N7 regioisomers as these isomers have found applications as 
antiviral agents.[1] N7 guanines are also important DNA adducts formed as a result of 
exposure to electrophiles.[2] Consequently, N7-alkylguanines are the main types of DNA 
adducts excreted in urine and are therefore important markers for the development of 
diagnostic methods to detect and quantitate specific types of DNA damages.[3] Studies of 
1,7-disubstituted guanines have shown that they are capable of inhibiting telomerase 
activity and possess the ability to enhance the efficacy of other chemotherapeutic agents 
in the treatment of cancer.[2] Earlier studies have shown that under kinetic control, 
alkylation of purines gives predominantly the N9 isomer.[4] Hence selective N7 alkylation 
of purine is important for achieving high regioselectivity.[5] Some strategies in the 
literature were known to achieve regioselective N7 alkylation in solution phase.[1,6] 
 78
However, to our knowledge there has been no prior reports on the solid-phase selective 
N7 alkylation.  
 
3.2 Outline of our strategy  
We herein describe a traceless solid-phase route for the synthesis of 1,7-disubstituted 
purines. The linkage strategy involves the use of the REM resin which has been widely 
used in the synthesis of tertiary amines.[7] It generally involves 1) coupling the starting 
secondary amine to REM linker via Michael addition; 2) further alkylation of  the 
attached amine; 3) quaternization of the resultant amine and 4) Hofmann elimination to 


























Scheme 3.1 REM resin cycle 
 
Our synthetic route was designed such that the linker was anchored at the N9 position of 
the purine scaffold, leaving the N7 position as the steric priority to be alkylated to form a 






















X= I orBr  
Scheme 3.2 Overall strategy 
 
3.3 Results and discussions 
3.3.1 Solution-phase synthesis study 
Prior to the solid-phase synthesis, preliminary solution-phase studies were carried out to 
survey the requisite reaction conditions and establish the modifications required for solid-





































































Scheme 3.3 Solution-phase study 
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3.3.1.1 Synthesis of benzyl acrylate (3-1): 
In the first step, benzyl acrylate (3-1) was chosen to mimic the structure of the REM 
resin. 3-1 was easily synthesized according to the standard procedure for the preparation 
of REM resin from the Wang resin.[7] 
 
3.3.1.2 Synthesis of benzyl 3-(6-chloro-9H-purin-9-yl)propanoate (3-2)  
Treatment of 3-1 with 6-chloropurine, in the presence of base, yielded 3-2 via Michael 
addition. Table 3.1 shows the various reaction conditions examined for this reaction.  
Table 3.1 Synthesis of compound 3-2 
 Reaction condition  Yield of 3-2 (%) 
1 No base/DMF - 
2 LiH/DMF - 
3 NaOCH3/DMF, rt -a 
4 K2CO3/DMF, rt <10 
5 K2CO3/DMF/18-crown-6 60 
6 DiEA/DMF, rt 74 
7 DiEA/DMF, 70°C 60b 
                  a) 3-(6-chloro-purin-9-yl)-propionic acid was obtained.  b) N7 alkylated regioisomer was also 
observed. 
 
LiH gave no product at either room temperature or elevated temperatures, whilst 
NaOCH3 gave 3-(6-chloro-purin-9-yl)-propionic acid, the ester hydrolysis product. The 
results of Entry 2 and 3 indicated both LiH and NaOCH3 are too strong bases for this 
Michael addition. Thus weaker bases should be inspected. Although reaction with 
K2CO3/DMF gave very low yield (<10%), it provided 3-2 in 60% yield when 18-crown-6 
was applied as a phase transfer catalyst (Entry 5). Therefore K2CO3/DMF/18-crown-6 
was satisfactory for solution-phase synthesis. However, it may not be an appropriate 
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system for the solid-phase synthesis because K2CO3 is only sparingly soluble in DMF. 
Since our aim is to develop a procedure for solid-phase synthesis, it is necessary to 
choose a base that would dissolve well in a solvent which as good resin swelling effect. 
Further investigation provided DiEA/DMF which gave 3-2 in 74% yield when the 
reaction was carried out at room temperature (Entry 6). However, the yields were lower 
at higher temperatures and the N7 alkylated regioisomer was observed at temperatures 
above 70oC (Entry 7). These results suggest that DiEA/DMF/room temperature is the best 
reaction condition for solid-phase synthesis. 
 
3.3.1.3 Synthesis of benzyl 3-(6-oxo-1,6-dihydropurin-9-yl)propanoate (3-3a) 
We next examined the hydrolysis of 3-2. Hydrolysis of chloride to hydroxyl group can be 
carried out under both basic and acidic condition. Since compound 3-2 contains an ester 
bond, acidic condition was chosen. Both TFA and formic acid were examined. When 
50% TFA (aq.) was used, the reaction was completed after stirring at room temperature 
for 24 h and 3-3a was obtained in 30% yield. This low yield may be due to the partial 
hydrolysis of the ester bond since TFA is a strong acid. When 85% formic acid (aq.) was 
used, the reaction was completed after reflux 3 h and 3-3a was obtained in 96% yield. 
The IR spectrum of 3-3a showed C=O stretch at 1724 cm-1 and 1692 cm-1 which could be 






























Scheme 3.4 Hydrolysis of compound 3-2 with formic acid 
 
The synthesis of benzyl 3-(6-thioxo-1,6-dihydropurin-9-yl)propanoate 3-3b was also 
studied. 3-2 reacted readily with thiourea in ethanol to give 3-3b as a pale yellow solid in 
85% yield.  
 
3.3.1.4 Synthesis of benzyl 3-(1-butyl-6-oxo-1,6-dihydropurin-9-yl)propanoate (3-4) 
N1-alkylation of 3-3a was examined with butyl bromide as the alkylation reagent. The 
reaction could be carried out with either DBU/DMF at room temperature or K2CO3/DMF 
at 90oC to provide 3-4 in over 90% yields. The structure of 3-4 was confirmed by 
NOESY experiments which clearly showed the CH2N1/HC2 interaction (Figure 3.2).  
However, when NaOEt was used as base, product 3-4 was isolated in only 37% yield. A 
side product 3-4a isolated during N1 alkylation gives NMR and MS data which are 
similar to compound 3-4. However the NOESY spectrum of compound 3-4a shows no 
CH2N1/HC2 interaction which suggests that the side product 3-4a could be the O-





































Figure 3.3 NOESY spectrum of compound 3-4a 
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Analogous alkylation of compound 3-3b gave only one product. NOESY experiment of 














Figure 3.4 NOESY spectrum of compound 3-4b 
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3.3.1.5 Synthesis of 3-(1,7-dibutyl-6-oxo-1,6-dihydro-purin-9-yl)-propionic acid 
phenyl ester salt (3-5) 
We next proceeded to N7 alkylation to form a quaternary salt. A number of 
quaternization conditions were experimented (Table 3.2) and nBuI/ 70oC / 18 h provided 
the most favorable condition. Since the quaternization process occurred rather slowly, a 
large excess (20 equiv.) of the alkylation reagent was used to ensure complete conversion 
to 3-5.  
Table 3.2 Solution-phase synthesis of compound 3-5 
 Reaction conditiona Yield of compound 3-5(%) 
1 nBuBr, 50°C, 48 h 52 
2 nBuBr, NaI, 50°C, 24 h 71 
3 nBuI, 50°C, 18 h 73 
4 nBuI, 70°C, 18 h 100 
          a) Equivalence of alkylating reagents was 20 equiv.. 
 
When 1-bromobutane was used as an alkylating reagent and the reaction mixture was 
heated at 50°C, only partial quaternization was observed even after 2 days. TLC showed 
the existence of starting material and the quaternary salt was isolated in 52% yield. 
Addition of NaI as a catalyst shortened the reaction time to 24 h, enabled complete 
consumption of the starting material and provided the quaternized product in 71% yield 
(Entry 2). Quaternization with 1-iodobutane gave similar results except for a shorter 
reaction time (18 h). However when the reaction temperature was raised to 70°C, 
quaternization of 3-4 with 1-iodobutane proceeded smoothly to give 3-5 in quantitative 
yield (Entry 4).  
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Quaternization resulted in a purinium salt with an electron-deficient imidazole ring. 
Consequently, the chemical shift of C8H was shifted to a lower field at 10.63 ppm 
(compared to the chemical shift of C8H before quaternizaiton which was at 7.78 ppm).   
 
3.3.1.6 Synthesis of 1,7-dibutyl-1,7-dihydro-purin-6-one (3-6a) 
Subsequent treatment of 3-5 with TEA or DiEA was expected to give the final product 3-
6a via Hoffmann elimination. However the yields obtained were very low (<20%) and 
the major product isolated was the imidazolium ring-opened compound 3-7 which was 
characterized using NMR and MS. The proposed mechanism for the formation of 3-7 is 



































Scheme 3.5 Formation of side product 3-7 in solution-phase cleavage step 
 
The formation of 3-7 may be attributed to the electron-deficient C8 which causes the 
imidazolium structure to be unstable even under mild basic conditions.[8] To effect the 
formation of 3-6a, ammonia in methanol, a milder base, was chosen and upon stirring for 
12 h, compound 3-6a was obtained in 72% yield. The mechanism for the Hoffmann 
























Scheme 3.6 Hoffmann elimination of compound 3-5 
 
Thus a solution-phase study oriented to solid-phase synthesis was successfully 
established. All the intermediates and final compound were obtained in good yield and 
high purity. 
 





























































Scheme 3.7 Solid-phase study 
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With the solution-phase synthetic pathway well established, the solid-phase synthesis was 
evaluated. As outlined in Scheme 3.7, REM resin 3-8 was developed by treating the 
Wang resin with acryloyl chloride in the presence of DiEA. The formation of 3-8 was 
amenable to KBr FTIR monitoring (i.e. appearance of carbonyl stretch at 1724 cm-1). 3-8 
was then reacted with 6-chloropurine to give 3-9 which was subsequently hydrolyzed 
with formic acid/H2O/DMF. Compared with the solution-phase reaction condition, DMF 
was added as a co-solvent in this hydrolysis step to facilitate resin swelling. This is 
because in the solution-phase hydrolysis, compound 3-2 easily dissolved in 85% aqueous 
formic acid and therefore the reaction mixture is homogeneous. However solid-phase 
hydrolysis is a heterogeneous reaction and resin swellability is important. In this case 
DMF not only gave good swelling of the Wang resin but was also inert to the hydrolysis 
reaction. The resin-bound hydrolyzed intermediate 3-10 was subsequently alkylated at the 
N1 position under basic condition followed by quaternization at N7 with different alkyl 
halides. When a bromide was used, the addition of sodium iodide as catalyst to the 
quaternization mixture improved the efficiency of the solid-phase alkylation. Our study 
also showed that lowering the temperature from 70oC to 60oC during quaternization gave 
less side products upon cleavage. The final product 3-6 was finally released from the 
resin by an overnight treatment with 2 M ammonia in methanol.  
 
To illustrate the general applicability of this synthetic procedure, a small library of 15 
compounds (3-6a ~3-6o) was prepared on solid-phase (Figure 3.5). The overall yields 
obtained were 13-27% (purities of >95% by NMR), indicating an average yield of at least 














































3-6a  18% 3-6b 17% 3-6c  15%
3-6d  20% 3-6e 19% 3-6f  18%
3-6g  14% 3-6h 16% 3-6i  18%
3-6j  13% 3-6k  13% 3-6l   27%













































Figure 3.6 X-ray crystal structure of 3-6f 
 
Figure 3.6 depicts the X-ray crystal structure and defines the atomic numbering of 
compound 3-6f. It gives direct evidence that regioselective alkylation had occurred at the 
N7 position rather than the N9 position.  
 
3.4 Conclusion 
In summary, a novel and facile solid-phase synthetic procedure has been developed for 
the synthesis of N1, N7-disubstituted-purine using REM resin. Key steps in the synthetic 
strategy involve (i) coupling of 6-chloropurine to the REM resin (Michael addition), (ii) 
hydrolysis, (iii) N1-alkylation, (iv) quaternization and (v) product release through 
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Hofmann elimination. This study gave the first example of a highly regioselective solid-
phase synthesis of 1, 7-disubstituted purine derivatives. Using this method a library of 
1,7-disubstituted-6-oxopurine was successfully synthesized. 
 
3.5 Experimental 
General Procedures.  1HNMR and 13CNMR spectra were measured at 298K on a Bruker 
DPX 300 Fourier Transform spectrometer. Chemical shifts were reported in δ (ppm), 
relative to the internal standard of tetramethylsilane (TMS). All Infra-red (IR) spectra 
were recorded on a Bio-Rad FTS 165 spectrometer. Mass spectra were performed on VG 
Micromass 7035 spectrometer under electron impact (EI). All chemical reagents were 
obtained from commercial suppliers and used without further purification. Analytical 
TLC was carried out on pre-coated plates (Merck silica gel 60, F254) and visualized with 
UV light. Flash column chromatography was performed with silica (Merck, 70-230 
mesh). 
 
3.5.1 Synthesis of benzyl acrylate (3-1) 
DiEA (4.79 g, 37.04 mmol) and acryloyl chloride (3.35 g, 37.04 mmol) were added to a 
solution of benzyl alcohol (0.50 g, 4.63 mmol) in CH2Cl2 (30 mL). The reaction mixture 
was stirred at room temperature for 4 h and then concentrated to dryness. The brown 
solid obtained was dissolved in EtOAc and water. The aqueous layer was extracted with 
EtOAc and the combined organic layer obtained was washed with brine, dried with 
MgSO4, concentrated to dryness and purified by column chromatography (EtOAc:hexane 
= 1:2). 3-1 was obtained as a colorless oil (0.69 g, 92%). 1HNMR (CDCl3): δ(ppm) 5.17 
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(s, 2H, PhCH2), 5.79 (dd, J=1.2 Hz, J=10.4 Hz, 1H, CHCH2), 6.14 (dd, J=10.5 Hz, 
J=17.3 Hz, 1H, CH), 6.42 (dd, J=1.2 Hz, J=17.3 Hz, 1H, CHCH2), 7.27-7.35 (m, 5H, 
ArH). 13CNMR (CDCl3): δ(ppm) 66.08, 128.04 (x2), 128.15, 128.37, 130.81, 135.75, 
165.72. HRMS(EI): Calcd for C10H10O2 162.0681; found: 162.0680. 
 
3.5.2 Synthesis of benzyl 3-(6-chloro-9H-purin-9-yl)propanoate (3-2) 
Compound 3-1 (0.16 g, 1.0 mmol) and DiEA (0.14 g, 1.1 mmol) were added to a solution 
of 6-chloropurine (0.17 g, 1.1 mmol) in DMF (2 mL). The reaction mixture was stirred at 
room temperature for 48 h and then extracted with EtOAc and water. The combined 
organic layer was washed with brine, dried with MgSO4, concentrated to dryness and 
purified by column chromatography (EtOAc:hexane = 1:2) to give 3-2 as a white solid 
(0.26 g, 74%). 1HNMR (CDCl3): δ(ppm) 3.03 (t, J=6.0 Hz, 2H, N9CH2CH2), 4.60 (t, 2H, 
J=6.2 Hz, N9CH2), 5.10 (s, 2H, PhCH2), 7.24-7.36 (m, 5H, ArH), 8.21 (s, 1H, C8H), 8.71 
(s, 1H, C2H). 13CNMR (CDCl3): δ(ppm) 33.69, 39.89, 67.01, 128.28, 128.53 (x2), 
131.52, 134.90, 145.90, 150.89, 151.56, 151.76, 170.30. HRMS(EI): Calcd for 
C15H13ClN4O2 316.0727; found: 316.0723. 
 
3.5.3 Synthesis of benzyl 3-(6-oxo-1,6-dihydropurin-9-yl)propanoate (3-3a) 
Compound 3-2 (0.44 g, 1.4 mmol) was dissolved in 80% formic acid (13 mL) and the 
reaction mixture was stirred at 70oC for 3 h and then evaporated to dryness. The white 
solid obtained was extracted with EtOAc and water. The combined organic layer was 
washed with brine, dried with MgSO4, concentrated to dryness and purified by column 
chromatography (MeOH:CH2Cl2 = 1:8) to provide 3-3a as a white solid (0.40 g, 96%). 
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1HNMR (DMSO-d6): δ(ppm) 3.02 (t, J=6.8 Hz, 2H, N9CH2CH2), 4.40 (t, J=6.8 Hz, 2H, 
N9CH2), 5.07 (s, 2H, PhCH2), 7.26-7.35 (m, 5H, ArH), 8.02 (s, 1H, C8H), 8.04 (s, 1H, 
C2H), 12.26 (s, 1H, N1H). 13CNMR (CDCl3): δ(ppm) 33.27, 38.83, 65.34, 123.44, 
127.46, 127.57, 127.89, 135.30, 139.81, 145.03, 147.82, 156.14, 169.86. HRMS(EI): 
Calcd for C15H14N4O3 298.1066; found: 298.1079. 
 
3.5.4 Synthesis of benzyl 3-(6-thioxo-1,6-dihydropurin-9-yl)propanoate (3-3b) 
Compound 3-2 (0.429 g, 1.36 mmol) was dissolved in absolute ethanol followed by 
addition of thiourea (0.83 g, 10.86 mmol). The reaction mixture was stirred under reflux 
for 3 h and then cooled under ice water bath until solid precipitated. The solid was 
filtered and washed with cold ethanol to give compound 3-3b as a pale yellow solid (0.36 
g, 85%). 1HNMR (DMSO-d6, 300 Hz) δ(ppm): 3.04 (t, 2H, J=7.0 Hz, N9CH2CH2), 4.43 
(t, J=7.0 Hz, 2H N9CH2), 5.06 (s, 2H, PhCH2), 7.25-7.35 (m, 5H, ArH), 8.16 (s, 1H, 
C8H), 8.25 (s, 1H, C2H). 13CNMR (DMSO-d6, 300 Hz) δ(ppm): 33.04, 38.82, 65.37, 
127.46, 127.57, 127.88, 134.45, 135.25, 142.57, 143.58, 144.36, 169.81, 175.27. 
HRMS(EI): Calcd for C15H14N4O2S 314.0837; found: 314.0836. 
 
3.5.5 Synthesis of benzyl 3-(1-butyl-6-oxo-1,6-dihydropurin-9-yl)propanoate (3-4) 
1-Butyl bromide (47.40 mg, 0.346 mmol) and DBU (52.70 mg, 34.6 mmol) were added 
to the solution of 3-3 (86 mg, 0.29 mmol) in DMF (2 mL). The reaction mixture was 
stirred at room temperature overnight and then extracted with EtOAc and brine. The 
combined organic layer was washed with brine, dried with MgSO4, concentrated to 
dryness and purified by column chromatography (EtOAC:hexane = 1:1 followed by 
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MeOH:CH2Cl2 = 1:10) to provide 3-4 as a pale yellow oil  (92.90 mg, 91%). 1HNMR 
(CDCl3): δ(ppm) 0.89 (t, J=7.3 Hz, 3H, CH3), 1.26-1.39 (m, 2H, CH2CH3), 1.65-1.75 (m, 
2H, CH2CH2CH3), 2.90 (t, J=6.3 Hz, 2H, N9CH2CH2), 3.99 (t, J=7.3 Hz, 2H, N1CH2), 
4.42 (t, J=6.4 Hz, 2H, N9CH2), 5.05 (s, 2H, PhCH2), 7.22-7.36 (m, 5H, ArH), 7.78 (s, 
1H, C8H), 7.99 (s, 1H, C2H). 13CNMR (CDCl3): δ(ppm) 13.44, 19.58, 31.62, 34.25, 
39.41, 46.52, 66.78, 124.21, 128.21, 128.33, 128.44, 134.96, 140.25, 146.86, 147.33, 
156.26, 170.19. HRMS(EI): Calcd for C19H22N4O3 354.1692; found: 354.1675. 
 
Benzyl 3-(6-butoxy-9H-purin-9-yl)propanoate (3-4a): 1HNMR (CDCl3): δ(ppm) 0.97 
(t, J=7.3 Hz, 3H, CH3), 1.49-1.56 (m, 2H, CH2CH3), 1.87-1.92 (m, 2H, CH2CH2CH3), 
2.99 (t, J=6.3 Hz, 2H, COCH2), 4.54 (t, J=7.3 Hz, 2H, OCH2), 4.58 (t, J=6.4 Hz, 2H, 
N9CH2), 5.08 (s, 2H, PhCH2), 7.25-7.34 (m, 5H, ArH), 7.95 (s, 1H, C8H), 8.49 (s, 1H, 
C2H). 13CNMR (CDCl3): δ(ppm) 13.76, 19.12, 30.84, 34.09, 39.55, 66.96, 67.06, 109.40, 
121.45, 128.38, 128.51, 128.60, 135.09, 142.58, 152.03, 161.02, 170.54.  
 
Benzyl 3-(6-(butylthio)-9H-purin-9-yl)propanoate (3-4b): 1HNMR (CDCl3): δ(ppm) 
0.91 (t, J=7.3 Hz, 3H, CH3), 1.40-1.45 (m, 2H, CH2CH3), 1.47-1.70 (m, 2H, 
CH2CH2CH3), 2.94 (t, J=6.1 Hz, 2H, COCH2), 3.34 (t, J=7.3 Hz, 2H, SCH2), 4.49 (t, 
J=6.3 Hz, 2H, N9CH2), 5.04 (s, 2H, PhCH2), 7.20-7.29 (m, 5H, ArH), 7.97 (s, 1H, C8H), 
8.63 (s, 1H, C2H). 13CNMR (CDCl3): δ(ppm) 13.49, 21.77, 28.19, 31.30, 33.82, 39.30, 
66.76, 109.40, 128.15, 128.30, 128.41, 131.16, 134.94, 143.01, 147.96, 151.58, 161.36, 
170.34. HRMS(EI): Calcd for C19H22N4O2S 370.1463 found: 370.1457. 
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3.5.6 Synthesis of 3-(1,7-dibutyl-6-oxo-1,6-dihydro-purin-9-yl)-propionic acid phenyl 
ester salt (3-5)  
1-Iodobutane (2.94 g, 16 mmol) was added to the solution of 3-4 (0.28 g, 0.8 mmol) in 
DMF (7 mL). The reaction mixture was stirred at 70oC for 24 h and then evaporated to 
dryness. The residue was purified by column chromatography (MeOH:CH2Cl2 = 1:15) to 
give 3-5 as a yellow solid (0.43 g, 100%). 1HNMR (CDCl3):  δ(ppm) 0.97 (t, J=7.3 Hz, 
6H, CH3), 1.37-1.47 (m, 4H, CH2), 1.70-1.80 (m, 2H, CH2), 1.94-2.05 (m, 2H, CH2), 3.24 
(t, J=6.4 Hz, 2H, CH2), 4.07 (t, J=7.5 Hz, 2H, CH2), 4.61 (t, J=7.5 Hz, 2H, CH2), 4.84 (t, 
J=6.4 Hz, 2H, CH2), 5.09 (s, 2H, PhCH2), 7.31-7.32 (m, 5H, ArH), 8.23 (s, 1H, C2H), 
10.63 (s, 1H, C8H). 13CNMR (CDCl3): δ(ppm) 13.34, 13.44, 19.41, 19.70, 31.44, 32.07, 
33.15, 42.37, 47.52, 50.13, 67.08, 114.04, 128.42, 128.46, 128.54, 135.12, 141.46, 
146.52, 150.83, 152.05, 169.84. HRMS(EI): Calcd for C23H31N4O3 411.2396; found: 
411.2391. 
 
3.5.7 Synthesis of 1,7-dibutyl-1,7-dihydro-purin-6-one (3-6a) 
3-5 (0.12 g, 0.23 mmol) was dissolved in the solution of 2 M ammonia in methanol (2.3 
mL). Reaction was stirred at room temperature for 24 h and then evaporated to dryness. 
The residue was purified by column chromatography (CH3CN:CH2Cl2 =1:1 followed by 
MeOH:CH2Cl2 = 1:15) to give 3-6a as a white solid  (41.00 mg, 72%). 
 
Benzyl 3-(1-butyl-5-(N-butylformamido)-6-oxo-1,6-dihydropyrimidin-4-ylamino) 
propanoate (3-7): 1HNMR (CDCl3): δ(ppm) 0.83-0.95 (m, 6H, 2CH3), 1.23-1.72 (m, 8H, 
4CH2), 2.62 (t, 2H, COCH2), 3.30-3.88 (m, 6H, 2CH2+NHCH2), 5.09 (s, 2H, PhCH2), 
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5.73 (t, 1H, NH), 7.30-7.31(m, 5H, ArH), 7.82 (s, 1H, C8H), 7.85 (s, 1H, C2H). MS(EI): 
m/z 277(M+), 428.2, 400.3, 91.1, 265.1. 
 
3.5.8 General procedure for the preparation of the REM resin (3-8) 
Wang resin (loading 1.47 mmol/g) was swollen in CH2Cl2. DiEA (8 equiv.) and acryloyl 
chloride (8 equiv.) were added and the reaction mixture was shaken at room temperature 
for 4 h. After which, the mixture was filtered and the resin washed sequentially with 
DMF (20 mL x 2), H2O (20 mL x 2), EtOH (20 mL x 2), CH2Cl2 (20 mL x 2) and Et2O 
(20 mL x 2), and dried overnight in a vacuum oven at 40°C to afford resin 3-8.  
 
3.5.9 General procedure for the preparation of resin bound benzyl 3-(6-chloro-9H-
purin-9-yl)propanoate (3-9) 
3-8 was swollen in DMF and 6-chloropurine (2 equiv.) and DiEA (2 equiv.) were added. 
The reaction mixture was shaken at room temperature for 48 h and then filtered and 
washed with DMF (20 mL x 2), EtOH (20 mL x 2) and CH2Cl2 (20 mL x 2) and dried in 
vacuum. This procedure was repeated once to afford resin 3-9.  
 
3.5.10 General procedure for the preparation of resin bound benzyl 3-(6-oxo-1,6-
dihydropurin-9-yl)propanoate (3-10) 
3-9 was swollen in DMF for 30 min. 80% formic acid was added and the reaction 
mixture was stirred at 70°C for 4 h. Then the resin was filtered and washed with DMF 
(20 mL x 2), EtOH (20 mL x 2) and CH2Cl2 (20 mL x 2) and dried in vacuum at 40°C to 
afford resin 3-10. 
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3.5.11 General procedure for the preparation of resin bound benzyl 3-(1-
substituted-6-oxo-1,6-dihydro-purin-9-yl)propanoate (3-11) 
3-10 was swollen in DMF for 30 min and 1-bromobutane (1.5 equiv.) and DBU (2 
equiv.) were added. After shaking at room temperature overnight, the resin was filtered 
and washed with DMF (20 mL x 2), EtOH (20 mL x 2) and CH2Cl2 (20 mL x 2) and 
dried in vacuum.  
 
3.5.12 General procedure for the preparation of resin bound benzyl 3-(1,7-
disubstituted-6-oxo-1,6-dihydro-purin-9-yl)propanoate (3-12) 
 3-11 was swollen in DMF for 30 min. 1-Iodobutane (20 equiv.) was added and the 
mixture was stirred slowly at 50oC for 24 h. After which, the resin was filtered and 
washed with DMF (20 mL x 2), H2O (20 mL x 2), EtOH (20 mL x 2) and CH2Cl2 (20 mL 
x 2) and dried in vacuum.  
 
3.5.13 General procedure for the preparation of 1,7-disubstituted-6-oxopurine (3-6)  
Resin 3-12 was swollen in DCM for 30 min. 2 M ammonia in methanol (20 equiv.) was 
added and the mixture was shaken at room temperature for 24 h. The resin was filtered 
and washed with methanol (20 mL x 2) and CH2Cl2 (20 mL x 2). The washings were 




1HNMR (CDCl3): δ(ppm) 0.90-0.96 (m, 6H, 2CH3), 1.29-1.41 (m, 4H, CH2), 1.68-1.78 
(m, 2H, CH2), 1.80-1.90 (m, 2H, CH2), 3.99 (t, J=7.3 Hz, 2H, CH2), 4.35 (t, J=7.3 Hz, 
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2H, CH2), 7.80 (s, 1H, C8H), 7.98 (s, 1H, C2H). 13CNMR (CDCl3): δ(ppm) 13.42, 13.52, 
19.50, 19.76, 31.82, 33.31, 46.26, 47.14, 115.10, 143.14, 146.31, 154.20, 156.95. 
HRMS(EI): Calcd for C13H20N4O 248.1637;  found: 248.1636. 
 
3-6b: 7-Allyl-1-butyl-1,7-dihydro-purin-6-one  
1HNMR (CDCl3): δ(ppm) 0.92 (t, J=7.3 Hz, 3H, CH3), 1.29-1.42 (m, 2H, CH2), 1.66-1.76 
(m, 2H, CH2), 3.97 (t, J=7.3 Hz, 2H, N1CH2), 5.01 (d, J=5.6 Hz, 2H, N7CH2), 5.21 (dd, 
J=10.5 Hz, J=23.0 Hz, 2H, CH2), 5.99-6.10 (m, 1H, CH), 7.82 (s, 1H, C8H), 7.97 (s, 1H, 
C2H). 13CNMR (CDCl3): δ(ppm) 13.48, 19.69, 31.75, 46.18, 49.12, 118.94, 132.41, 
139.59, 143.01, 146.41, 154.19, 156.76. HRMS(EI): Calcd for C12H16N4O 232.1324; 
found: 232.1320. 
 
3-6c: 7-Benzyl-1-butyl-1,7-dihydro-purin-6-one  
1HNMR (CDCl3): δ(ppm) 0.95 (t, J=7.3 Hz, 3H, CH3), 1.32-1.44 (m, 4H, CH2), 1.68-1.78 
(m, 2H, CH2), 3.99 (t, J=7.3 Hz, 2H, N1CH2), 5.59 (s, 2H, PhCH2), 7.29-7.36 (m, 5H, 
ArH), 7.83 (s, 1H, C8H), 7.98 (s, 1H, C2H). 13CNMR (CDCl3): δ(ppm) 13.53, 19.76, 
31.83, 46.25, 50.53, 115.11, 127.90, 128.45, 129.00, 135.66, 143.16, 146.48, 154.37, 
156.87. HRMS(EI): Calcd for C16H18N4O 282.1481; found: 282.1478. 
 
3-6d: 7-Allyl-1-heptyl-1,7-dihydro-purin-6-one  
1HNMR (CDCl3): δ(ppm) 0.84 (t, J=7.3 Hz, 3H, CH3), 1.22-1.31 (m, 8H, 4CH2), 1.71-
1.76 (m, 2H, CH2), 3.98 (t, J=7.3 Hz, 2H, N1CH2), 5.04 (dd, J=1.4 Hz, J=5.9 Hz, 2H, 
N7CH2), 5.24 (dd, J=10.1 Hz, J=20.2 Hz, 2H, CHCH2), 5.99-6.11 (m, 1H, CH), 7.96 (s, 
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1H, C8H), 8.00 (s, 1H, C2H). 13CNMR (CDCl3): δ 13.90, 22.41, 26.46, 28.70, 29.76, 
31.53, 46.56, 49.30, 119.19, 132.30, 142.89, 146.69, 152.21, 154.13, 156.28. HRMS(EI): 
Calcd for C15H22N4O: 274.1794; found: 274.1781. 
 
3-6e: 7-Butyl-1-heptyl-1,7-dihydro-purin-6-one  
1HNMR (CDCl3): δ(ppm) 0.86 (t, J=6.6 Hz, 3H, CH3), 0.95 (t, J=7.3 Hz, 3H, CH3), 1.26-
1.39 (m, 10H, 5CH2), 1.73-1.92 (m, 4H, 2CH2), 1.80-1.90 (m, 2H, CH2), 4.00 (t, J=7.5 
Hz, 2H, N1CH2), 4.38 (t, J=7.3 Hz, 2H, N7CH2), 7.90 (s, 1H, C8H), 8.00 (s, 1H, C2H). 
13CNMR (CDCl3): δ(ppm) 13.45, 13.94, 19.55, 22.47, 26.54, 28.77, 29.85, 31.60, 33.33, 
46.61, 47.30, 115.16, 143.06, 146.52, 154.18, 156.64. HRMS(EI): Calcd for C16H26N4O 
290.2107; found: 290.2100. 
 
3-6f: 7-Benzyl-1-heptyl-1,7-dihydro-purin-6-one  
1HNMR (CDCl3): δ(ppm) 0.88 (t, J=6.8 Hz, 3H, CH3), 1.25-1.35 (m, 8H, 4CH2), 1.75-
1.79 (m, 2H, CH2), 4.01 (t, J=7.5 Hz, 2H, N1CH2), 5.64 (s, 2H, PhCH2), 7.35-7.36 (m, 
5H, ArH), 8.02 (s, 1H, C8H), 8.05 (s, 1H, C2H). 13CNMR (CDCl3): δ(ppm) 13.99, 22.51, 
26.55, 28.80, 29.88, 31.63, 46.72, 50.91, 128.13 (x2), 128.70, 129.14 (x2), 142.77, 
147.03. HRMS(EI): Calcd for C19H24N4O 324.1950; found: 324.1947. 
 
3-6g: 1-Benzyl-7-butyl-1,7-dihydro-purin-6-one  
1HNMR (CDCl3): δ(ppm) 0.87 (t, J=7.5 Hz, 3H, CH3), 1.23-1.33 (m, 2H, CH2), 1.75-
1.85(m, 2H, CH2), 4.30 (t, J=7.3 Hz, 2H, N7CH2), 5.14 (s, 2H, PhCH2), 7.21-7.26 (m, 
5H, ArH), 7.78 (s, 1H, C8H), 8.07 (s, 1H, C2H). 13CNMR (CDCl3): δ(ppm) 13.24, 19.27, 
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33.04, 46.92, 48.77, 114.87, 127.57, 127.93, 128.69, 135.71, 143.13, 146.24, 153.94, 
156.71. HRMS(EI): Calcd for C16H18N4O 282.1481; found: 282.1479. 
 
3-6h: 7-Allyl-1-benzyl-1,7-dihydro-purin-6-one  
1HNMR (CDCl3): δ(ppm) 5.04 (dd, J=1.4 Hz, J=5.9 Hz, 2H, N7CH2), 5.19 (dd, J=1.0 
Hz, J=10.5 Hz, 2H, CHCH2), 5.16 (s, 2H, PhCH2), 5.93-6.06 (m, 1H, CH), 7.21-7.26 (m, 
5H, ArH), 7.81 (s, 1H, C8H), 8.08 (s, 1H, C2H). 13CNMR (CDCl3): δ(ppm) 48.79, 48.96, 
114.78, 118.81, 127.58, 127.96, 128.70, 132.23, 135.65, 143.03, 146.35, 153.98, 156.59. 
HRMS(EI): Calcd for C15H14N4O 266.1168; found: 266.1164. 
 
3-6i: 1-Allyl-7-butyl-1,7-dihydro-purin-6-one  
1HNMR (CDCl3): δ(ppm) 0.83 (t, J=7.3 Hz, 3H, CH3), 1.20-1.33 (m, 2H, CH2), 1.71-1.81 
(m, 2H,CH2), 4.28 (t, J=7.2 Hz, 2H, N7CH2), 4.55 (d, J=6.0 Hz,  2H, N1CH2), 5.13 (dd, 
J=10.4 Hz, J=13.7 Hz, 2H, CH2), 5.83-5.92 (m, 1H CH), 7.77 (s, 1H, C8H), 7.92 (s, 1H, 
C2H). 13CNMR (CDCl3): δ(ppm) 13.16, 19.21, 33.01, 46.89, 47.46, 114.70, 118.32, 
131.88, 143.11, 146.01, 153.66, 156.67. HRMS(EI): Calcd for C12H16N4O 232.1324; 
found: 232.1321. 
 
3-6j: 7-Benzyl-1-isopropyl-1,7-dihydro-purin-6-one  
1HNMR (CDCl3): δ(ppm) 1.47 (d, J= 6.9 Hz, 6H, 2CH3), 5.15-5.24 (m, 1H, N1CH), 5.60 
(s, 2H, PhCH2), 7.30-7.35 (m, 5H, ArH), 7.85 (s, 1H, C8H), 8.09 (s, 1H, C2H). 13CNMR 
(CDCl3): δ(ppm) 22.46 (x2), 45.51, 50.53, 127.97, 128.50, 129.06, 135.68, 143.28, 
143.61, 154.22, 156.34. HRMS(EI): Calcd for C15H16N4O 268.1324; found: 268.1356. 
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3-6k: 7-Butyl-1-isopropyl-1,7-dihydro-purin-6-one  
1HNMR (CDCl3): δ(ppm) 0.92 (t, J=7.3 Hz, 3H, CH3), 1.29-1.36 (m, 2H, CH2), 1.45 (d, 
J=6.9 Hz, 6H, 2CH3), 1.79-1.89 (m, 2H, CH2), 4.35 (t, J=7.3 Hz, 2H, N7CH2), 5.10-5.24 
(m, 1H, N1CH), 7.82 (s, 1H, C8H), 8.06 (s, 1H, C2H). 13CNMR (CDCl3): δ(ppm) 13.39, 
19.49, 22.40, 33.28, 45.43, 47.10, 114.78, 143.19, 143.41, 153.96, 156.31. HRMS(EI): 
Calcd for C12H18N4O 234.1481; found: 234.1475. 
 
3-6l: 7-Butyl-1-prop-2-ynyl-1,7-dihydro-purin-6-one  
1HNMR (CDCl3): δ(ppm) 0.82 (t, J=7.3 Hz, 3H, CH3), 1.19-1.27 (m, 2H, CH2), 1.71-1.81 
(m, 2H, CH2), 2.43-2.45 (m, 1H, CH), 4.27 (t, J=7.3 Hz, 2H, N7CH2), 4.74 (dd, J=1.0 
Hz, 2.8 Hz, 2H, N1CH2), 7.77 (s, 1H, C8H), 8.19 (s, 1H, C2H). 13CNMR (CDCl3): 
δ(ppm) 13.19, 19.23, 32.98, 34.51, 46.95, 74.70, 114.45, 139.85, 143.27, 145.18, 153.22, 
156.74. HRMS(EI): Calcd for C12H14N4O 230.1168; found: 232.1162. 
 
3-6m: 7-Benzyl-1-prop-2-ynyl-1,7-dihydro-purin-6-one 
1HNMR (CDCl3): δ(ppm) 2.46-2.48 (m, 1H, CH), 4.77 (d, J=2.4 Hz, 2H, N1CH2), 5.55 
(s, 2H, PhCH2), 7.27-7.31 (m, 5H, ArH), 7.86 (s, 1H, C8H), 8.24 (s, 1H, C2H). 13CNMR 
(CDCl3): δ(ppm) 34.62, 50.48, 74.97, 114.63, 127.80 (x2), 128.39, 128.91, 135.44, 
143.40, 145.39, 153.53, 156.86. HRMS(EI): Calcd for C15H12N4O 264.1011; found: 
264.1011. 
 
3-6n: 7-Butyl-1-methyl-1,7-dihydro-purin-6-one  
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1HNMR (CDCl3): δ(ppm) 0.84 (t, J=7.3 Hz, 3H, CH3), 1.20-1.28 (m, 2H, CH2), 1.72-1.82 
(m, 2H, CH2), 3.52 (s, 3H, N1CH3), 4.28 (t, J=7.1 Hz, 2H, N7CH2), 7.75 (s, 1H, C8H), 
7.97 (s, 1H, C2H). 13CNMR (CDCl3): δ(ppm) 13.24, 19.28, 33.09, 33.40, 46.96, 114.76, 
143.06, 146.46, 154.39, 156.94. HRMS(EI): Calcd for C10H14N4O 206.1168; found: 
206.1167. 
 
3-6o: 7-Benzyl-1-methyl-1,7-dihydro-purin-6-one  
1HNMR (CDCl3): δ(ppm) 3.57 (s, 3H, N1CH3), 5.57 (s, 2H, PhCH2), 7.30 (m, 5H, ArH), 
7.85 (s, 1H, C8H), 8.01 (s, 1H, C2H). 13CNMR (CDCl3): δ(ppm) 33.51, 50.51, 114.96, 
127.82, 128.42, 128.96, 135.65, 143.19, 146.69, 154.70, 157.07. HRMS(EI): Calcd for 
C13H12N4O 240.1011; found: 240.1013.    
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CHAPTER 4: Traceless Solid-Phase Synthesis of Various Substituted 
Purines From p-Benzyloxybenzylamine (BOBA) Resin 
 
4.1 Introduction  
Combinatorial technologies encompass numerous strategies to prepare and screen 
collections or ‘libraries’ of structurally related molecules. In SPS strategies, a substrate is 
attached to a functionalized polymer. These functionalized polymers are prepared using 
copolymerization processes that incorporate the functionalized monomer, or by direct 
derivatization of the polymer itself. The selection of an appropriate linkage is critical to 
the success of any SPS. The primary function of the linker is to covalently attach the 
initial substrate to the polymer support. However a major drawback to the traditional 
linkers used in SPS is that, upon cleavage, it leaves a functional group on the final 
compound. The presence of these appendages is fine if the compounds require these 
functionalities. However complications may arise if these appendages are redundant and 
affect the activities of the compounds. To overcome this drawback, traceless linkers 
which leave the target compound with no “memory” of the SPS was developed and has 
become a major area of interest in SPS.[1]  
The purine moiety is a principle component in nucleic acids and substrates of many 
regulatory, biosynthetic and signal transduction proteins including kinases, DNA and 
RNA polymerases, G proteins, and purine biosynthetic and metabolic enzymes.[2] Their 
importance in biology has generated much interest and over the years various solid-phase 
synthetic methodologies have been studied. These methodologies generally involve two 
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main strategies. In the first strategy, a halogenated/aminated purine is used. Modification 
on the purine ring can generate substituents at the 2-, 6- and 9- positions. The second 
strategy is based on the synthesis of substituted pyrimidine ring followed by the closure 
of the imidazole ring. Although this strategy is less straightforward than the first, it has an 
important advantage of providing the possibility to introduce C8 substituents more easily. 
However the difficult reaction condition for cyclization in solid-phase synthesis could 
have limited the usage of this strategy as only one paper using this strategy has thus far 
been reported.[3] In this paper, 4,6-dichloro-5-nitropyrimidine was coupled to Rink amide 
resin. Subsequent amination at C4 and reduction of nitro group at C5 provided the 
precursor for closure of the imidazole ring (Chapter 1, Scheme 1.22). Limitations of this 
reported method are (i) the substitution on C6 is invariable because an NH2 group is 
always left after the cleavage of the Rink amide resin and (ii) low yield (overall yield was 
7% indicating an average yield of 59% for each step). In order to introduce greater 
diversity on the purine moiety, a new linker and methodology should be developed.  
 
4.2 Outline of our strategy 
Herein we present our results on the development of a traceless solid-phase synthesis of 
various substituted purines starting from 5-amino-4,6-dichloropyrimidine and p-
benzyloxybenzylamine (BOBA) resin 4-27. 5-Amino-4,6-dichloropyrimidine was 
coupled to BOBA resin to form a resin bound diamine 4-28 as the key intermediate for 
elaboration to various substituted purines. After cyclization, the N7 position possessed 
the steric priority to be alkylated. This, in turn, resulted in a regioselective N7 alkylation 
being achieved. At the end of the reaction, the BOBA linker was easily cleaved and the 
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target purines were released (Scheme 4.1). During this study, we have also extended the 














































Scheme 4.1 Overall strategy 
 
4.3 Results and discussions  
4.3.1 Solution-phase study towards 1,7,8-trisubstituted purines 
The initial solution-phase validation used (4-(benzyloxy)phenyl)methanamine (4-1a) to 
mimic the p-benzyloxybenzylamine (BOBA) resin. The solution-phase synthetic route is 























































2) LiAlH4 or BH3
X=Br or Cl
 
Scheme 4.2 Solution-phase study  
 
4.3.1.1 Synthesis of (4-(benzyloxy)phenyl)methanamine (4-1a) 
Compound 4-1a was synthesized by first treating benzyl bromide or benzyl chloride with 
4-hydroxybenzamide in the presence of NaOH in DMSO. Benzyl bromide gave a much 
higher yield than benzyl chloride (80% vs. 25%). After which, reduction was carried out 
by using BH3/THF (4 equiv.) under reflux or LiAlH4/THF (4 equiv.) at room temperature 
to give 4-1a in 88% yield. Compound 4-1a was not stable and turned from white to 




4.3.1.2 Synthesis of N4-(4-(benzyloxy)benzyl)-6-chloropyrimidine-4,5-diamine (4-2a) 
The pyrimidine core 5-amino-4,6-dichloropyrimidine was reacted with (4-
(benzyloxy)phenyl)methanamine (4-1a) through a SNAr displacement. The reaction was 
studied using different bases and solvents and the results are summarized in Table 4.1.  
Table 4.1 Synthesis of compound 4-2a 
 Base Reaction conditions Yield of 4-2a (%) 
1 - Reflux in BuOH overnight - 
2 NaHCO3 Reflux in THF for 2 h 18 
3 NaHCO3 Reflux in BuOH for 24 h 66 
4 DiEA Stirred at 100oC in DMF for 5 h 25 
5 DiEA Reflux in BuOH for 24 h 88 
 
It is evident that the presence of a base is important for the SNAr displacement. Without 
base, formation of compound 4-2a was not observed. At the same time, the reaction 
solvent was also a crucial entity. Table 4.1 shows that the reaction proceeded more 
favorably in the presence of a protic solvent than an aprotic solvent, such as DMF or 
THF. Since DiEA had a better solubility than NaHCO3 in BuOH (Entry 5), it resulted in a 
higher yield and was used as the base for our SPS. 
 
4.3.1.3 Studies of cyclization of N4-(4-(benzyloxy)benzyl)-6-chloropyrimidine-4,5-
diamine (4-2a) 
Different methods for cyclization of 4-2a were studied. That included cyclization with 




4.3.1.3.1 Cyclization with triethyl orthoacetate 
Various solution-phase cyclization of 4,5-diaminopyrimidine with orthoesters have been 
reported earlier.[4] However treatment of diamine (4-2a) with triethyl orthoacetate in the 
presence of TsOH or HCl at room temperature for 3 h resulted in a pale yellow oil (99% 
yield) which upon analysis by 1HNMR, 13CNMR, Dept135 and accurate MS showed that 
this oil was not the desired cyclized product 4-8 but could be the intermediate ethyl N-4-


























Scheme 4.3 Cyclizaiton with triethyl orthoacetate 
 
A possible mechanism for the reaction of diamine (4-2a) with triethyl orthoacetate is 

















































Scheme 4.4 Mechanism of reaction of compound 4-2a with triethyl orthoacetate 
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In order to obtain the cyclized compound 4-8, the reaction was attempted at room 
temperature for 24 h and then at elevated temperature (100oC). However these reaction 
conditions did not provide 4-8. Then Lewis acid was added to promote the cyclization. 
The isolated intermediate compound 4-7 was stirred with ferric chloride in anhydrous 
ethanol. After 1 h, TLC showed the disappearance of the starting material and the 
formation of two new products. Analysis of both products revealed that the first 
compound (major product) isolated was 4-2a whilst the second compound was the 
desired cyclized product 4-8 (46%). Since 4-2a was the major product, a one-pot reaction 
of compound 4-2a with triethyl orthoacetate in the presence of ferric chloride was carried 
out. However, it generated a lot of side products which gave the procedure no preparative 
utility. 
 


























4-11 X=OH  
Scheme 4.5 Cyclization with benzoyl chloride 
 
A less straightforward two-step cyclization method was also examined.[5] As shown in 
Scheme 4.5, starting diamine 4-2a was first reacted with benzoyl chloride to give 
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compound 4-9 in near quantitative yield. Different ring closure conditions applied on 4-9 
were examined (Table 4.2).  
Table 4.2 Various ring closure conditions applied on 4-9 
 Ring closure conditions Products 
1 HMDS/(NH4)2SO4, reflux o/n 4-9 and 4-10 
2 10% KOH (aq.)/CH3CN, reflux o/n 4-9, 4-10 and 4-11 
3 10% NaOH (aq.)/CH3OH, 60oC, o/n 4-9 and 4-11 
4 10% NaOH (aq.)/DMA, 100oC, o/n 4-9 
 
From Table 4.2 it is clear that all the examined conditions failed to provide complete 
disappearance of the starting material 4-9. However, reaction with 10% KOH 
(aq.)/CH3CN under reflux condition (Entry 2) gave both 6-chloro-cyclized product 4-10 
and 6-hydroxy-cyclized product 4-11. This implied that cyclization and hydrolysis of 6-
chloro had occurred during the one-pot reaction. Replacing acetonitrile with methanol 
(Entry 3) resulted only in the formation of 6-hydroxy-cyclized product 4-11. Though the 
desired product was formed using 10% NaOH (aq.)/CH3OH, the yield obtained was low 
(20%) and thus we had to press on in the search for a better cyclization method. 
 
4.3.1.3.3 Cyclization with aldehydes 
Condensation of diaminopyrimidine with an aldehyde is a classic method to generate 
purine imidazole ring.[3,6] With the intention of seeking a high yielding and 
straightforward reaction condition for solid-phase synthesis, this cyclization method was 
studied (Table 4.3). Treatment of diamine 4-2a with heptan-1-al (5 equiv.) in the 
presence of acetic acid (40 equiv.) under reflux condition gave complete disappearance of 
the starting material 4-2a. After that reaction mixture was evaporated to dryness and 
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treated with ferric chloride at room temperature for 3 h, 6-hydroxy-cyclized product 4-3 
was isolated in 51% yield (Entry 1). This result indicated that hydrolysis had occurred 
during the reaction and this may be attributed to the presence of acetic acid. Overnight 
treatment with ferric chloride (Entry 2) further increased the yield of 4-3 (69%). 
However, when 1,4-dioxane was used as solvent[6b] and treatment with ferric chloride 
was carried out  at 100oC, it generated a very dirty reaction mixture and no product was 
isolated (Entry 3). Since the reaction was made more complex by ferric chloride, we 
decided to study this reaction in a stepwise manner. First, we examined the treatment of 
diamine 4-2a with heptan-1-al. With disappearance of the starting material, there were 
two products formed in a 1:1 ratio (Entry 4). NMR and MS identification showed that the 
first product (colourless oil) was the 6-chloro-cyclized product, 9-(4-(benzyloxy)benzyl)-
6-chloro-8-hexyl-9H-purine (4-12), whilst the second product (pale yellow solid) was the 
6-hydroxy-cyclized product 4-3. This result showed that cyclization was already 
completed even without treatment of ferric chloride and hydrolysis had already taken 
place. This inspired us to perform the cyclization and hydrolysis in one pot without ferric 
chloride. We also tried to raise the ratio of acetic acid from 40 equiv. to 80 equiv.. But 
this did not improve the yields of compounds 4-3 (Entry 5).  At the same time, reaction 
with formic acid, a stronger acid than acetic acid, was also examined. However neither 4-
3 nor 4-12 was obtained and the starting diamine 4-2a was recovered (Entry 6). Finally 4-
2a was treated with heptan-1-al and acetic acid in THF overnight and then evaporated to 
dryness. The obtained residue was then stirred with 85% formic acid at 70°C for another 





Table 4.3 Cyclization with aldehyde 
 Reaction conditions Yield of product 4-3 (%) 
1 1) AcOH (40 equiv.)/MeOH reflux o/n 2) FeCl3/EtOH, rt, 3 h 
51 
2 1) AcOH (40 equiv.)/MeOH reflux o/n 2) FeCl3/EtOH, rt, o/n 
69 
3 1) AcOH (40 equiv.)/MeOH reflux o/n 2) FeCl3/dioxane, reflux, o/n 
- 
4 AcOH (40 equiv.)/MeOH reflux o/n 53a 
5 AcOH (80 equiv.)/MeOH reflux 24 h 50a 
6 HCOOH(80 equiv.)/MeOH reflux 5 h - 
7 1) AcOH (80 equiv.)/THF reflux o/n 2) 85% HCOOH (aq.) 81 











Figure 4.1 Structure of 9-(4-(benzyloxy)benzyl)-6-chloro-8-hexyl-9H-purine (4-12) 
 
The mechanism of this reaction is depicted in Scheme 4.6. During the reaction the 






































































Scheme 4.6 Mechanism of cyclization with aldehyde 
 
4.3.1.4 Synthesis of 9-(4-(benzyloxy)benzyl)-8-hexyl-1-(prop-2-ynyl)-1H-purin-
6(9H)-one (4-4)  
Next N1 alkylation was easily achieved using propargyl bromide as alkylating reagent 
(1.2 equiv.) in the presence of DBU (1.2 equiv.) as base. The alkylation was initially 
carried out according to the reaction condition described in Chapter 3 (Section 3.3.1.4). 
However after reacting at room temperature overnight, TLC showed the existence of 
starting material and product 4-4 was isolated in 60% yield. We subsequently increased 
the amount of alkylating reagent and DBU to 4 equiv.. This provided complete 






4.3.1.5. Synthesis of 9-(4-(benzyloxy)benzyl)-7-butyl-8-hexyl-1-(prop-2-ynyl)-1H-
purin-6(9H)-one salt (4-5) 
Quarternization of 4-4 with 1-iodobutane was carried out initially with 20 equiv. of 1-
iodobutane according to the reaction condition described in Chapter 3 (Section 3.3.1.5). 
However after stirring at 70°C in DMF for 48 h, TLC showed the existence of starting 4-
4. Increasing the reaction temperature to 90oC resulted in a very dirty reaction mixture. 
Hence, we proceeded to increase the equivalence of 1-iodobutane to 40 equiv.. Under this 
reaction condition, the quarternization reaction was completed after stirring at 70°C 
overnight and gave product 4-5 in 93% yield. This result suggested that quaternization 
was more sluggish with substitution at the C8 position. 
 
4.3.1.6 Synthesis of 7-butyl-8-hexyl-1-(prop-2-ynyl)-1H-purin-6(7H)-one (4-6a) 
Having accomplished the quarternization, we proceeded with the N9-debenzylation. This 
reaction was carried out to mimic the cleavage of the solid support to achieve a traceless 
character. Initial attempts to carry out the N9-benzylation with TFA/DCM did not provide 
the desired 4-6a. Subsequently, we treated 4-5 with 10 equiv. of 96% H2SO4 at room 
temperature in the presence of toluene and provided the final product 4-6a in 95% yield. 
The debenzylation proceeded via carbonium formation.[7] In this reaction, toluene was 
used as both a solvent and a carbonium trap which led the reaction to completion 
(Scheme 4.7). It is worth noting that in order to obtain a neutral final product, it is 


































Scheme 4.7 Mechanism of cleavage with sulfuric acid/toluene 
 
Another cleavage method was also investigated. CAN/CH3CN/H2O is a classic method 
for oxidative debenzylation.[8] With this method, the 4-(benzyloxy)benzyl group was 
cleaved via benzylic oxidation (Scheme 4.8). Treatment of compound 4-5 with 4 equiv. 































Scheme 4.8 Mechanism of cleavage with CAN/CH3CN/H2O 
 
4.3.2 Solution-phase study of other various substituted purines 
We were interested to expand the chemistry at the C8 position of purine. As described 
above, 4-2a could react with orthoesters, acid chloride or aldehydes to generate 8-
substituted purine. Besides this, other utilizations of this key diamine 4-2a were also 
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investigated. The following sections describe the use of 4-2a for the preparation of 1,7-
disubstituted purines, 8-azapurines and [i]-condensed purines. 
 
4.3.2.1 Solution-phase synthesis of 1,7-disubstituted purines (4-17a) 
Starting from N4-(4-(benzyloxy)benzyl)-6-chloropyrimidine-4,5-diamine (4-2a) 1,7-













































Scheme 4.9 Synthesis of 1,7-dibutyl-1H-purin-6(7H)-one (4-17a) 
 
In this case cyclization of imidazole was achieved using either orthoformate or 
formamide. Compared to the cyclization of 4-2a with triethyl orthoacetate (section 
4.3.1.3.1), cyclization of 4-2a with trimethyl orthoformate proceeded more readily. 
Compound 4-2a reacted smoothly with trimethyl orthoformate in the presence of acid to 
give 9-(4-(benzyloxy)benzyl)-6-chloro-9H-purine (4-13a). 1HNMR of 4-13a showed the 
presence of the purine C8H peak indicating the formation of the imidazole ring. The X 
ray crystal structure of 4-13a is shown in Figure 4.2.  
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Figure 4.2 X ray crystal structure of 4-13a 
 
On the other hand, cyclization with formamide was less mild. In order to facilitate 
cyclization, compound 4-2a had to react with formamide at 160oC for 24 h. Analysis of 
the product showed that the compound obtained was 4-14. Although the reaction was 
quite straightforward, the overall yield obtained for two steps was low (29%). This 
together with the harsh reaction condition made it impracticable for solid-phase synthesis. 
 
We next proceeded to study the hydrolysis reaction. Unlike REM linker (Chapter 3) that 
is base labile, BOBA linker is more stable under basic condition. Thus both acidic and 




Table 4.4 Different hydrolysis conditions of 4-13a 
 Hydrolysis conditions Yield of 4-14 (%) 
1 1 M NaOH, reflux in CH3CN for 3 h 11 
2 2 M NaOH, reflux in CH3CN for 3 h 59 
3 2 M NaOH, stirred in DMF at 80oC for 3 h 76 
4 2 M NaOH, reflux in CH3CN for 1 h 75 
5 1.5 M HCl, reflux in CH3CN for 1.5 h 90 
6 TFA/H2O(2:1), rt, 48 h 41 
7 85% HCOOH (aq), 70oC, 1 h 92 
 
According to Table 4.4 basic hydrolysis provided lower yields than acidic hydrolysis. 
This could be attributed to side product formed. We observed that whenever hydrolysis 
was performed under basic condition, a side product was isolated. NMR and MS of this 
product suggested that it was the ring-open product 4-2a. This implied that the imidazole 
ring in 4-13a was not stable under refluxing basic conditions. It is worth noting that 
neutralization was always required after base hydrolysis because compound 4-14 could 
be deprotonated to form a salt which is soluble in the aqueous layer during extraction 
workup. Amongst the various reactions listed in Table 4.4, 85% formic acid gave the best 
result (Entry 7). IR spectrum of 4-14 showed the cyclic amide C=O stretch at 1680 cm-1 
and phenyl alkyl ether C-O stretch at 1247 cm-1 and 1019 cm-1.  
 
Having obtained 4-14, we proceeded with the N1 alkylation, N7 quaternization and N9 
debenzylation according to the methods described in Sections 4.3.1.4~4.3.1.6 to obtain 




4.3.2.2 Preliminary solution-phase synthesis of 8-azapurine 
Although the solution-phase synthesis of 8-azapurines via the cyclization of 4,5-
diaminopyrimidine with sodium nitrite had been reported earlier, [9] there are no earlier 
reports on the application of this reaction on solid phase. Since purine is prone to 
substantial changes in reactivity due to substituents effect, we decided to study the 
cyclization of 4-2a and subsequent hydrolysis in solution before adapting the reaction 




















Scheme 4.10 Solution-phase synthesis of 8-azapurine 
 
Cyclization with sodium nitrite was first examined in THF. Starting diamine 4-2a was 
dissolved in THF and 50% HOAc (aq.) followed by the addition of sodium nitrite. The 
reaction mixture was stirred at room temperature for 30 min and product 4-18a was 
isolated in 43% yield. When DCM was used as the reaction solvent, a heterogeneous 
reaction mixture was obtained but with vigorous stirring at room temperature for 30 min, 
product 4-18a was obtained in 96% yield. The X ray crystal structure of 4-18a is shown 
in Figure 4.3. Hydrolysis of 4-18a could be achieved with established method described 
in Section 4.3.2.1.  
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Since N1 alkylation and N9 debenzylation conditions were well examined in Section 
4.3.1.4 and Section 4.3.1.6, further study of N1 alkylation and N9 debenzylation of 4-19 
was not performed.  
 
Figure 4.3 X ray crystal structure of 4-18a 
 
4.3.2.3 Solution-phase synthesis of [i]-condensed purines 
Studies showed [i]-condensed purines were effective for reducing side effects of 
xanthines.[10a] However there are very few reports on the synthesis of purine derivatives 
condensed with other heterocyclic rings to generate [i]-condensed purines [10] and, to our 
knowledge, no study on solid-phase synthesis of [i]-condensed purines have been 
reported. In this section of our research, commercially available 4-methoxybenzyl amine 
was chosen to mimic BOBA resin instead of (4-(benzyloxy)phenyl)methanamine (4-1a) 
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due to the laborious preparation and unstable nature of the latter. The procedure described 
for the syntheses of 4-2a and 4-18a were adopted for the preparation of the key 
intermediate diamine 4-2b and 4-18b respectively. 4-18b was subsequently reacted with 







































































Scheme 4.11 Solution-phase synthesis of [i]-condensed purines 
 
An earlier report had described the synthesis of heterocycle-condensed purines from 6-
hydroxyethylaminopurine and MsCl/TEA, SOCl2/DCM, or POCl3.[10] Applying these 
reaction conditions to our system, various studies on the cyclization of 4-20a were 
performed (Table 4.5).  
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Table 4.5 Studies on the cyclization of 4-20a 
 Cyclization conditions Solvent Temp. and Time  Yield of 4-
21a (%) 
1 MsCl(2 equiv.), TEA(2 equiv.) DCM rt, 6 h 59 
2 MsCl(2 equiv.), TEA(2 equiv.) DCM rt, o/n 66a 
3 MsCl(5 equiv.), TEA(5 equiv.) DCM rt, o/n 43 
4 MsCl(2 equiv), TEA(2 equiv.) DMF rt, 6 h 52 
5 MsCl(2 equiv.), TEA(2 equiv.) DMF 50oC, 6 h - 
6 SOCl2(90 equiv.) DCM rt, 6 h -b 
7 SOCl2(90 equiv.) CHCl3 reflux, 4 h -b 
8 SOCl2(90 equiv.) CHCl3 reflux, o/n 60c 
9 SOCl2(3 equiv.) CHCl3 reflux, o/n 36c 
10 SOCl2(1.5 equiv.) CHCl3 MW 80oC, 10 min 30 
11 SOCl2(1.5 equiv.) DMF MW 180oC, 10 min 85 
a) Side product 4-25was isolated. b) Starting 4-20a was recovered. c) Side product 4-26 was isolated. 
 
Entries 1-5 showed that increasing the quantities of MsCl and TEA gave lower yield 
(Entry 3) whilst higher reaction temperature gave more complex reaction mixture and 
practically no cyclized product (Entry 5). The best result obtained with MsCl/TEA is 
shown in Entry 2. However the intermediate, 2-(3-(4-methoxybenzyl)-3H-
[1,2,3]triazolo[4,5-d]pyrimidin-7-ylamino)ethyl methanesulfonate (4-25), was isolated 

























Figure 4.4 Structures of side products 4-25 and 4-26 
 
Entries 6-9 summarize the cyclization with thionyl chloride. It shows that larger excess of 
SOCl2 and longer reaction time gave better result (Entry 8). However there was always a 
side product isolated. This was identified as 3-(4-methoxybenzyl)-N-(2-chloroethyl)-3H-
[1,2,3]triazolo[4,5-d]pyrimidin-7-amine (4-26) (Figure 4.4).  
 
Cyclization under microwave conditions are given in Entries 10-11. When CHCl3 was 
used as the reaction solvent and 4-20a was treated with 1.5 equiv. SOCl2 at 80oC for 10 
min under microwave condition, 4-21a was obtained in 30% yield (Entry 10). This low 
yield may be attributed to the poor solubility of starting 4-20a in CHCl3. Replacing 
CHCl3 with DMF permitted higher reaction temperature to be used and product 4-21a 
was obtained in 85% yield (Entry 11). NOESY spectrum of 4-21a clearly showed the 
interaction between N1CH2 and C2H which indicates the successful formation of the 
















Figure 4.5 NOESY of compound 4-21a 
 
For compound 4-13b, the first attempt to generate the third ring involves a one-pot 
reaction between 4-13b and 3-bromopropylamine hydrobromide followed by cyclization 
(Scheme 4.12).  Unfortunately this reaction failed to provide complete disappearance of 
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the starting material and gave a very complicated reaction mixture. Pretreatment of 3-




















Scheme 4.12 Initial attempt to 4-21b 
 
Next, we proceeded to investigate the stepwise formation of the third ring for compound 
4-13b. As in the formation of 4-21a from 4-18b, 4-13b was reacted first with 
ethanolamine in THF to give 4-20b in high yield (96%) (Scheme 4.11). Subsequent 
formation of the third ring was carried out according to the reaction condition described 
in Table 4.5 Entry 11. However, unlike 4-20a, 4-20b appeared to undergo cyclization via 























Figure 4.6 Two possible pathways of the cyclization of the pendant alcohol 
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Earlier studies have shown that the pendant alcohol always cyclizes at the N1 position 
because of (i) the greater nucleophilicity of N1 compared to N7 and (ii) the greater 
probability of forming a five-member ring.[10c] In order to obtain experimental evidence 
for the cyclization direction, NOESY experiment of 4-21b was carried out (Figure 4.7). 
The NOESY data clearly showed the interaction between C2H and N1CH2, which 
confirmed the cyclization direction of the third ring. 
 
To expand the diversity of the library, compound 4-21b was subjected to quaternization 
with BuI in DMF. After stirring with 10 equiv. BuI at 70oC overnight, compound 4-21b 
was completely consumed and the product was obtained as a yellow solid. NMR and MS 
data confirmed that this yellow solid was the alkylated product of 4-21b. In order to 
determine the position of the butyl group, NOESY experiment was carried out (Figure 
4.8). The NOESY spectrum showed the interaction between Ha and Hb which indicated 
the direction of cyclization of the ring fused to purine. The NOESY data also showed 
interaction between Hc and Hd and the lack of interaction between Hd and He which 
gave evidence that the butyl group is located at C6N rather than N7 position. Thus the 
quaternization product is 4-23. Subsequent debenzylation of 4-23 can be achieved using 







































Figure 4.8 NOESY of compound 4-23 
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4.3.3 Solid-phase study 
4.3.3.1 Preparation of BOBA resin 
Having validated the approach to synthesize 1,7,8-trisubstituted purines in solution, we 
proceeded to adapt the strategy on solid support. p-Benzyloxybenzylamine (BOBA) resin 
(4-27)  was firstly prepared in two steps using reported procedure[11]: Bromo Merrifield 
resin (2.3 mmol/g) was reacted with 4-hydroxybenzamide in the presence of NaOH 











Scheme 4.13 Preparation of BOBA resin from bromomethylated polystyrene resin 
 
Since the borane solution was difficult to handle and harsh reaction condition was needed 
for the reaction to proceed, we attempted a simple and milder method to prepare the 
BOBA resin (Scheme 4.14). Since Mitsunobu reaction is known to convert an alcohol to 
a primary amine, the Wang resin (1.6 mmol/g) was chosen as the starting resin and was 
firstly treated with PPh3, DiAD and phthalimide, followed by hydrazinolysis with 1 M 
hydrazine in THF. IR spectrum of the resin showed the appearance of C=O stretch at 
1770 cm-1 and 1714 cm-1 and the disappearance of these stretches after hydrazinolysis. 
Meanwhile loading of BOBA resin calculated from the loading of Fmoc release UV 
assay[12] showed almost quantitatively conversion from the starting Wang resin to the 


































































Scheme 4.14 Solid-phase synthesis of 1,7,8-trisubstituted purines 
 
The prepared BOBA resin (4-27) was then subjected to SNAr displacement with 5-amino-
4,6-dichloropyrimidine at elevated temperature as established in solution-phase study 
(Scheme 4.14). However in the solid-phase reaction, DMA was required as a co-solvent 
to ensure good swelling of the resin (DMF was also examined as a possible co-solvent 
but it decomposed at the high temperature under basic condition). Formation of 1,7,8-
trisubstituted purines was then performed by cyclization of resin 4-28 with various 
aldehydes in the presence of acetic acid according to our solution-phase study. Resin 4-28 
was stirred with various aldehydes in THF under reflux followed by hydrolysis with 85% 
formic acid to offer polymer supported 9-(4-(benzyloxy)benzyl)-8-hexyl-1-(prop-2-ynyl)-
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1H-purin-6(9H)-one (4-29). Subsequent N1 alkylation introduced the second point of 
diversity followed by quaternization at N7 with different alkyl halides. For the 
quaternization reaction, when an alkyl bromide was used, the addition of sodium iodide 
to the quaternization mixture improved the efficiency of the alkylation. The final product 
4-6 was then released from the solid support by treatment with 96% sulfuric acid at room 
temperature for 3 h in the presence of toluene. In this step CH2Cl2 was required as a co-
solvent to achieve good swelling of the resin. Using this strategy compounds 4-6a~4-6i 
were prepared in 8-12% overall yields (Figure 4.12), indicating an average yield of at 
least 73% for each step of the reaction. The solid-phase cyclization chemistry with 
aldehydes has been validated for both aliphatic and aromatic aldehydes. With the 
aromatic aldehydes, it was observed that having an electron-donating group on the para 
position, such as 4-methoxybenzaldehyde, gave better result whilst the presence of an 
electron-withdrawing group on the para position, e.g. 4-nitrobenzaldehyde, did not give 
the desired product. X-ray crystal analysis of 4-6i confirmed the structure obtained.  
 




 4.3.3.3 Solid-phase synthesis of simple 1,7-disubstituted purines and 8-azapurines 
As shown from our solution-phase study, 1,7-disubstituted purines and 8-azapurines can 
be prepared from diamine 4-2a through different routes. We now proceeded to adapt the 
methodology for SPS. Resin bound diamine 4-28 was employed as a key intermediate for 
















































4-32a   X=CH




4-34a   X=CH




Scheme 4.15 Solid-phase synthesis of simple purines and 8-azapurines 
 
Formation of simple 1,7-disubstituted purines by cyclization of the key intermediate resin 
bound diamine 4-28 was first studied (Scheme 4.15). Treatment of resin 4-28 with 
trimethyl orthoformate facilitated cyclization to offer 4-32a. Subsequent hydrolysis of the 
6-choride, N1 alkylation and regioselective N7 alkylation can also be accomplished 
according to the method described in solution-phase study. With this strategy, compounds 
4-17a~4-17d were prepared in ~18% overall yields which implied that an average 81% 
yield was obtained for each step of the reaction (Figure 4.12). X-ray crystal analyses of 4-




Figure 4.10 X ray crystal structure of compound 4-17b 
 
 
Figure 4.11 X ray crystal structure of compound 4-17c 
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Then the SPS of 8-azapurines was studied. Reaction of resin 4-28 with sodium nitrite in 
the presence of 50% HOAc in DCM easily gave resin bound 8-azapurine 4-32b. Similar 
hydrolysis and N1 alkylation can also be performed to give 4-35 which was directly 
cleaved from the resin with 96% H2SO4 or CAN/CH3CN/H2O. (Scheme 4.15) With this 
synthetic route, compounds 4-35a~4-35d were prepared on solid-phase in high yields 
(Figure 4.12). This study gave the first example of SPS of 8-azapurines. 
 
4.3.3.4 Solid-phase synthesis of [i]-condensed purine 
Additionally, [i]-condensed purine can be prepared from the key intermediate resin bound 










































4-32a   X=CH




4-38a   X=CH
4-38b   X=N
4-37a   X=CH
4-37b   X=N
C4H9 C4H9
 
Scheme 4.16 Solid-phase synthesis of [i]-condensed purine 
 
Resin 4-32 was obtained from 4-28 using the same methods as described above. Resin 4-
32 was subsequently treated with ethanolamine to give resin 4-37 which in turn reacted 
with SOCl2 in DMF under microwave condition to form the third five-member ring. The 
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final [i]-condensed purine was obtained through cleavage with H2SO4/toluene. Obtained 
4-38a could be treated with 1-iodobutane to enable quarternizaiton at the C6N position. 
Using this strategy, compounds 4-22 and 4-24 were prepared in 28% overall yield. This is 
the first reported solid-phase synthesis of [i]-condensed purines.  
4.4 Conclusions 
In conclusion, we have demonstrated both the solution-phase study and the traceless 
solid-phase synthesis of various substituted purines with BOBA resin. The target purines 
were obtained in high purity and yields. This solid-phase approach offers various 
advantages - 1) key intermediate resin bound diamine 4-28 can provide more 
combinatorial modification on the purine C8 position; 2) regioselective N7 alkylation can 
be achieved; 3) the first SPS of 8-azapurines and [i]-condensed purines have been 


















































































4-17d   16%
4-6g   12%
4-6f   11%
4-6c   9%
4-6d   11%
4-6b   8%4-6a   9%
4-6e   11%
4-6h   8% 4-6i   9%
4-17b   18% 4-17c   19%






























4-35d   34%4-35c   24%
4-35b   25%4-35a   36%
 




4.5 Experimental  
General Procedures.  1HNMR and 13CNMR spectra were measured at 298K on a Bruker 
DPX 300 or AMX500 Fourier Transform spectrometer. Chemical shifts were reported in 
δ (ppm), relative to the internal standard of tetramethylsilane (TMS). All Infra-red (IR) 
spectra were recorded on a Bio-Rad FTS 165 spectrometer. Mass spectra were performed 
on VG Micromass 7035 spectrometer under electron impact (EI). All chemical reagents 
were obtained from commercial suppliers and used without further purification. 
Analytical TLC was carried out on pre-coated plates (Merck silica gel 60, F254) and 
visualized with UV light. Flash column chromatography was performed with silica 
(Merck, 70-230 mesh). Microwave reaction was performed on InitiatorTM microwave 
synthesizer. 
 
4.5.1 Synthesis of (4-(benzyloxy)phenyl)methanamine (4-1a) 
4.5.1.1 Synthesis of 4-(benzyloxy)benzamide 
NaOH (1.50 g, 37.5 mmol) was added to a solution of 4-hydroxybenzamide (3.09 g, 22.5 
mmol) in DMSO (40 mL). The mixture was stirred at 90°C for 1 h before benzyl bromide 
(2.57 g, 15 mmol) was added. The reaction was then stirred at 90°C for an additional 3 h 
and extracted with EtOAc and water. The combined organic layer was washed with brine, 
dried with MgSO4, concentrated to dryness and purified by column chromatography 
(EtOAc:hexane = 2:1) to give 4-(benzyloxy)benzamide as a white solid (3.00g, 87%). 
1HNMR (DMSO-d6, 300 Hz) δ(ppm): 5.16 (s, 2H, PhCH2), 7.05 (m, 2H, ArH), 7.33-7.47 
(m, 5H, ArH), 7.84 (m, 2H, ArH). 13CNMR (DMSO-d6, 300 Hz) δ(ppm): 68.76, 113.64, 
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136.18, 127.13, 127.32, 127.85, 128.73, 136.16, 160.06, 166.79. HRMS(EI) Calcd for 
C14H13NO2 227.0946; found: 227.0946.    
 
4.5.1.2 Synthesis of (4-(benzyloxy)phenyl)methanamine (4-1a) 
To a solution of borane (0.60 mmol) in THF (1 mL) was added 4-(benzyloxy)benzamide 
(67.00 mg, 0.30 mmol) in THF (2 mL). The reaction mixture was stirred under reflux 
overnight and then concentrated to dryness. The white solid obtained was dissolved in 
EtOAc and washed with water. The aqueous layer was then extracted with EtOAc and the 
combined organic layer was washed with brine, dried with MgSO4, concentrated to 
dryness and purified by column chromatography (EtOAc 100% followed by 
MeOH:CH2Cl2=1:8) to give 4-1a as a white solid (55.00 mg, 88%). 1HNMR (MeOD, 300 
Hz) δ(ppm): 4.43 (s, 4H, 2CH2), 6.49-6.97 (m, 9H, ArH). 13CNMR (DMSO-d6, 300 Hz) 
δ(ppm): 45.59, 70.99, 116.11, 128.50, 128.81, 129.45, 130.07, 132.32, 138.69, 159.53. 
MS(EI): m/z 213.1. 
 
4.5.2 Synthesis of N4-(4-(benzyloxy)benzyl)-6-chloropyrimidine-4,5-diamine (4-2a) 
and N4-(4-methoxybenzyl)-6-chloropyrimidine-4,5-diamine (4-2b) 
A solution of compound 4-1a or 4-methoxybenzyl amine, 5-amino-4,6-
dichloropyrimidine (1.5 equiv.) and DiEA (3 equiv.) in 1-butanol was stirred under reflux 
for 24 h and then evaporated to dryness. The residue obtained was extracted with EtOAc 
and water. The combined organic layer was washed with brine, dried with MgSO4, 
concentrated to dryness and purified by column chromatography (EtOAc:hexane=1:4) to 
give 4-2a and 4-2b in 75% and 100% yield respectively.  
 141
4-2a: 1HNMR (CDCl3, 300 Hz) δ(ppm): 3.62 (s, 2H, NH2), 4.57 (d, J=5.2 Hz, 2H, 
NHCH2), 5.03 (s, 2H, OCH2), 5.45 (s, 1H, NH), 6.90-7.43 (m, 9H, ArH), 8.03 (s, 1H, 
C2H). 13CNMR (DMSO-d6, 300 Hz) δ(ppm): 45.00, 69.96, 114.94, 121.96, 127.34, 
127.93, 128.52, 129.23, 130.36, 136.76, 142.00, 149.09, 154.32, 158.18. HRMS(EI) 
Calcd for C18H17N4OCl 340.1091 found: 340.1087.  
4-2b: 1HNMR (DMSO-d6, 300 Hz) δ(ppm): 2.85(s, 3H, CH3), 3.68 (d, J=5.2 Hz, 2H, 
NHCH2), 4.21 (s, 2H, PhCH2), 5.45 (s, 1H, NH), 6.00-6.40 (m, 4H, ArH), 8.03 (s, 1H, 
C2H). 13CNMR (DMSO-d6, 300 Hz) δ(ppm): 43.17, 54.54, 113.21, 123.03, 128.32, 
130.75, 136.38, 145.11, 151.26, 157.81. HRMS(EI) Calcd for C12H13N4OCl 264.0778; 
found: 264.0776. 
 
4.5.3 Synthesis of 9-(4-(benzyloxy)benzyl)-8-hexyl-1H-purin-6(9H)-one (4-3) and 9-
(4-(benzyloxy)benzyl)-6-chloro-8-hexyl-9H-purine (4-12) 
Acetic acid (0.5 mL) was added to a solution of 4-2a (66.00 mg, 0.2 mmol) and heptan-1-
al (0.11 mL, 0.8 mmol) in THF (2 mL). The reaction mixture was stirred under reflux for 
24 h and then concentrated to dryness. The residue was dissolved in 85% formic acid (2.1 
mL), stirred at 70°C for 3 h and then evaporated to dryness and chromatographed on 
silica gel column using EtOAc:hexane=1:1 followed by EtOH:CH2Cl2=1:10 as eluent to 
give 4-3 as pale yellow solid (65.00 mg, 81%). 4-3: 1HNMR (DMSO-d6, 300 Hz) 
δ(ppm): 0.83 (t, J=6.6 Hz, 3H, CH3), 1.19-1.59 (m, 8H, 4CH2), 2.67 (t, J=7.7 Hz, 2H, 
C8CH2), 5.05 (s, 2H, N9CH2), 5.28 (s, 2H, OCH2), 6.96 (m, 2H, ArH), 7.11-7.42 (m, 9H, 
ArH), 8.02 (s, 1H, C2H), 12.25 (s, 1H, N1H). 13CNMR (DMSO-d6, 300 Hz) δ(ppm): 
13.29, 21.34, 25.81, 26.04, 27.60, 30.34, 73.94, 68.68, 114.44, 122.13, 127.03, 127.23, 
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127.73, 127.82, 128.23, 136.38, 144.49, 148.60, 150.54, 155.71, 157.27. HRMS(EI) 
Calcd for C25H28N4O2 416.2212; found: 416.2200.  
 
9-(4-(Benzyloxy)benzyl)-6-chloro-8-hexyl-9H-purine (4-12): 1HNMR (CDCl3, 300 Hz) 
δ(ppm): 0.86 (t, J=6.6 Hz, 3H, CH3), 1.25-1.37 (m, 6H, 3CH2), 1.70-1.77 (m, 2H, CH2), 
2.83 (t, J=7.7 Hz, 2H, C8CH2), 5.01 (s, 2H, N9CH2), 5.37 (s, 2H, OCH2), 6.89-7.39 (m, 
9H, ArH), 8.69 (s, 1H, C2H). 13CNMR (CDCl3, 300 Hz) δ(ppm): 13.89, 22.33, 27.10, 
28.20, 28.97, 31.26, 45.79, 70.01, 115.33, 127.29, 127.36, 127.96, 128.43, 128.51, 
130.86, 136.53, 148.92, 151.14, 153.23, 158.74, 158.86. HRMS(EI) Calcd for 
C25H27ClN4O 434.1873; found: 434.1873. 
 
4.5.4 Synthesis of 9-(4-(benzyloxy)benzyl)-8-hexyl-1-(prop-2-ynyl)-1H-purin-6(9H)-
one (4-4) 
Propargyl bromide (0.14 g, 1.2 mmol) and DBU (0.18 g, 1.2 mmol) were added to a 
solution of 4-3 (0.11 g, 0.3 mmol) in DMF (2 mL). The reaction mixture was stirred at 
room temperature overnight and then extracted with EtOAc and brine. The combined 
organic layer was washed with brine, dried with MgSO4, concentrated to dryness and 
purified by column chromatography (EtOAc:hexane = 1:1 followed by acetone:hexane= 
1:4) to provide 4-4 as yellow oil  (0.13 g, 98%). 1HNMR (CDCl3, 300 Hz) δ(ppm): 0.84 
(t, J=6.4 Hz, 3H, CH3), 1.22-1.76 (m, 8H, 4CH2), 2.49 (t, J=2.4 Hz, 1H, CH), 2.68 (t, 
J=7.8 Hz, 2H, C8CH2), 4.86 (d, J=2.0 Hz, 2H, N1CH2), 5.01 (s, 2H, N9CH2), 5.24 (s, 
2H, OCH2), 6.89 (m, 2H, ArH), 7.05 (m, 2H, ArH), 7.30-7.39 (m, 5H, ArH), 8.25 (s, 1H, 
C2H). 13CNMR (CDCl3, 300 Hz) δ(ppm): 13.93, 22.40, 27.05, 27.72, 28.92, 31.35, 
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34.87, 45.39, 70.02, 75.38, 76.58, 115.24, 127.33, 127.94 (x2), 127.98, 128.21, 128.53, 
136.63, 145.17, 148.46, 152.88, 155.65, 158.57. HRMS(EI) Calcd for C28H30N4O2  
454.2369; found: 454.2360.   
 
4.5.5 Synthesis of 9-(4-(benzyloxy)benzyl)-7-butyl-8-hexyl-1-(prop-2-ynyl)-8,9-
dihydro-1H-purin-6(7H)-one salt (4-5) 
1-Iodobutane (0.8 mL, 7 mmol) was added to a solution of 4-4 (0.08 g, 0.18 mmol) in 
DMF (2 mL). The reaction mixture was stirred at 70oC for 24 h and then evaporated to 
dryness. The residue was purified by column chromatography (ethanol:CH2Cl2 = 1:15) to 
give 4-5 (0.11 g, 93%). 1HNMR (CDCl3, 300 Hz) δ(ppm): 0.77 (t, J=7.0 Hz, 3H, CH3), 
0.92 (t, J=7.3 Hz, 3H, CH3), 1.04-1.94 (m, 12H, 6CH2), 2.53 (t, J=2.4 Hz, 1H, CH), 3.22 
(t, J=8.0 Hz, 2H, C8CH2), 4.36 (t, J=8.0 Hz, 2H, N7CH2), 4.91 (d, J=2.4 Hz, 2H, 
N1CH2), 4.97 (s, 2H, N9CH2), 5.64 (s, 2H, OCH2), 6.88 (m, 2H, ArH), 7.21 (m, 2H, 
ArH), 7.24-7.32 (m, 5H, ArH), 8.69 (s, 1H, C2H). 13CNMR (CDCl3, 300 Hz) δ(ppm): 
13.32, 13.82, 19.83, 22.14, 26.81, 27.37, 29.01, 30.91, 32.50, 36.27, 48.27, 48.86, 70.07, 
75.42, 76.45, 113.36, 115.57, 125.55, 127.32, 128.07, 128.56, 129.51, 136.31, 146.74, 
150.27, 151.36, 153.43, 159.26. HRMS(ESI) Calcd for C32H39N4O2 511.3073; found: 
511.3070.    
 
4.5.6 Synthesis of 7-butyl-8-hexyl-1-(prop-2-ynyl)-1H-purin-6(7H)-one (4-6a) 
Method A: 96% Sulfuric acid (0.5 mL) and toluene (0.5 mL) were added to a solution of 
4-5 in dichloromethane (1 mL). The reaction mixture was stirred vigorously at room 
temperature for 3 h, neutralized with saturated NaHCO3 to pH8 and then extracted with 
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EtOAc and water. The combined organic layer was washed with brine, dried with 
MgSO4, concentrated to dryness and purified by column chromatography (EtOAc:hexane 
= 1:1 followed by acetone:hexane= 1:2) to provide 4-6a as yellow oil  (0.13 g, 95%). 
1HNMR (CDCl3, 300 Hz) δ(ppm): 0.87 (t, J=7.0 Hz, 3H, CH3), 0.90 (t, J=7.4 Hz, 3H, 
CH3), 1.29-1.91 (m, 12H, 6CH2), 2.46 (t, J=2.6 Hz, 1H, CH), 2.78 (t, J=7.8 Hz, 2H, 
C8CH2), 4.33 (t, J=7.4 Hz, 2H, N7CH2), 4.79 (d, J=2.8 Hz, 2H, N1CH2), 8.23 (s, 1H, 
C2H). 13CNMR (CDCl3, 300 Hz) δ(ppm): 13.63, 13.95, 19.75, 22.45, 27.04, 27.56, 
29.03, 31.43, 33.48, 34.63, 45.25, 74.82, 76.58, 114.70, 114.93, 147.38, 153.19, 156.34. 
HRMS(EI) Calcd for C18H26N4O 314.2107; found: 314.2103.    
 
Method B: CAN (4 equiv.) was added protionwise to a stirred solution of compound 4-5 
and in acetonitrile/H2O (4:1). The reaction mixture was stirred rapidly at room 
temperature for 8 h and then quenched with NaHCO3 (aq.). The quenched mixture was 
stirred vigorously for 10 min before extraction with EtOAc and brine. The combined 
organic layer was washed with brine, dried with MgSO4, concentrated to dryness and 
purified by column chromatography (EtOAc:hexane = 1:1 followed by acetone:hexane= 
1:2) to provide 4-6a. 
 
4.5.7 Synthesis of ethyl N4-(4-(benzyloxy)benzylamino)-6-chloropyrimidin-5-yl- 
acetimidate (4-7) 
Catalytic amount of TsOH or HCl was added to the solution of 4-2a (0.12 g, 0.34 mmol) 
in triethyl orthoacetate (4 mL). The reaction mixture was stirred at room temperature for 
3 h, concentrated to dryness and purified by silica gel column chromatography 
(EtOAc:Hexane = 1:1) to give 4-7 as a pale yellow oil (0.24 g, 99%). 1HNMR (CDCl3, 
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300 Hz) δ(ppm): 1.33 (t, J=7.0 Hz, 3H, CH3), 1.86 (s, 3H, CH3), 4.27-4.29 (m, 2H, 
OCH2), 4.61 (d, J=5.6 Hz, 2H, NHCH2), 5.05 (s, 2H, CH2), 6.93-7.43 (m, 9H, ArH), 8.19 
(s, 1H, C2H). 13CNMR (CDCl3, 300 Hz) δ(ppm): 13.92, 17.62, 44.41, 62.67, 69.87, 
114.91, 123.83, 127.26, 127.82, 128.43, 128.72, 130.55, 136.73, 145.49, 152.41, 156.42, 
158.10, 166.89. HRMS(EI) Calcd for C22H23ClN4O2 410.1510; found: 410.1497. 
 
4.5.8 Synthesis of 9-(4-(benzyloxy)benzyl)-6-chloro-8-methyl-9H-purine (4-8) 
A solution of ferric chloride (0.05 g, 0.31 mmol) in ethanol (1 mL) was added to a 
solution of 4-7 (0.07 g, 0.18 mmol) in ethanol (3 mL). The reaction mixture was stirred 
under reflux condition for 1 h then concentrated to dryness and purified by silica gel 
column chromatography (EtOAc:Hexane = 1:1) to give 4-8 as a white solid (0.03 g, 
46%). 1HNMR (CDCl3, 300 Hz) δ(ppm): 2.60 (s, 3H, CH3), 5.03 (s, 2H, CH2), 5.36 (s, 
2H, CH2), 6.87-8.06 (m, 9H, ArH), 8.71 (s, 1H, C2H). 13CNMR (CDCl3, 300 Hz) 
δ(ppm): 14.78, 46.04, 77.06, 114.99, 115.41, 127.01, 127.37, 127.97, 128.04, 128.57, 
128.65, 129.33, 136.52, 149.49, 151.32, 155.23. HRMS(EI) Calcd for C20H17ClN4O 
364.1091; found: 364.1091. 
 
4.5.9 Synthesis of N4-(4-(benzyloxy)benzylamino)-6-chloropyrimidin-5-yl)benzamide 
(4-9) 
A solution of 4-2a (138 mg, 0.41 mmol), benzoyl chloride (63 mg, 0.45 mmol) and DiEA 
(78 mg, 0.61 mmol) in THF was stirred at room temperature for 7 h and then 
concentrated to dryness and purified by silica gel column chromatography 
(EtOAc:Hexane = 1:4-1:2) to give 4-9 (163 mg, 91%). 1HNMR (CDCl3, 300 Hz) δ(ppm): 
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4.63 (d, J=5.2 Hz, 2H, C4NH), 5.01 (s, 2H, CH2), 5.36 (s, 2H, CH2), 6.89-7.88 (m, 14H, 
ArH), 7.99 (s, 1H, C2H). 13CNMR (CDCl3, 300 Hz) δ(ppm): 44.71, 69.95, 113.17, 
114.97, 127.36, 127.49, 127.89, 128.50, 128.81, 128.85, 130.24, 132.49, 132.71, 136.82, 
154.17, 155.71, 158.12, 158.74, 166.44.  HRMS(EI) Calcd for C25H21ClN4O2 444.1353; 
found: 444.1357. 
 
4.5.10 Synthesis of 9-(4-(benzyloxy)benzyl)-6-chloro-8-phenyl-9H-purine (4-10) and 
9-(4-(benzyloxy)benzyl)-8-phenyl-1H-purin-6(9H)-one (4-11) 
A mixture of 4-9 and 10% KOH in CH3CN was stirred under reflux for overnight and 
then was neutralized to pH7-8, concentrated to dryness and purified by silica gel column 
chromatography (EtOAc:Hexane = 1:1-Acetone:Hexane=1:1) to give 4-10 and 4-11 in 
ratio of 1:1.   
4-10: 1HNMR (CDCl3, 300 Hz) δ(ppm): 5.01 (s, 2H, CH2), 5.50 (s, 2H, CH2), 6.85-7.70 
(m, 14H, ArH), 8.78 (s, 1H, C2H). MS(EI): m/z 426.0.  
4-11: 1HNMR (MeOD, 300 Hz) δ(ppm): 5.02 (s, 2H, CH2), 5.46 (s, 2H, CH2), 6.85-7.62 
(m, 14H, ArH), 8.25(s, 1H, C2H).  MS(EI): m/z 407.0. 
 
4.5.11 Synthesis of 9-(4-(benzyloxy)benzyl)-6-chloro-9H-purine (4-13a) and 9-(4-
methoxybenzyl)-6-chloro-9H-purine (4-13b)  
Compounds 4-13a and 4-13b were prepared from 4-2a and 4-2b correspondingly using 
the method described in Section 4.5.7 (trimethyl orthoformate was used instead of triethyl 
orthoacetate) in 91% and 90% yield respectively.  
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4-13a: 1HNMR (CDCl3, 300 Hz) δ(ppm): 5.01 (s, 2H, OCH2), 5.34 (s, 1H, CH2), 6.92-
7.36 (m, 9H, ArH), 8.07 (s, 1H, C8H), 8.75 (s, 1H, C2H). 13CNMR (CDCl3, 300 Hz) 
δ(ppm): 47.28, 69.91, 115.36, 126.66, 127.22, 127.90, 128.44, 129.40, 131.39, 136.38, 
144.81, 150.79, 151.64, 151.88, 158.95. MS(EI): m/z 350.0.  
4-13b: 1HNMR (CDCl3, 300 Hz) δ(ppm): 3.62 (s, 3H, CH3), 5.26 (s, 1H, CH2), 6.69-7.15 
(m, 4H, ArH), 8.06 (s, 1H, C8H), 8.59 (s, 1H, C2H). 13CNMR (CDCl3, 300 Hz) δ(ppm): 
46.91, 54.77, 113.94, 126.09, 129.02, 130.93, 144.75, 150.10, 151.27, 151.37, 159.28. 
HRMS(EI) Calcd for C13H11N4OCl  274.0621; found: 274.0613. 
 
4.5.12 Synthesis of 9-(4-(benzyloxy)benzyl)-1H-purin-6(9H)-one (4-14) 
A solution of 4-13a in 85% formic acid was stirred at 70oC for 1 h and then concentrated 
to dryness. The residue obtained was dissolved in EtOAc and brine. The aqueous layer 
was extracted with EtOAc and the combined organic layer was washed with brine, dried 
with MgSO4 and purified by silica gel column chromatography (MeOH:DCM = 1:15) to 
give 4-14 as a white solid in 92% yield. 1HNMR (DMSO-d6, 300 Hz) δ(ppm): 5.07 (s, 
2H, OCH2), 5.28 (s, 1H, CH2), 6.96-7.40 (m, 9H, ArH), 8.03 (s, 1H, C8H), 8.16 (s, 1H, 
C2H). 13CNMR (DMSO-d6, 300 Hz) δ(ppm): 46.06, 69.19, 114.94, 123.98, 127.62, 
127.81, 128.40, 128.99, 129.12, 136.93, 140.13, 145.68, 148.22, 156.64, 157.97. MS(EI): 
m/z 332.0.  
 
4.5.13 Synthesis of 9-(4-(benzyloxy)benzyl)-1-butyl-1H-purin-6(9H)-one (4-15) 
Compound 4-15 was prepared from 4-14 using the method described in Section 4.5.4 in 
89% yield. 1HNMR (CDCl3, 300 Hz) δ(ppm): 0.94 (t, 3H, J=7.4 Hz, CH3), 1.33-1.71 (m, 
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2H, CH2), 1.74-1.77 (m, 2H, CH2), 4.03 (t, 3H, J=7.4 Hz, N1CH2), 5.03 (s, 2H, OCH2), 
5.21 (s, 1H, CH2), 6.91-7.34 (m, 9H, ArH), 7.59 (s, 1H, C8H), 7.95 (s, 1H, C2H). 
13CNMR (CDCl3, 300 Hz) δ(ppm): 13.51, 19.71, 31.77, 46.61, 46.90, 70.00, 115.31, 
124.33, 127.30, 127.51, 127.95, 128.51, 129.19, 136.57, 139.60, 146.98, 147.60, 156.52, 
158.83. HRMS(EI) Calcd for C23H24N4O2 388.1899; found: 388.1893. 
 
4.5.14 Synthesis of 9-(4-(benzyloxy)benzyl)-1,7-dibutylpurin-6-one salt (4-16) 
Compound 4-16 was prepared from 4-15 using the method described in Section 4.5.5 in 
92% yield. 1HNMR (CDCl3, 300 Hz) δ(ppm): 0.91-0.97 (m, 6H, 2CH3), 1.35-1.43 (m, 
4H, 2CH2), 1.71-1.75 (m, 2H, CH2), 1.96-2.01 (m, 2H, CH2), 4.10 (t, 3H, J=7.5 Hz, 
CH2), 4.10 (t, 3H, J=7.6 Hz, CH2), 4.98 (s, 2H, OCH2), 5.64 (s, 1H, CH2), 6.91-7.34 (m, 
9H, ArH), 8.43 (s, 1H, C2H), 10.87 (s, 1H, C8H). 13CNMR (CDCl3, 300 Hz) δ(ppm): 
13.23, 13.37, 19.32, 19.57, 47.38, 49.11, 49.96, 69.86, 114.02, 115.39, 124.96, 127.26 
(x2), 127.89, 128.42 (x2), 131.07, 136.33, 139.97, 146.16, 151.18, 151.99, 159.40. 
HRMS(ESI) Calcd for C27H33N4O2 445.2604; found: 445.2590. 
 
4.5.15 Synthesis of 1,7-dibutyl-1H-purin-6(7H)-one (4-17a) 
Compound 4-17a was prepared from 4-16 using the method described in Section 4.5.6 in 
96% yield. 1HNMR (CDCl3, 300 Hz) δ(ppm): 0.92-0.98 (m, 6H, 2CH3), 1.31-1.43 (m, 
4H, 2CH2), 1.70-1.92 (m, 4H, 2CH2), 4.00 (t, 3H, J=7.3 Hz, CH2), 4.40 (t, 3H, J=7.3 Hz, 
CH2), 7.81 (s, 1H, C8H), 7.99 (s, 1H, C2H). 13CNMR (CDCl3, 300 Hz) δ(ppm): 13.44, 
13.55, 19.54, 19.81, 31.86, 33.34, 46.32, 47.21, 115.41, 143.15, 146.38, 154.25, 156.94. 
HRMS(ESI) Calcd for C13H20N4O 248.1637; found: 248.1637. 
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4.5.16 Synthesis of 3-(4-(benzyloxy)benzyl)-7-chloro-3H-[1,2,3]triazolo[4,5-d] 
pyrimidine (4-18a) and 3-(4-methoxybenzyl)-7-chloro-3H-[1,2,3]triazolo[4,5-d] 
pyrimidine (4-18b) 
Sodium nitrite (4.7 equiv.) was added to a solution of 4-2a or 4-2b in DCM and 50% 
HOAc (aq). The reaction mixture was stirred vigorously at room temperature for 30 min 
and then concentrated to dryness and purified by silica gel column chromatography 
(EtOAc:Hexane = 1:2) to give 4-18a or 4-18b in 96% and 94% yield respectively.  
4-18a:  1HNMR (CDCl3, 300 Hz) δ(ppm): 5.01 (s, 2H, CH2), 5.80 (s, 2H, CH2), 6.91-7.44 
(m, 9H, ArH), 8.91 (s, 1H, C2H). 13CNMR (CDCl3, 300 Hz) δ(ppm): 50.86, 69.85, 
115.14, 126.09, 127.26, 127.92, 128.46, 130.00, 133.99, 136.41, 149.42, 153.91, 155.34, 
159.02. HRMS(EI) Calcd for C18H14N5OCl 351.0887; found: 351.0890.  
4-18b: 1HNMR (CDCl3, 300 Hz) δ(ppm): 3.77 (s, 3H, CH3), 5.82 (s, 2H, CH2), 6.85-7.45 
(m, 4H, ArH), 8.92 (s, 1H, C2H). 13CNMR (CDCl3, 300 Hz) δ(ppm): 50.66, 54.97, 
113.98, 125.67, 129.75, 133.75, 149.24, 153.57, 155.13, 159.59. HRMS(EI) Calcd for 
C12H10N5OCl 275.0574; found: 275.0579. 
 
4.5.17 Synthesis of 3-(4-(benzyloxy)benzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7 
(6H) -one (4-19) 
Compound 4-19 was prepared from 4-18 using the method described in Section 4.5.12 in 
92% yield. 1HNMR (DMSO-d6, 300 Hz) δ(ppm): 5.07 (s, 2H, CH2), 5.67 (s, 2H, CH2), 
6.97-7.41 (m, 9H, ArH), 8.26 (s, 1H, C2H). 13CNMR (DMSO-d6, 300 Hz) δ(ppm): 49.39, 
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69.19, 115.00, 127.54, 127.66, 127.85, 128.16, 128.43, 129.50, 129.67, 148.38, 149.83, 
155.28, 158.21. HRMS(EI) Calcd for C18H15N5O2 333.1226; found: 333.1229. 
 
4.5.18 Synthesis of 2-(3-(4-methoxybenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7-
ylamino)ethanol (4-20a) and 2-(9-(4-methoxybenzyl)-9H-purin-6-ylamino)ethanol 
(4-20b) 
A solution of 4-18b or 4-13b and ethanolamine (3 equiv.) in THF was stirred at 0oC for 3 
h and then concentrated to dryness and purified by silica gel column chromatography 
(EtOAc:Hexane = 1:2) to give 4-20a or 4-20b in 100% and 96% yield respectively.  
4-20a:  1HNMR (DMSO-d6, 300 Hz) δ(ppm): 3.60-3.62 (m, 4H, 2CH2), 3.71 (s, 3H, 
CH3), 5.67 (s, 2H, CH2), 6.88-7.31 (m, 5H, ArH), 8.39 (s, 1H, C2H). 13CNMR (CDCl3, 
300 Hz) δ(ppm): 50.86, 69.85, 115.14, 126.09, 127.26 (x2), 127.92, 128.46 (x2), 130.00, 
133.99, 136.41, 149.42, 153.91, 155.34, 159.02. HRMS(EI) Calcd for C14H16N6O 
300.1335; found: 300.1339.   
4-20b: 1HNMR (CDCl3, 300 Hz) δ(ppm): 3.66-3.82 (m, 7H, CH3+2CH2), 5.13 (s, 2H, 
CH2), 6.76-7.18 (m, 4H, ArH), 7.61 (s, 1H, C8H), 8.27 (s, 1H, C2H). 13CNMR (CDCl3, 
300 Hz) δ(ppm): 43.40, 46.41, 54.98, 61.25, 114.06, 118.97, 127.22, 129.04, 139.19, 







4.5.19 Synthesis of 4-21a and 4-21b 
4.5.19.1 Synthesis of 4-21a and 4-21b 
A solution of 4-20a or 4-20b and thionyl chloride (1.5 equiv.) in DMF was stirred at 
180oC under microwave irradiation for 20 min. After evaporating all the volatile 
materials, the residue was dissolved in CH2Cl2 and saturated Na2CO3. The aqueous layer 
was extracted with CH2Cl2. The combined organic layer was washed with brine, dried 
with MgSO4 and purified by silica gel column chromatography (Acetone:DCM=1:1-
EtOH:DCM= 1:10) to give 4-21a (83%) and 4-21b (88%).  
4-21a: 1HNMR (DMSO-d6, 300 Hz) δ(ppm): 3.72 (s, 3H, CH3), 3.98 (t, J=9.5 Hz, 2H, 
CH2), 4.10 (t, J=9.2 Hz, 2H, CH2), 5.51 (s, 2H, CH2), 6.81-7.33 (m, 4H, ArH), 7.77 (s, 
1H, C2H). 13CNMR (CDCl3, 300 Hz) δ(ppm): 45.89, 49.93, 54.33, 55.13, 113.99, 125.99, 
126.71, 129.55, 146.19, 147.99, 156.62, 159.48. HRMS(EI) Calcd for C14H14N6O 
282.1229; found: 282.1240.  
 4-21b: 1HNMR (DMSO-d6, 300 Hz) δ(ppm): 3.71 (s, 3H, CH3), 3.88 (t, J=9.1 Hz, 2H, 
CH2), 4.10 (t, J=9.6 Hz, 2H, CH2), 5.20 (s, 2H, CH2), 6.87-7.26 (m, 4H, ArH), 8.02 (s, 
1H, C8H), 8.06 (s, 1H, C2H). 13CNMR (CDCl3, 300 Hz) δ(ppm): 43.40, 46.41, 54.98, 
61.25, 114.06, 118.97, 127.22, 129.04, 139.19, 148.65, 152.75, 154.69, 159.29. 
HRMS(EI) Calcd for C15H15N5O 281.1277; found: 281.1287.  
 
4.5.19.2 Data of side products 4-25 and 4-26 
2-(3-(4-Methoxybenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7-ylamino)ethyl methane 
sulfonate (4-25): 1HNMR (DMSO-d6, 300 Hz) δ(ppm): 2.89 (s, 3H, CH3), 3.29-3.35 (m, 
2H, NHCH2), 4.11 (m, 2H, OCH2), 5.68 (s, 2H, PhCH2), 6.90-7.34 (m, 4H, ArH), 7.32 
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(br, 1H, NH), 8.46 (s, 1H, C2H). 13CNMR (DMSO-d6, 300 Hz) δ(ppm): 40.34, 41.39, 
47.47, 50.22, 56.00, 113.65, 126.73, 128.66, 129.08, 147.30, 152.17, 154.37, 158.68. 
HRMS(EI) Calcd for C15H18N6O4S 378.1110; found: 378.1113.  
 
3-(4-Methoxybenzyl)-N-(2-chloroethyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7-amine 
(4-26): 1HNMR (DMSO-d6, 300 Hz) δ(ppm): 3.71 (s, 3H, OCH3), 3.83-3.85 (m, 4H, 
2CH2), 5.70 (s, 2H, PhCH2), 6.89-7.33 (m, 4H, ArH), 8.43 (s, 1H, C2H), 9.13 (br, 1H, 
NH). HRMS(EI) Calcd for C14H15N6OCl 318.0996; found: 318.0992.  
 
4.5.20 9-Butyl-4-(4-methoxybenzyl)-tetrahydro-imidazo[2,1-i]purine salt (4-23) 
Compound 4-23 was prepared using the method described in Section 4.5.5 in 84% yield. 
1HNMR (CDCl3, 300 Hz) δ(ppm): 0.94 (t, J=7.3 Hz, 3H, CH3), 1.38-1.45 (m, 2H, CH2), 
1.74-1.81 (m, 2H, CH2), 3.77 (s, 3H, CH3), 4.09 (t, J=7.3 Hz, 2H, N7CH2), 4.33 (t, J=9.8 
Hz, 2H, CH2), 5.27 (t, J=9.6 Hz, 2H, CH2), 5.34 (s, 2H, CH2), 6.85-7.30 (m, 4H, ArH), 
8.00 (s, 1H, C8H), 8.89 (s, 1H, C2H). 13CNMR (CDCl3, 300 Hz) δ(ppm): 12.81, 18.91, 
28.25, 46.43, 46.76, 47.90, 48.15, 54.67, 113.56, 115.36, 125.78, 129.08, 143.27, 143.29, 
148.78, 149.51, 158.86. HRMS(ESI) Calcd for C19H24N5O 338.1981; found: 338.1986.  
 
4.5.21 Tetrahydro-imidazo[1,2-c][1,2,3]triazolo[4,5-e]pyrimidine (4-22) and 9-butyl-
tetrahydro-imidazo[2,1-i]purine (4-24) 
Compounds 4-22 and 4-24 were prepared according to the procedure given in Section 
4.5.6.  
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4-22: 1HNMR (DMSO-d6, 300 Hz) δ(ppm): 4.17 (t, J=9.4 Hz, 2H, CH2), 4.69 (t, J=9.5 
Hz, 2H, CH2), 8.81 (s, 1H, C2H). 13CNMR (MeOD, 300 Hz) δ(ppm): 45.32 (x2), 114.84, 
148.25, 148.53, 159.58. HRMS(EI) Calcd for C6H6N6 162.0654;  found: 162.0651.  
4-24: 1HNMR (MeOD, 300 Hz) δ(ppm): 1.00 (t, J=7.3 Hz, 3H, CH3), 1.44-1.54 (m, 2H, 
CH2), 1.79-1.86 (m, 2H, CH2), 4.11-4.22 (m, 4H, 2CH2), 4.80 (t, J=7.3 Hz, 2H, N1CH2), 
8.35 (s, 1H, C8H), 8.51 (s, 1H, C2H). 13CNMR (MeOD, 300 Hz) δ(ppm): 12.99, 19.66, 
29.28, 47.04, 47.84, 48.41, 117.07, 144.52, 145.45, 151.08, 152.81. HRMS(EI) Calcd for 
C11H15N5 217.1327; found: 217.1324.    
 
4.5.22 Preparation of BOBA resin (4-27) 
DiAD (3 equiv.) was added dropwise to a mixture of Wang resin (loading 1.6 mmol/g), 
phthalimide (3 equiv.) and triphenylphosphine (3 equiv.) in THF under ice water bath 
temperature. The reaction mixture was shaken at room temperature overnight and the 
resin was filtered and washed sequentially with DMF (20 mL x 2), H2O (20 mL x 2), 
EtOH (20 mL x 2), CH2Cl2 (20 mL x 2) and ether (20 mL x 2), and dried overnight in a 
vacuum oven at 40°C. The dried resin was then subjected to hydrazinolysis using a 
solution of hydrazine (15 equiv.) in THF at room temperature overnight. After which, the 
resin was washed sequentially with DMF (20 mL x 2), H2O (20 mL x 2), EtOH (20 mL x 






4.5.23 Synthesis of resin bound N4-(4-(benzyloxy)benzyl)-6-chloropyrimidine-4,5-
diamine (4-28) 
Resin 4-27 was swollen in DMA for 30 min and 1-butanol, 5-amino-4,6-dichloro- 
pyrimidine and DiEA were added. The reaction mixture was stirred slowly at 140°C for 
24 h. After which, the resin was filtered and washed sequentially with DMF (20 mL x 2), 
H2O (20 mL x 2), EtOH (20 mL x 2), CH2Cl2 (20 mL x 2) and ether (20 mL x 2), and 
dried overnight in a vacuum oven at 40°C. 
 
4.5.24 General solid-phase cyclization of 4-28 with aldehydes  
Resin 4-28 was swollen in THF for 30 min and acetic acid and the appropriate aldehydes 
(8 equiv.) were added. The reaction mixture was then slowly stirred under reflux 
condition for 24 h. After which, the resin was filtered and treated with 85% formic acid 
and DMF and stirred at 70°C for 3 h. 
 
4.5.25 General procedure for solid-phase N1 alkylation  
The resin 4-29 was swollen in DMF for 30 min and the respective alkylating reagents (3 
equiv.) and DBU (3 equiv.) were added. After shaking at room temperature overnight, the 
resin was filtered and washed with DMF (20 mL x 2), EtOH (20 mL x 2) and CH2Cl2 (20 
mL x 2) and dried in vacuum.  
 
4.5.26 General procedure for solid-phase N7 quaternization 
Resin 4-30 was swollen in DMF for 30 min. The respective quarternization reagent (40 or 
50 equiv.) was added and the mixture was stirred slowly at 70oC for 36 h. After which, 
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the resin was filtered and washed with DMF (20 mL x 2), H2O (20 mL x 2), EtOH (20 
mL x 2) and CH2Cl2 (20 mL x 2) and dried in vacuum. 
 
4.5.27 Synthesis of resin bound 9-(4-(benzyloxy)benzyl)-6-chloro-9H-purine (4-32a):  
Resin 4-28 was swollen in DMF for 30 min and then trimethyl orthoformate (50 equiv.) 
was added. The reaction mixture was then cooled in an ice water bath and HCl (cat.) was 
added. The reaction mixture was then shaken at room temperature overnight. After 
which, the resin was filtered and washed with DMF (20 mL x 2), H2O (20 mL x 2), EtOH 
(20 mL x 2) and CH2Cl2 (20 mL x 2) and dried in vacuum. 
 
4.5.28 Synthesis of resin bound 3-(4-(benzyloxy)benzyl)-7-chloro-3H-[1,2,3] triazolo 
[4,5-d]pyrimidine (4-32b) 
Resin 4-28 was swollen in DCM for 30 min and 50% aqueous acetic acid and NaNO2 (2 
equiv.) were added. After shaking vigorously at room temperature for 30 min, the resin 
was filtered and washed with EtOH (20 mL x 2) and CH2Cl2 (20 mL x 2) and dried in 
vacuum. 
 
4.5.29 Solid-phase synthesis of 4-37 via amination at C6 with ethanolamine 
The loaded resin 4-32 was swollen in THF for 30 min and then ethanolamine was added. 
The reaction mixture was stirred slowly at 60oC for 4 h. After which, the resin was 
filtered and washed sequentially with EtOH (20 mL x 2), CH2Cl2 (20 mL x 2) and Et2O 
(20 mL x 2), and dried overnight in a vacuum oven at 40°C. 
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4.5.30 Solid-phase synthesis of 4-38 with thionyl chloride  
Resin 4-37 was swollen in DMF for 30 min and then SOCl2 (2 equiv.) was added. The 
reaction mixture was stirred at 180oC under microwave irradiation for 20 min. After 
which, the resin was filtered and washed sequentially with EtOH (20 mL x 2), saturated 
NaHCO3 (20 mL x 2), H2O (20 mL x 2), EtOH (20 mL x 2), CH2Cl2 (20 mL x 2) and 
ether (20 mL x 2), and dried overnight in a vacuum oven at 40°C. 
 
4.5.31 General cleavage procedure 
Resin was swollen in DCM for 30 min. Toluene and 96% sulfuric acid were added and 
the reaction mixture was shaken at room temperature for 4 h. The resin was then filtered 
and washed with EtOAc. The filtrate was neutralized with saturated NaHCO3 and 
extracted with EtOAc and water.  The combined organic layer was washed with brine, 
dried with MgSO4, concentrated to dryness and purified by column chromatography. 
  
4-6a: 7-Butyl-8-hexyl-1-(prop-2-ynyl)-1H-purin-6(7H)-one  
1HNMR (CDCl3, 300 Hz) δ(ppm): 0.87 (t, J=7.0 Hz, 3H, CH3), 0.90 (t, J=7.4 Hz, 3H, 
CH3), 1.29-1.91 (m, 12H, 6CH2), 2.46 (t, J=2.6 Hz, 1H, CH), 2.78 (t, J=7.8 Hz, 2H, 
C8CH2), 4.33 (t, J=7.4 Hz, 2H, N7CH2), 4.79 (d, J=2.8 Hz, 2H, N1CH2), 8.23 (s, 1H, 
C2H). 13CNMR (CDCl3, 300 Hz) δ(ppm): 13.63, 13.95, 19.75, 22.45, 27.04, 27.56, 
29.03, 31.43, 33.48, 34.63, 45.25, 74.82, 76.58, 114.70, 114.93, 147.38, 153.19, 156.34. 





1HNMR (CDCl3, 300 Hz) δ(ppm): 0.84 (t, J=6.6 Hz, 3H, CH3), 1.24-1.31 (m, 6H, 3CH2), 
1.71-1.75 (m, 2H, CH2), 2.71 (t, J=7.7 Hz, 2H, N7CH2), 5.2 (s, N1CH2), 5.66 (s, 1H, 
N7CH2), 7.12-7.34 (m, 10H, ArH), 8.09 (s, 1H, C2H). 13CNMR (CDCl3, 300 Hz) δ(ppm): 
13.96, 22.40, 27.22, 27.26, 28.92, 31.36, 48.37, 49.03, 115.25, 126.72 (x2), 127.84, 
127.92, 128.22 (x2), 128.90, 128.97, 135.96, 136.25, 146.19, 154.10, 156.05, 156.98. 
HRMS(EI) Calcd for C25H28N4O 400.2263; found: 400.2257.  
 
4-6c: 1-Allyl-7-benzyl-8-hexyl-1H-purin-6(7H)-one 
1HNMR (CDCl3, 300 Hz) δ(ppm): 0.84 (t, J=6.6 Hz, 3H, CH3), 1.24-1.34 (m, 6H, 3CH2), 
1.71-1.76 (m, 2H, CH2), 2.72 (t, J=7.7 Hz, 2H, C8CH2), 4.63 (d, J=5.6 Hz, N1CH2), 5.24 
(m, 2H, CH2), 5.65 (s, 2H, N7CH2), 5.93-6.02 (m, 1H, CH), 7.11-7.33 (m, 5H, ArH), 8.00 
(s, 1H, C2H). 13CNMR (CDCl3, 300 Hz) δ(ppm): 13.96, 22.40, 27.22, 27.26, 28.92, 
31.36, 48.37, 49.03, 126.72, 127.84, 127.92, 128.22, 128.90, 128.97, 135.96, 136.25, 




1HNMR (CDCl3, 300 Hz) δ(ppm): 0.82 (t, J=7.5 Hz, 3H, CH3), 1.19-1.27 (m, 2H, CH2), 
1.73-1.81 (m, 2H, CH2), 4.43 (t, J=7.5 Hz, 2H, N7CH2), 4.65 (d, J=6.0 Hz, N1CH2), 5.23 
(m, 2H, CHCH2), 5.93-6.03 (m, 1H, CH), 7.48-7.69 (m, 5H, ArH), 8.01 (s, 1H, C2H). 
13CNMR (CDCl3, 300 Hz) δ(ppm): 13.37, 19.47, 33.57, 46.34, 47.80, 116.00, 118.53, 
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128.72, 129.21, 129.27, 130.17, 132.15, 146.39, 153.88, 154.13, 156.35. HRMS(EI) 
Calcd for C18H20N4O 308.1637; found: 308.1637.    
 
4-6e: 7-Benzyl-1-butyl-8-phenyl-1H-purin-6(7H)-one  
1HNMR (CDCl3, 300 Hz) δ(ppm): 0.95 (t, J=7.3 Hz, 3H, CH3), 1.32-1.42 (m, 2H, CH2), 
1.69-1.79 (m, 2H, CH2), 4.00 (t, J=7.3 Hz, 2H, N1CH2), 5.74 (s, 2H, N7CH2), 6.99-7.64 
(m, 10H, 2ArH), 8.05 (s, 1H, C2H).  13CNMR (CDCl3, 300 Hz) δ(ppm): 13.57, 19.76, 
31.87, 46.34, 49.54, 126.33, 127.72, 127.81, 128.23, 128.77, 128.96, 129.37, 130.35, 
136.95, 146.80, 154.19, 154.58, 156.36. HRMS(EI) Calcd for C22H22N4O 358.1794; 
found: 308.1788.   
 
4-6f: 7-Butyl-8-(4-methoxyphenyl)-1-(prop-2-ynyl)-1H-purin-6(7H)-one  
1HNMR (CDCl3, 300 Hz) δ(ppm): 0.86 (t, J=7.3 Hz, 3H, CH3), 1.24-1.31 (m, 2H, CH2), 
1.77-1.84 (m, 2H, CH2), 2.49 (t, J=2.6 Hz, 2H, N1CH2), 3.88 (s, 3H, OCH3), 4.44 (t, 
J=7.7 Hz, N7CH2), 4.83 (d, J=2.6 Hz, CH), 7.02 (m, 2H, ArH), 7.64(m, 2H, ArH), 8.30 
(s, 1H, C2H). 13CNMR (CDCl3, 300 Hz) δ(ppm): 13.47, 19.59, 33.58, 34.83, 46.48, 
55.39, 74.99, 76.70, 114.26, 121.36, 130.79, 145.48, 153.40, 154.38, 156.42, 161.14. 
HRMS(EI) Calcd for C19H20N4O2 336.1586; found: 336.1588.  
 
4-6g: 7-Allyl-1-benzyl-8-(4-methoxyphenyl)-1H-purin-6(7H)-one  
1HNMR (CDCl3, 300 Hz) δ(ppm): 3.88 (s, 3H, CH3), 5.04 (m, 2H, N7CH2), 5.17 (dd, 
J=13.7 Hz, J=81.2 Hz, CHCH2), 5.23 (s, 2H, N1CH2), 6.09-6.20 (m, 1H, CH), 7.02-7.23 
(m, 2H, ArH), 7.34-7.36 (m, 5H, ArH), 7.74 (m, 2H, ArH), 8.16 (s, 1H, C2H). 13CNMR 
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(CDCl3, 300 Hz) δ(ppm): 48.47, 49.03, 55.29, 114.11, 115.98, 116.98, 120.95, 127.79, 
128.14, 128.89, 130.69, 133.68, 135.89, 146.62, 153.92, 154.29, 156.20, 161.19. 
HRMS(EI) Calcd for C22H20N4O2 372.1586; found: 372.1578.    
 
4-6h: 7-Butyl-1-(prop-2-ynyl)-8-styryl-1H-purin-6(7H)-one 
1HNMR (CDCl3, 300 Hz) δ(ppm): 0.97 (t, J=7.3 Hz, 3H, CH3), 1.35-1.48 (m, 2H, CH2), 
1.79-1.89 (m, 2H, CH2), 2.49 (t, J=2.4 Hz, 1H, CH), 4.53 (t, J=7.3 Hz, 2H, N7CH2), 4.81 
(d, J=2.8 Hz, 2H, N1CH2), 6.95 (d, J=15.7 Hz, 1H, CH), 7.36-7.60 (m, 5H, ArH), 8.04 
(d, J=15.7 Hz, 1H, CH), 8.29 (s, 1H, C2H).  13CNMR (CDCl3, 300 Hz) δ(ppm): 13.66, 
19.72 (x2), 33.67 (x2), 34.78, 45.09, 75.07, 111.31, 127.47, 128.91 (x2), 129.56, 135.49, 
145.67, 151.62, 153.17, 156.34. HRMS(EI) Calcd for C20H20N4O 332.1637; found: 
332.1621.   
 
4-6i: 7-Allyl-1-butyl-8-styryl-1H-purin-6(7H)-one  
1HNMR (CDCl3, 300 Hz) δ(ppm): 0.96 (t, J=7.3 Hz, 3H, CH3), 1.36-1.44 (m, 2H, CH2), 
1.73-1.78 (m, 2H, CH2), 3.99 (t, J=7.4 Hz, 2H, N1CH2), 5.05-5.28 (m, 2H, CH2), 5.23 (d, 
J=5.0 Hz, N7CH2), 5.99-6.10 (m, 1H, CH), 6.92 (d, J=15.8 Hz, 1H, CH), 7.36-7.57 (m, 
5H, ArH), 7.99 (d, J=15.7 Hz, 1H, CH), 8.04 (s, 1H, C2H). 13CNMR (CDCl3, 300 Hz) 
δ(ppm): 13.56, 19.79, 31.85, 46.29, 46.92, 111.63, 117.53, 127.41, 128.39, 128.83, 
129.44, 132.68, 135.50, 139.38, 146.71, 151.71, 153.91, 156.24. HRMS(EI) Calcd for 





4-17b: 7-Benzyl-1-(prop-2-ynyl)-1H-purin-6(7H)-one  
1HNMR (CDCl3, 300 Hz) δ(ppm): 2.48 (t, J=2.4 Hz, 1H, CH3), 4.80 (d, J=2.8 Hz, 2H, 
N1CH2), 5.58 (s, 2H, N7CH2), 7.32-7.36 (m, 5H, ArH), 7.87 (s, 1H, C8H), 8.27 (s, 1H, 
C2H). 13CNMR (CDCl3, 300 Hz) δ(ppm): 34.75, 50.62, 75.13, 114.73, 127.91, 128.55 
(x2), 129.04, 135.41, 143.45, 145.46, 153.63, 156.92. HRMS(EI) Calcd for C15H12N4O 
264.1.11; found: 264.1.11.    
 
4-17c: 7-Butyl-1-(prop-2-ynyl)-1H-purin-6(7H)-one  
1HNMR (CDCl3, 300 Hz) δ(ppm): 0.89 (t, J=7.3 Hz, 3H, CH3), 1.25-1.35 (m, 2H, CH2), 
1.77-1.86 (m, 2H, CH2), 2.46 (dt, J=0.7 Hz, J=2.4 Hz, 1H, CH3), 4.32 (t, J=7.3 Hz, 2H, 
N1CH2), 4.77 (dd, J=0.7 Hz, J=2.6 Hz, 2H, N1CH2), 7.81 (s, 1H, C8H), 8.23(s, 1H, 
C2H). 13CNMR (CDCl3, 300 Hz) δ(ppm): 12.90, 18.95, 32.70, 34.22, 46.71, 74.48, 
76.07, 114.45, 142.95, 144.87, 152.94, 156.40. HRMS(EI) Calcd for C12H14N4O 
230.1168,     found: 230.1162.   
 
4-17d: 7-Benzyl-1-butyl-1H-purin-6(7H)-one  
1HNMR (CDCl3, 300 Hz) δ(ppm): 0.95 (t, J=7.3 Hz, 3H, CH3), 1.35-1.43 (m, 2H, CH2), 
1.69-1.79 (m, 2H, CH2), 4.00 (t, J=7.5 Hz, 2H, N1CH2), 5.60 (s, 2H, N7CH2), 7.30-7.34 
(m, 5H, ArH), 7.84 (s, 1H, C8H), 7.99 (s, 1H, C2H). 13CNMR (CDCl3, 300 Hz) δ(ppm): 
13.57, 19.77, 31.84, 46.30, 50.55, 127.92, 128.48, 129.02, 135.64, 143.17, 143.29, 





1HNMR (CDCl3, 300 Hz) δ(ppm): 3.42 (t, J=2.5 Hz, 1H, CH), 4.85 (d, J=2.6 Hz, 2H, 
N1CH2), 8.55 (s, 1H, C2H). 13CNMR (CDCl3, 300 Hz) δ(ppm): 34.49, 75.38, 77.94, 
126.91, 149.86, 151.95, 153.73. HRMS(EI) Calcd for C7H7N5O 175.0494; found: 
175.0494.    
 
4-35b: 6-Benzyl-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7(6H)-one  
1HNMR (DMSO-d6, 300 Hz) δ(ppm): 5.22 (s, 2H, CH2), 7.29-7.34 (m, 5H, ArH), 8.59 (s, 
1H, C2H). 13CNMR (DMSO-d6, 300 Hz) δ(ppm): 47.85, 127.05, 127.17 (x2), 128.14, 
136.44, 149.76, 152.74, 154.61. HRMS(EI) Calcd for C11H9N5O 227.0807; found: 
227.0805.    
 
4-35c: 6-Allyl-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7(6H)-one  
1HNMR (DMSO-d6, 300 Hz) δ(ppm): 4.64 (d, J=5.2 Hz, 2H, N1CH2), 5.13 (m, 2H, 
CH2), 5.92-6.05 (m, 1H, CH), 8.40 (s, 1H, C2H). 13CNMR (DMSO-d6, 300 Hz) δ(ppm): 
46.70, 116.95, 126.97, 132.69, 149.99, 152.36, 154.23. HRMS(EI) Calcd for C7H7N5O 
177.0651,     found: 177.0646.   
 
4-35d: 6-Butyl-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7(6H)-one  
1HNMR (MeOD, 300 Hz) δ(ppm): 0.95 (t, J=7.3 Hz, 3H, CH3), 1.32-1.45 (m, 2H, CH2), 
1.69-1.79 (m, 2H, CH2), 4.09 (t, J=7.5 Hz, 2H, N1CH2), 8.38 (s, 1H, C2H). 13CNMR 
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(MeOD, 300 Hz) δ(ppm): 13.94, 20.75, 32.60, 47.51, 128.75, 152.23, 153.80, 156.91. 
HRMS(EI) Calcd for C8H11N5O 193.0964; found: 193.0956.  
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  Table 1.  Crystal data and structure refinement for 2-3. 
Identification code  2-3 
Empirical formula  C12 H10 N4 O 
Formula weight  226.24 
Temperature  223(2) K 
Wavelength  0.71073 Å 
Crystal system  Orthorhombic 
Space group  P2(1)2(1)2(1) 
Unit cell dimensions a = 8.3887(9) Å α= 90°. 
 b = 9.8874(10) Å β= 90°. 
 c = 12.8009(13) Å γ = 90°. 
Volume 1061.74(19) Å3 
Z 4 
Density (calculated) 1.415 Mg/m3 
Absorption coefficient 0.096 mm-1 
F(000) 472 
Crystal size 0.47 x 0.26 x 0.26 mm3 
Theta range for data collection 2.60 to 27.49°. 
Index ranges -10<=h<=10, -10<=k<=12, -16<=l<=16 
Reflections collected 7565 
Independent reflections 2437 [R(int) = 0.0395] 
Completeness to theta = 27.49° 100.0 %  
Absorption correction SADABS 
Max. and min. transmission 0.9754 and 0.9562 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2437 / 0 / 162 
Goodness-of-fit on F2 0.965 
Final R indices [I>2sigma(I)] R1 = 0.0450, wR2 = 0.0845 
R indices (all data) R1 = 0.0566, wR2 = 0.0887 
Absolute structure parameter 0.00 
Largest diff. peak and hole 0.197 and -0.199 e.Å-3 
 167
  Table 1.  Crystal data and structure refinement for 2-4b. 
Identification code  2-4b 
Empirical formula  C15 H16 N4 O 
Formula weight  268.32 
Temperature  295(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 5.380(5) Å α= 99.932(16)°. 
 b = 10.617(10) Å β= 90.153(18)°. 
 c = 12.547(11) Å γ = 92.275(18)°. 
Volume 705.4(11) Å3 
Z 2 
Density (calculated) 1.263 Mg/m3 
Absorption coefficient 0.083 mm-1 
F(000) 284 
Crystal size 0.52 x 0.34 x 0.34 mm3 
Theta range for data collection 1.65 to 25.00°. 
Index ranges -6<=h<=6, -12<=k<=12, -14<=l<=14 
Reflections collected 7522 
Independent reflections 2491 [R(int) = 0.0322] 
Completeness to theta = 25.00° 100.0 %  
Absorption correction Sadabs, (Sheldrick 2001) 
Max. and min. transmission 0.9723 and 0.9580 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2491 / 0 / 183 
Goodness-of-fit on F2 1.087 
Final R indices [I>2sigma(I)] R1 = 0.0627, wR2 = 0.1578 
R indices (all data) R1 = 0.0787, wR2 = 0.1674 
Largest diff. peak and hole 0.253 and -0.151 e.Å-3 
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Table 1.  Crystal data and structure refinement for 2-23a. 
Identification code  2-23a 
Empirical formula  C9 H12 N4 O 
Formula weight  192.23 
Temperature  293(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/c 
Unit cell dimensions a = 9.686(13) Å α= 90°. 
 b = 9.044(11) Å β= 95.32(17)°. 
 c = 11.075(12) Å γ = 90°. 
Volume 966(2) Å3 
Z 4 
Density (calculated) 1.322 Mg/m3 
Absorption coefficient 0.092 mm-1 
F(000) 408 
Crystal size 0.60 x 0.38 x 0.05 mm3 
Theta range for data collection 2.11 to 24.99°. 
Index ranges -11<=h<=11, -8<=k<=10, -11<=l<=13 
Reflections collected 4138 
Independent reflections 1679 [R(int) = 0.0672] 
Completeness to theta = 24.99° 98.5 %  
Absorption correction SADABS 
Max. and min. transmission 0.9954 and 0.9469 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 1679 / 12 / 132 
Goodness-of-fit on F2 1.072 
Final R indices [I>2sigma(I)] R1 = 0.0925, wR2 = 0.2523 
R indices (all data) R1 = 0.1204, wR2 = 0.2726 
Largest diff. peak and hole 0.455 and -0.367 e.Å-3 
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Table 1.  Crystal data and structure refinement for 2-23b. 
Identification code  2-23b 
Empirical formula  C8 H12 N4 O2 
Formula weight  196.22 
Temperature  223(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/n 
Unit cell dimensions a = 9.6078(7) Å α= 90°. 
 b = 8.9381(6) Å β= 113.3110(10)°. 
 c = 11.8443(8) Å γ = 90°. 
Volume 934.11(11) Å3 
Z 4 
Density (calculated) 1.395 Mg/m3 
Absorption coefficient 0.104 mm-1 
F(000) 416 
Crystal size 0.52 x 0.52 x 0.26 mm3 
Theta range for data collection 2.33 to 27.50°. 
Index ranges -12<=h<=12, -11<=k<=11, -9<=l<=15 
Reflections collected 6469 
Independent reflections 2145 [R(int) = 0.0184] 
Completeness to theta = 27.50° 100.0 %  
Absorption correction None 
Max. and min. transmission 0.9735 and 0.9479 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2145 / 0 / 141 
Goodness-of-fit on F2 1.083 
Final R indices [I>2sigma(I)] R1 = 0.0378, wR2 = 0.0997 
R indices (all data) R1 = 0.0440, wR2 = 0.1028 
Largest diff. peak and hole 0.300 and -0.193 e.Å-3 
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Table 1.  Crystal data and structure refinement for 2-23d. 
Identification code  2-23d 
Empirical formula  C8 H9 I N4 O 
Formula weight  304.09 
Temperature  496(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 7.7879(4) Å α= 85.3740(10)°. 
 b = 8.1761(4) Å β= 70.7910(10)°. 
 c = 9.1395(4) Å γ = 62.0530(10)°. 
Volume 483.58(4) Å3 
Z 2 
Density (calculated) 2.088 Mg/m3 
Absorption coefficient 3.283 mm-1 
F(000) 292 
Crystal size 0.26 x 0.13 x 0.13 mm3 
Theta range for data collection 2.37 to 27.50°. 
Index ranges -10<=h<=10, -10<=k<=10, -11<=l<=11 
Reflections collected 6365 
Independent reflections 2219 [R(int) = 0.0184] 
Completeness to theta = 27.50° 99.9 %  
Absorption correction None 
Max. and min. transmission 0.6749 and 0.4823 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2219 / 0 / 133 
Goodness-of-fit on F2 1.073 
Final R indices [I>2sigma(I)] R1 = 0.0175, wR2 = 0.0428 
R indices (all data) R1 = 0.0180, wR2 = 0.0430 
Largest diff. peak and hole 0.606 and -0.620 e.Å-3 
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Table 1.  Crystal data and structure refinement for 3-6f. 
Identification code  3-6f 
Empirical formula  C19 H26 N4 O2 
Formula weight  342.44 
Temperature  223(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/c 
Unit cell dimensions a = 17.164(3) Å α= 90°. 
 b = 8.4372(14) Å β= 99.752(4)°. 
 c = 13.333(2) Å γ = 90°. 
Volume 1902.9(6) Å3 
Z 4 
Density (calculated) 1.195 Mg/m3 
Absorption coefficient 0.079 mm-1 
F(000) 736 
Crystal size 0.78 x 0.65 x 0.26 mm3 
Theta range for data collection 2.41 to 23.29°. 
Index ranges -14<=h<=19, -9<=k<=8, -14<=l<=11 
Reflections collected 9008 
Independent reflections 2736 [R(int) = 0.0274] 
Completeness to theta = 23.29° 99.7 %  
Absorption correction Sadabs 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2736 / 26 / 270 
Goodness-of-fit on F2 1.045 
Final R indices [I>2sigma(I)] R1 = 0.0465, wR2 = 0.1256 
R indices (all data) R1 = 0.0591, wR2 = 0.1345 
Largest diff. peak and hole 0.249 and -0.154 e.Å-3 
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Table 1.  Crystal data and structure refinement for 4-6i. 
Identification code  4-6i 
Empirical formula  C20 H22 N4 O 
Formula weight  334.42 
Temperature  223(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/c 
Unit cell dimensions a = 10.9860(5) Å α= 90°. 
 b = 20.6191(9) Å β= 90.5090(10)°. 
 c = 16.1222(6) Å γ = 90°. 
Volume 3651.9(3) Å3 
Z 8 
Density (calculated) 1.216 Mg/m3 
Absorption coefficient 0.078 mm-1 
F(000) 1424 
Crystal size 0.23 x 0.13 x 0.10 mm3 
Theta range for data collection 1.60 to 27.50°. 
Index ranges -14<=h<=11, -26<=k<=26, -20<=l<=18 
Reflections collected 26060 
Independent reflections 8397 [R(int) = 0.0771] 
Completeness to theta = 27.50° 100.0 %  
Absorption correction None 
Max. and min. transmission 0.9920 and 0.9821 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 8397 / 0 / 453 
Goodness-of-fit on F2 1.019 
Final R indices [I>2sigma(I)] R1 = 0.0802, wR2 = 0.1413 
R indices (all data) R1 = 0.1558, wR2 = 0.1679 
Largest diff. peak and hole 0.234 and -0.185 e.Å-3 
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Table 1.  Crystal data and structure refinement for 4-13a. 
Identification code  4-13a 
Empirical formula  C21.71 H17.14 Cl1.14 N4.57 O1.14 
Formula weight  400.91 
Temperature  223(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 9.7872(8) Å α= 100.106(2)°. 
 b = 17.9940(15) Å β= 91.111(2)°. 
 c = 19.4196(16) Å γ = 97.268(2)°. 
Volume 3336.9(5) Å3 
Z 7 
Density (calculated) 1.397 Mg/m3 
Absorption coefficient 0.244 mm-1 
F(000) 1456 
Crystal size 0.39 x 0.24 x 0.23 mm3 
Theta range for data collection 1.07 to 27.50°. 
Index ranges -12<=h<=12, -23<=k<=23, -25<=l<=25 
Reflections collected 43958 
Independent reflections 15307 [R(int) = 0.0614] 
Completeness to theta = 27.50° 99.9 %  
Absorption correction None 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 15307 / 0 / 901 
Goodness-of-fit on F2 1.077 
Final R indices [I>2sigma(I)] R1 = 0.0862, wR2 = 0.1611 
R indices (all data) R1 = 0.1526, wR2 = 0.1899 
Largest diff. peak and hole 0.420 and -0.265 e.Å-3 
 174
Table 1.  Crystal data and structure refinement for 4-18a. 
Identification code  4-18a 
Empirical formula  C18 H14 Cl N5 O 
Formula weight  351.79 
Temperature  223(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/c 
Unit cell dimensions a = 7.479(3) Å α= 90°. 
 b = 20.043(10) Å β= 99.58(5)°. 
 c = 11.195(7) Å γ = 90°. 
Volume 1654.6(15) Å3 
Z 4 
Density (calculated) 1.412 Mg/m3 
Absorption coefficient 0.248 mm-1 
F(000) 728 
Crystal size 0.40 x 0.30 x 0.28 mm3 
Theta range for data collection 2.03 to 27.50°. 
Index ranges -9<=h<=9, -26<=k<=19, -13<=l<=14 
Reflections collected 11703 
Independent reflections 3802 [R(int) = 0.0214] 
Completeness to theta = 27.50° 100.0 %  
Absorption correction Sadabs(Sheldrick,2001) 
Max. and min. transmission 0.9339 and 0.9074 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3802 / 0 / 226 
Goodness-of-fit on F2 1.069 
Final R indices [I>2sigma(I)] R1 = 0.0527, wR2 = 0.1243 
R indices (all data) R1 = 0.0607, wR2 = 0.1297 
Largest diff. peak and hole 0.472 and -0.392 e.Å-3 
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Table 1.  Crystal data and structure refinement for 4-17b. 
Identification code  4-17b 
Empirical formula  C15 H12 N4 O 
Formula weight  264.29 
Temperature  223(2) K 
Wavelength  0.71073 Å 
Crystal system  Orthorhombic 
Space group  P2(1)2(1)2(1) 
Unit cell dimensions a = 8.1795(6) Å α= 90°. 
 b = 8.7638(6) Å β= 90°. 
 c = 18.5052(12) Å γ = 90°. 
Volume 1326.52(16) Å3 
Z 4 
Density (calculated) 1.323 Mg/m3 
Absorption coefficient 0.088 mm-1 
F(000) 552 
Crystal size 0.52 x 0.39 x 0.26 mm3 
Theta range for data collection 2.20 to 27.50°. 
Index ranges -10<=h<=10, -11<=k<=11, -18<=l<=24 
Reflections collected 9573 
Independent reflections 3053 [R(int) = 0.0533] 
Completeness to theta = 27.50° 100.0 %  
Absorption correction None 
Max. and min. transmission 0.9776 and 0.9558 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3053 / 0 / 181 
Goodness-of-fit on F2 1.037 
Final R indices [I>2sigma(I)] R1 = 0.0534, wR2 = 0.1005 
R indices (all data) R1 = 0.0787, wR2 = 0.1095 
Absolute structure parameter 1(2) 
Largest diff. peak and hole 0.184 and -0.149 e.Å-3 
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 Table 1.  Crystal data and structure refinement for 4-17c. 
Identification code  4-17c 
Empirical formula  C24 H25 N8 O3 
Formula weight  473.52 
Temperature  223(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  C2/c 
Unit cell dimensions a = 20.7072(14) Å α= 90°. 
 b = 10.7727(7) Å β= 102.957(2)°. 
 c = 11.6071(8) Å γ = 90°. 
Volume 2523.3(3) Å3 
Z 4 
Density (calculated) 1.246 Mg/m3 
Absorption coefficient 0.087 mm-1 
F(000) 996 
Crystal size 0.39 x 0.31 x 0.31 mm3 
Theta range for data collection 2.02 to 27.45°. 
Index ranges -26<=h<=26, -13<=k<=11, -15<=l<=13 
Reflections collected 8634 
Independent reflections 2876 [R(int) = 0.0294] 
Completeness to theta = 27.45° 99.7 %  
Absorption correction None 
Max. and min. transmission 0.9735 and 0.9670 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2876 / 2 / 170 
Goodness-of-fit on F2 1.058 
Final R indices [I>2sigma(I)] R1 = 0.0649, wR2 = 0.1829 
R indices (all data) R1 = 0.0765, wR2 = 0.1940 
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Spectrum 4.18 13CNMR of 4-35d 
